Mitochondria-derived PEP licenses glycerolipid synthesis via SLC25A35

Tadashi Yamamuro [1], Daisuke Katoh [1], Guilherme Martins Silva [2], Hiroshi Nishida [1], Satoshi Oikawa [1], Yusuke Higuchi [1], Dandan Wang [1], Masanori Fujimoto [1], Naofumi Yoshida [1], Mark Li [1], Jihoon Shin [1], Zezhou Zhao [1], Jin-Seon Yook [1], Lijun Sun [2], and Shingo Kajimura [1]

[1] Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA

[2] Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

Corresponding Author: skajimur@bidmc.harvard.edu

ABSTRACT

Mitochondria provide a variety of metabolites, in addition to ATP, to meet cell-specific needs. One such metabolite is phosphoenolpyruvate (PEP), which contains the highest energy phosphate bond above ATP, and has diverse biological functions, including glycolysis, gluconeogenesis, and glyceroneogenesis. Although PEP is generally considered a cytosolic intermediate, it can also be synthesized within mitochondria by the mitochondria-localized carboxykinase (PCK2, also known as M-PEPCK). However, the mechanism by which mitochondrial PEP is delivered to the cytosolic compartment and caters to cell-specific requirements remains elusive. Here, we identify SLC25A35, a previously uncharacterized mitochondrial inner-membrane protein, as the long-sought carrier responsible for mitochondrial PEP efflux. SLC25A35 is highly expressed in lipogenic cells, such as adipocytes, which employ the mitochondrial pyruvate-to-PEP bypass, and is upregulated by lipogenic stimuli. Reconstitution studies by proteo-liposomes, together with structural analyses, demonstrated specific PEP transport by SLC25A35 in a pH gradient-dependent manner. Importantly, loss of SLC25A35 in adipocytes impaired the conversion of mitochondrial PEP into glycerol-3-phosphate, the glycerol backbone in triglyceride, resulting in reduced glycerolipid synthesis while preserving substrate oxidation in the TCA cycle. Furthermore, blockade of SLC25A35 in the liver of obese mice markedly decreased glycerolipid accumulation, ameliorated hepatic steatosis, and improved systemic glucose homeostasis. Together, the present study identifies mitochondrial PEP transport via SLC25A35 as a metabolic checkpoint of fatty acid esterification, offering a selective target for "lipogenic mitochondria" to limit glycerolipid synthesis, a pivotal step in the pathogenesis of hepatic steatosis and Type 2 diabetes.

Key Words: Bioenergetics, Mitochondria, Glyceroneogenesis, Obesity, Hepatic Steatosis, Diabetes

INTRODUCTION

Mitochondria serve as metabolic hubs that provide ATP, as well as essential metabolites, to various subcellular compartments, including the nucleus, endoplasmic reticulum, and lipid droplets [1,2]. A prime example linked to mitochondrial activity is phosphoenolpyruvate (PEP). PEP harbors one of the highest energy phosphate bonds in cells, with a standard Gibbs free energy change (ΔG°') of approximately -61.9 kJ mol^{-1} for the hydrolysis of PEP to pyruvate and inorganic phosphate, which is substantially higher than for ATP to ADP (-30.5 kJ mol^{-1}). This very large negative ΔG°' makes PEP a versatile energy donor in a variety of metabolic processes. In glycolysis, it drives ATP production via pyruvate kinase; in gluconeogenesis, PEP is an essential substrate in the liver; and in glyceroneogenesis, PEP is converted to glycerol-3-phosphate (G3P), the glycerol backbone necessary for the esterification of fatty acids into glycerolipids, including triglycerides and phospholipids in adipose tissue and liver [3-7]. Furthermore, PEP contributes to ATP-dependent insulin secretion in pancreatic β-cells [6,8-13] and the regulation of Ca^{2+} signaling in activated T cells [14]. However, how such an energetically high molecule is generated, delivered, and fulfills cell-type-specific needs remains elusive.

To regenerate this high-energy-containing PEP from pyruvate, cells must overcome the energetic barrier by two-step reactions: the first step is an ATP-consuming reaction to convert pyruvate to oxaloacetate (OAA) by pyruvate carboxylase (PC), and the second step is a GTP-consuming reaction to convert OAA to PEP by phosphoenolpyruvate carboxykinase (PEPCK) [15,16]. Of note, PEP can be synthesized from OAA either in the cytosolic compartment via PEPCK (C-PEPCK or PCK1) or within the mitochondria by PCK2 (also known as M-PEPCK) (**Figure 1A**). Historically, much attention has been paid to PCK1 in the context of gluconeogenesis because 1) PCK1 is more abundant than PCK2 in the liver of rodents [3] (note: human PCK2 accounts for approximately 50%), 2) PCK1 expression and activity are dynamically regulated by nutritional and hormonal cues, including fasting [3], 3) overexpression of PCK1 in the liver caused hyperglycemia [17,18], and 4) inhibition of PCK1 attenuated hepatic gluconeogenesis from lactate/pyruvate, although liver-specific *Pck1* knockout mice maintain euglycemia due to compensatory renal gluconeogenesis [19-24]. Thus, it is reasonable to consider that PEP is generated primarily in the cytosolic compartment.

From a bioenergetic point of view, however, PEP synthesis in the mitochondrial compartment appears more efficient than the cytosolic pathway, considering the availability of mitochondrial GTP and the need for fewer enzymatic steps and metabolite transports [25]. In addition, mitochondria contain abundant amounts of PEP at concentrations of 10 μM and higher [26,27]. Notably, when $^{13}C_3$-labeled pyruvate tracing experiments were performed in isolated mitochondria of white adipocytes, M+3 PEP was the dominant form relative to

M+1 or M+2 PEP (**Figure 1B**). Furthermore, the mitochondria from brown adipocytes generated significantly higher levels of M+3 PEP than M+1 or M+2 PEP (**Figure 1C**). Additionally, the mitochondria from white preadipocytes dominantly generated M+3 PEP from $^{13}C_3$-labeled pyruvate (**Supplementary Figure 1A**). Of note, the oxidative TCA cycle was active in the mitochondria of brown adipocytes, although less activities were found in the mitochondria of white adipocytes and preadipocytes (**Supplementary Figure 1B-D**). These results suggest that the conversion from pyruvate → OAA → PEP, *a.k.a.* pyruvate-to-PEP bypass, is the primary pathway of PEP synthesis in adipocyte mitochondria regardless of their oxidative TCA cycle activities. In contrast, mitochondria from C2C12 myoblasts and HEK293T cells generated M+1 or M+2 PEP, through the oxidation of ^{13}C-pyruvate in the TCA cycle, at higher levels than M+3 PEP (**Supplementary Figure 1E, F**). These results suggest that mitochondria regenerate PEP in a cell-type-selective manner.

These findings raise a critical question: How is mitochondrial-derived PEP exported into the cytosolic compartment? Since the inner mitochondrial membrane (IMM) is impermeable to metabolites, the export of PEP from the mitochondrial matrix to the cytosol necessitates specific mitochondrial carrier proteins [28]. Accordingly, this study aimed to identify an as-of-yet uncharacterized mitochondrial carrier that mediates PEP transport across the IMM and further investigate its biological significance.

RESULTS

Mitochondrial carrier proteins that are linked to PEP synthesis.

The cytosolic PCK1 has been recognized as the primary PEPCK; however, previous studies reported that the depletion of PCK2 in rat liver reduces gluconeogenesis from lactate, pyruvate, and amino acids [25,29]. Furthermore, PCK2 is expressed highly in neuronal progenitors [30] and in the pancreatic islets, where mitochondria-derived PEP, generated by PCK2 using mitochondrial GTP, significantly contributes to the total PEP pool and controls glucose-stimulated insulin secretion [6,8-13]. Intriguingly, PCK2 was the dominant PEPCK in inguinal white adipose tissue (WAT)-derived adipocytes, whereas PCK1 expression was low (**Figure 1D, Supplementary Fig.2A**). Similarly, brown adipocytes expressed high protein levels of PCK2 relative to PCK1. Thus, we next deleted *Pck1* or *Pck2* by the CRISPR-Cas9 system and examined the function in lipogenesis (**Supplementary Fig. 2B**). To assess glycerolipid synthesis in adipocytes, we used 1-^{14}C pyruvate as a tracer, which ensures that labeled GA3P and G3P are not produced directly from glucose via glycolysis and that labeled acetyl-CoA is not generated in mitochondria, because the first carbon of the tracer is released as carbon dioxide. Thus, the assay primarily measures ^{14}C incorporation into the glycerol backbone of glycerolipids through carboxylation of pyruvate to oxaloacetate. Insulin promoted ^{14}C incorporation into the lipid fraction in adipocytes, validating the assay. We found that adipocytes lacking

Pck2, induced by two distinct gRNAs, showed a significant decrease in glycerolipid synthesis relative to control cells (**Figure 1E**). In agreement, incorporation of ^{14}C-labeled glucose into the lipid fraction was significantly reduced in adipocytes lacking *Pck2,* reflecting the contribution of PCK2 to lipogenesis under more physiological conditions, although this assay cannot differentiate whether the tracer is incorporated into the glycerol backbone or the fatty acid moiety of glycerolipids (**Supplementary Fig. 2C**). On the other hand, adipocytes with sg*Pck1* retained the ability to synthesize lipids from ^{14}C-labeled glucose. These results suggest that mitochondrial PEP generated via PCK2 contributes to glycerolipid synthesis in adipocytes. The results also suggest the existence of an as-yet-unidentified mitochondrial carrier that mediates PEP export in these cells.

To identify such mitochondrial carriers, we performed the following analyses: First, we searched for genes encoding mitochondrial carrier proteins that were enriched in brown and white adipocytes, which primarily generated M+3 PEP compared to other cell types. This analysis identified several mitochondrial carrier proteins, including *Slc25a1* (mitochondrial citrate carrier), *Slc25a9* (also known as UCP3), *Slc25a19* (thiamine carrier), and *Slc25a35* (**Figure 1F**). Second, we searched for genes that showed positive correlations with *Acaca* (acetyl-CoA carboxylase alpha) and *Fasn* (fatty acid synthase), the two representative genes that control lipogenesis [31]. The analyses identified several mitochondrial carrier proteins, including *Slc25a1, Slc25a15* (ornithine carrier), *Slc25a19* (thiamine carrier), *Slc25a20* (carnitine/acylcarnitine carrier), *Slc25a35,* and *Slc25a51* (NAD carrier) (**Figure 1G**). Third, we searched for genes that were induced by lipogenic stimuli, especially synthetic agonists for peroxisome proliferator-activated receptor-gamma (PPARγ), such as troglitazone, rosiglitazone, pioglitazone, and AG035029, in rat adipose tissue (**Supplementary Fig. 2D**). These analyses identified SLC25A1 and SLC25A35 that met the above three criteria (**Figure 1H**). While SLC25A1 is known to export citrate [32-34], SLC25A35 is currently an orphan carrier that is expressed abundantly in adipocyte populations of adipose tissue (**Supplementary Fig. 2E**). At the single-cell resolution, *Slc25a35* is co-expressed with *Acaca* and *Fasn* across all adipocyte populations, with particular enrichment in a population (mAd5) that displays the high lipogenic capacity [35] (**Supplementary Fig. 2F**). These observations motivated us to examine the function of SLC25A35 further.

Although many members of the SLC25 family are expected to localize to the inner mitochondrial membrane (IMM), SLC25A17 resides in peroxisomes, while SLC25A46, SLC25A49, and SLC25A50 localize to the outer mitochondrial membrane (OMM) [36-38]. Hence, we next examined the subcellular localization of SLC25A35 in preadipocytes expressing SLC25A35 with a Flag-tag at its C-terminus (SLC25A35-Flag). High-resolution microscopy revealed that the SLC25A35 protein was expressed selectively in the mitochondria, but the signal did not overlap with the OMM marker TOM20 (**Figure 1I**). Rather, SLC25A35

was localized in the IMM as proteinase K treatment degraded TOM20, whereas SLC25A35 and an IMM-localized protein, ATP5A, remained intact (**Figure 1J**). Additionally, we validated the mitochondrial localization of the SLC25A35 protein in differentiated adipocytes (**Supplementary Fig. 2G**).

SLC25A35 is required for mitochondrial PEP efflux.

To examine the biological role of SLC25A35, we generated inguinal WAT-derived preadipocytes that lacked SLC25A35 (*Slc25a35* KO cells) and control cells by the *Easi*-CRISPR (Efficient additions with ssDNA inserts-CRISPR) system [39] (**Figure 2A**). We then rapidly isolated mitochondria from these cells using Mito-Tag [40], and analyzed their metabolites by liquid chromatography-mass spectrometry (LC-MS) (**Figure 2B, Supplementary Fig. 3A**). We found that *Slc25a35* KO cell-derived mitochondria contained higher levels of several metabolites than control cell-derived mitochondria, including PEP, NAD^+ (detected by positive and negative ion modes), and 1,3-bisphosphoglycerate (BPG) (**Figure 2C, Supplementary Table 1**). In contrast, we did not observe substantial changes in these metabolites at the whole-cell level, whereas *Slc25a35* KO cells exhibited modestly elevated levels of TCA intermediates (malate, citrate, succinate, and isocitrate) compared to control cells (**Figure 2D, Supplementary Table 2**). When mitochondrial metabolites were normalized by whole-cell metabolites to calculate metabolite enrichment in the mitochondria of *Slc25a35* KO cells relative to control cells, we found that PEP was the most enriched metabolite (9.4-fold enrichment) in the mitochondria of *Slc25a35* KO cells (**Figure 2E, Supplementary Table 3**). There was no change in ATP and GTP levels between the two groups. In differentiated adipocytes, we also found that PEP was significantly enriched in *Slc25a35* KO mitochondria, while other metabolites (e.g., succinate or malate) were not enriched (**Supplementary Fig. 3B-D**). These results suggest that elevated PEP levels in *Slc25a35* KO mitochondria reflected mitochondrial accumulation of PEP rather than an overall increase in cellular PEP, while the changes in other metabolites were due to alterations occurring in whole-cell levels.

Next, we performed ^{13}C tracing experiments in isolated mitochondria from control and *Slc25a35* KO cells, in which we incubated the mitochondria with $^{13}C_3$-pyruvate for 5 min, quickly washed them twice, and analyzed labeled metabolites by LC-MS (**Figure 2F**). We found that mitochondria from *Slc25a35* KO cells contained significantly higher levels of M+3 PEP than those from control cells, while there was no difference in M+2 PEP levels between the two (**Figure 2G**). While M+1 PEP was slightly elevated in *Slc25a35* KO cells, M+3 PEP was by far the dominant form in white preadipocyte-derived mitochondria. The accumulation of M+3 PEP in the mitochondria of *Slc25a35* KO cells occurred in a time-dependent manner (**Supplementary Fig. 3E**). These results suggest that the accumulated PEP in the mitochondria is largely derived from M+3 OAA by the action of PC and PCK2, rather than OAA derived through oxidation

of pyruvate in the TCA cycle. Supporting this, we found that pyruvate oxidation in the TCA cycle was largely unchanged in *Slc25a35* KO cells, as there was no difference in ^{13}C-labeled succinate and citrate levels in whole cells (**Supplementary Fig.3F, G**). Similar results were found in isolated mitochondria, where the oxidative TCA cycle activity remained largely unchanged between control and *Slc25a35* KO cells, although a modest reduction in some intermediates, such as M+3 citrate, was seen (**Supplementary Fig. 3H-K**). In addition, we found no differences in PDH phosphorylation, PDH, and PC protein expression between the two groups (**Supplementary Fig. 3L**). Together, the data suggest that SLC25A35 deletion leads to the mitochondrial accumulation of OAA-derived PEP through limiting PEP efflux, rather than resulting from enhanced PC activity or reduced oxidative TCA cycle or PDH activity in the mitochondria.

To test this possibility, we next developed an experimental system to directly measure mitochondrial PEP export (**Figure 2H**). In brief, isolated mitochondria from white preadipocytes were incubated with ^{13}C-pyruvate in media containing malate, succinate, and glutamine to energize the mitochondria. Subsequently, we harvested the incubation media at 15 min, 30 min, 60 min, and 120 min following incubation, in which we detected M+3 PEP in the media. We found that isolated mitochondria actively secreted ^{13}C-labeled PEP in a time-dependent manner. However, mitochondrial PEP export was substantially reduced in *Slc25a35* KO mitochondria (**Figure 2I**). The data suggest that active PEP export from mitochondria requires SLC25A35.

Reconstitution of PEP transport by SLC25A35.

To reconstitute PEP transport by SLC25A35, we developed a cell-free liposome system with purified SLC25A35 protein (**Figure 3A**). In brief, Sf9 cells infected with baculovirus expressing either a SLC25A35-TwinStrep construct or an empty vector (control) were subjected to affinity purification (**Figure 3B**). Purified SLC25A35 protein or control precipitants were subsequently inserted into liposomes. We excluded the background signals from empty liposomes without proteins, as the signal represents non-specific binding to liposome membranes. In the SLC25A35 liposomes preloaded with unlabeled PEP, we observed significantly higher transport of ^{13}C-labeled PEP than in control liposomes (**Figure 3C**). To determine the transport specificity, we next tested ^{13}C-labeled PEP transport in the presence of excess unlabeled PEP as a competitor. We found that ^{13}C-labeled PEP transport into SLC25A35 liposomes was completely blunted, supporting the substrate specificity of SLC25A35 for PEP. This PEP transport was consistently observed at various concentrations of PEP inside and outside the liposomes (**Figure 3D**). Additionally, partial digestion of the proteo-liposomes with proteinase K significantly reduced the PEP transport activity (**Supplementary Figure 4A**).

To further determine the substrate specificity, we next measured the transport of ^{13}C-PEP in SLC25A35 liposomes in the presence of unlabeled OAA, malate, succinate, and fumarate as competitors (**Figure 3E**). While the ^{13}C-PEP uptake was consistently observed in proteo-liposomes containing SLC25A35, there was a modest but significant inhibition of ^{13}C-PEP transport in the presence of OAA, malate, and succinate (**Figure 3F**). On the other hand, an excess amount of fumarate did not block ^{13}C-PEP transport in SLC25A35 liposomes (**Figure 3G**). These results suggest that PEP is a high-affinity substrate for SLC25A35, while other TCA cycle intermediates, such as OAA, malate, and succinate, could be transported via SLC25A35, albeit with lower affinity.

PEP carries a net negative charge under physiological conditions. This raises the possibility that mitochondrial PEP transport is coupled with the proton gradient across the membrane, *i.e.,* mitochondrial membrane potential. To test this, we prepared proteo-liposomes under the condition of pH 3.0 to pH 8.0 to determine the extent to which PEP transport depends on the pH gradient (**Figure 3H**). We found that PEP transport was significantly enhanced at lower pH conditions in proteo-liposomes containing SLC25A35, but not in control liposomes (**Figure 3I**). The data suggest that mitochondrial PEP transport can be facilitated when mitochondrial membrane potential is high.

Structural insights into SLC25A35-mediated PEP transport.

Next, we applied computational simulations to further assess the ability of SLC25A35 to transport PEP as a substrate. There are currently no reported three-dimensional (3D) protein structures for SLC25A35, and its low sequence similarity to other template structures (<30% of identity by BLASTp search) renders homology modeling a less reliable approach. Thus, we utilized the AlphaFold structure [41] of SLC25A35 (AF-Q3KQZ1-F1-model_v4) to evaluate PEP as a substrate. This structure shows overall high confident prediction scores (**Supplementary Fig. 5A**) and resembles a shape that is common to solute carriers, such as a channel-like central cavity formed by six transmembrane alpha helices perpendicular to the inner mitochondrial membrane [42] (**Figure 4A, Supplementary Fig. 5B, C**). In addition, the inner walls of this cavity are lined with polar and basic amino acids, including Y72, Q73, N77, R80, Y124, K127, R175, and R276 (**Figure 4B**).

We next performed induced-fit docking to generate a stable and low-energy interaction between PEP and SLC25A35 in which PEP adopted a conformation that was accommodated by the SLC25A35 central cavity (**Figure 4C, Supplementary Fig. 6A**). At this state, the following interactions were observed: hydrogen bonds and/or salt bridge between the phosphate oxygens of PEP and residues Q73 and R276 of SLC25A35, as well as hydrogen bonds between the carboxylate of PEP and residues R175, Y124, and Y72 of

SLC25A35 (**Figure 4D, Supplementary Fig. 6B**). Subsequently, we performed molecular dynamics (MD) studies considering SLC25A35 orientation at the mitochondrial inner membrane, in the absence and presence of PEP. This allowed us to infer that PEP produces a stable and reproducible complex formation with SLC25A35. The average Root Mean Square Deviation (RMSD) value for the SLC25A35-PEP interaction was 1.73 Å, which is lower than the 2.10 Å observed in the corresponding *apo* simulation (**Supplementary Figure 6C**). Importantly, the average ΔG binding affinity (MMGBSA) estimated for the PEP-SLC25A35 interaction was equal to -26.58 ± 10.53 kcal/mol (**Figure 4E**), and the key interactions were kept throughout trajectories, in particular the hydrogen bonds with R276 and R175 (**Figure 4F, Supplementary Fig. 6D, E**).

To determine the functional requirements of the key residues for PEP transport, we next generated four mutants of SLC25A35 carrying mutations at Y124, R175, R276, and their combination, based on the above structural prediction. Subsequently, we developed proteo-liposomes containing each mutant and tested the involvement of these residues for PEP transport. We found that single SLC25A35 mutants (Y124A, R175A) exhibited similar PEP transport activity to the wild-type form. Unexpectedly, the double mutant (Y124A/R175A) and triple mutant (Y124A/R175A/R276A) showed higher PEP transport than the wild-type form (**Figure 4G, Supplementary Fig. 6F, G**). It is notable that a similar observation has been described for SLC25 carriers, such as the ADP/ATP carrier, where weakening the cytoplasmic salt-bridge network ("gate") by mutating key residues lowers the conformational energy barrier between the cytoplasmic (c) and matrix (m) states, thereby altering the kinetics of substrate access, *i.e.,* "leaky" gate [43]. In reconstituted liposomes, especially under saturating substrate conditions where assays read out Vmax, such gate-loosening substitutions could lead to higher apparent transport than wild-type. Nonetheless, these results support the *in silico* prediction that Y124, R175, and R276 are functionally important for SLC25A35-mediated PEP transport.

PEP transport via SLC25A35 is required for glyceroneogenesis in adipose tissue.

In the cytosolic compartment of adipocytes, PEP can be converted to glyceraldehyde-3-P (GA3P) and dihydroxyacetone phosphate (DHAP), and subsequently glycerol-3-phosphate (G3P). G3P serves as the glycerol backbone necessary for the esterification of fatty acids into glycerolipids, including triglycerides, diglycerides, and phospholipids in adipose tissue and the liver (**Figure 5A**). The synthesis of G3P from pyruvate, a process known as glyceroneogenesis, contributes to the triglyceride pool in adipose tissue and the liver [5,44-48]. Accordingly, we asked the extent to which mitochondria-derived PEP via SLC25A35 contributes to the synthesis of GA3P and DHAP in adipocytes. To this end, we performed $^{13}C_3$-pyruvate tracing experiments in inguinal WAT-derived adipocytes lacking *Slc25a35.* The tracing experiment found

that *Slc25a35* KO cells produced significantly lower levels of ^{13}C-labeled GA3P/DHAP by 77.2% compared to control cells (**Figure 5B**). Note that GA3P and DHAP are isomers with the same molecular weight, and our LC-MS platform does not distinguish between them; thus, the measured signal represents the combined abundance of GA3P and DHAP in these samples. Importantly, deletion of SLC25A35 led to a significant reduction in G3P levels in inguinal WAT-derived differentiated adipocytes as well as in preadipocytes, albeit at lower levels (**Figure 5C**).

To test whether SLC25A35 is required for triglyceride (TG) synthesis in adipocytes, we measured the lipid incorporation of 1-^{14}C-pyruvate, which ensures that labeled G3P cannot be directly synthesized from glucose via glycolysis, and that labeled PEP is generated primarily via carboxylation of pyruvate. We found that *Slc25a35* KO adipocytes exhibited significantly lower incorporation of ^{14}C-labeled pyruvate into lipids compared to control adipocytes, by 27.9 % in the absence of insulin, and by 57.1% following insulin stimulation (**Figure 5D**). Consistent results were observed when using ^{14}C-glucose as a tracer (**Supplementary Fig. 7A**). Importantly, total cellular TG contents in *Slc25a35* KO adipocytes were significantly lower than control adipocytes by 31.2% (**Figure 5E**). We then asked whether the total PEP level within a cell is the rate-limiting step for TG synthesis, or if the origin of PEP (i.e., mitochondrial-derived PEP) is the key element. If the former is the case, overexpression of PCK1 (the cytosolic form) could restore TG levels in *Slc25a35* KO adipocytes. However, we found that PCK1 overexpression was insufficient to restore cellular TG levels in *Slc25a35* KO cells. Consistently, cellular G3P levels were significantly lower in *Slc25a35* KO adipocytes than in control cells, whereas PCK1 overexpression failed to restore cellular G3P levels (**Supplementary Fig. 7B**). We then asked whether SLC25A35 and PCK2 act in the same pathway or independently for glyceroneogenesis by performing $^{13}C_3$-pyruvate tracing in cells lacking *Slc25a35* and *Pck2.* Consistent with the above results, *Slc25a35* KO cells produced significantly lower amounts of ^{13}C-labeled GA3P/DHAP than control cells. Similarly, *Pck2* deletion alone reduced ^{13}C-labeled GA3P/DHAP levels (**Supplementary Fig. 7C**). However, the deletion of *Pck2* did not further attenuate the production of GA3P/DHAP (**Figure 5F**). These results suggest that reduced glyceroneogenesis in *Slc25a35* KO cells depends on mitochondria-derived PEP synthesis by PCK2, rather than the total cellular PEP pool.

White adipose tissue expresses low levels of glycerol kinase that generates G3P from glycerol [49,50]. Thus, G3P synthesis via glyceroneogenesis is considered the primary pathway for fatty acid esterification in adipose tissue [5,44-48] . However, the contribution of mitochondria-derived PEP, as opposed to the cytosolic compartment-derived PEP, to the triglyceride pool remains unclear. In this regard, the identification of SLC25A35 as a mitochondrial PEP exporter enables us to rigorously address this question *in vivo*. Hence,

we generated *Slc25a35*$^{flox/flox}$ mice and subsequently crossed them with *Adipoq*-Cre to develop fat-specific KO mice (Adiponectin-Cre x *Slc25a35*$^{flox/flox}$, herein *Slc25a35*^{Adipo} KO mice) (**Supplementary Fig. 7D**). To minimize the contribution of adaptive thermogenesis by skeletal muscle and BAT, *Slc25a35*^{Adipo} KO mice and littermate control mice (*Slc25a35*$^{flox/flox}$) were kept under a thermoneutral condition (30˚C) on a 60% high-fat diet (HFD) (**Figure 5G**). There was no difference in birth weight between the genotypes; however, male *Slc25a35*^{Adipo} KO mice gained modest but significantly less weight than controls at 18 weeks of age and thereafter (**Figure 5H**). The difference in body weight was primarily due to lower tissue mass of inguinal and epididymal WAT as well as interscapular BAT, but not in the liver or other tissues (**Figure 5I**). Consistently, histological analyses showed that adipocyte size in the interscapular BAT of *Slc25a35*^{Adipo} KO mice was significantly smaller than in control mice (**Figure 5J**). Note that mice were kept at 30˚C for 23 weeks, and thus, the interscapular BAT was composed of unilocular adipocytes [51]. This is notable because previous studies reported active glyceroneogenesis in the BAT of rats that express high levels of PCK2 [52-54]. Similarly, adipocyte size in the inguinal WAT of *Slc25a35*^{Adipo} KO mice was significantly smaller than in control mice (**Supplementary Fig. 7E**). We also found that female *Slc25a35*^{Adipo} KO mice exhibited a consistent metabolic phenotype with male mice on a high-fat diet at 30˚C (**Supplementary Fig. 7F-I**). When mice were on a normal-chow diet (NCD) at room temperature, there was no difference in body weight (**Supplementary Fig. 7J, K**).

The pyruvate-PEP cycle is suggested to be a "futile" thermogenic pathway [55]. However, our data suggest that SLC25A35 in adipose tissue is dispensable for activation of thermogenesis because *Slc25a35*^{Adipo} KO mice could elevate their whole-body energy expenditure at an equivalent level to littermate control mice in response to a β3-adrenergic receptor agonist CL316,243 at 30˚C (**Supplementary Fig. 8A**). Furthermore, whole-body energy expenditure of *Slc25a35*^{Adipo} KO mice was comparable to control mice at 30˚C (**Supplementary Fig. 8B**). During the metabolic cage analysis, there were no differences in food intake and locomotor activities between the two groups (**Supplementary Fig. 8C, D**). In addition, we found no difference in adipose tissue lipolysis and glucose oxidation between the genotypes (**Supplementary Fig. 8E-G**). However, we found a significant difference in glycerolipid synthesis in the adipose tissue. To determine ^{14}C glucose incorporation into the glycerol backbone of glycerolipids in adipose tissue, we used saponification of the lipids extracted from adipose tissues followed by the periodic acid–Schiff staining and thin-layer chromatography (PAS–TLC) [56]. We found that the inguinal WAT from *Slc25a35*^{Adipo} KO mice exhibited significantly lower ^{14}C-glucose incorporation into the glycerol backbone of glycerolipids than in control mice in the absence and presence of insulin (**Figure 5K**). Similarly, the epididymal WAT of *Slc25a35*^{Adipo} KO mice showed significantly lower ^{14}C incorporation into the glycerol backbone of lipids than control mice, both at a basal state and following insulin stimulation (**Figure 5L**). Taken together, these

results suggest that mitochondrial PEP export into the cytosolic compartment via SLC25A35 contributes to glycerolipid synthesis in adipose tissue.

Blockade of mitochondrial PEP export ameliorates hepatic steatosis *in vivo.*

Approximately 50% or more of the fatty acids taken up by the liver are re-esterified into triglycerides and released as very low-density lipoproteins (VLDL); a disruption of this process leads to metabolic dysfunction-associated steatotic liver disease (MASLD) [57,58]. Previous studies have shown that glyceroneogenesis plays a key role in triglyceride synthesis in the liver of both rats and humans, particularly during prolonged fasting [59,60]. Additionally, glyceroneogenesis seems to contribute to VLDL triglycerides in individuals with Type 2 diabetes [61]. However, the contribution of mitochondria-derived PEP to glyceroneogenesis in the liver and its impact on the pathogenesis of hepatic steatosis remain unknown. Notably, data analyses of publicly available transcriptomics revealed a modest but significant upregulation of *SLC25A35* in the human liver with MASLD relative to those in healthy subjects (**Figure 6A**). Similarly, higher *Slc25a35* mRNA levels were found in the liver of mice on a high-fat diet (HFD) than those on a normal-chow diet (NCD) (**Figure 6B**). Consistent with the results in adipocytes, we found that SLC25A35 loss in hepatocytes leads to the accumulation of PEP in the mitochondria, suggesting that SLC25A35 also plays a role in mitochondrial PEP export and glycerolipid synthesis in the liver (**Supplementary Fig. 9A**). Hence, we examined the extent to which liver-specific blockade of SLC25A35 prevents the pathogenesis of diet-induced hepatic steatosis. To this end, we developed mice that lacked *Slc25a35* in a liver-specific fashion by crossing *Slc25a35*$^{flox/flox}$ mice with *Alb*-Cre (Alb-Cre x *Slc25a35*$^{flox/flox}$, herein *Slc25a35*^{Liver} KO mice) (**Supplementary Fig. 9B**). When mice were housed at 30 ˚C on a high-fat diet, *Slc25a35*^{Liver} KO mice showed a modest trend of lower body weight than littermate control mice (*Slc25a35*$^{flox/flox}$ mice), although there was no significant difference between the genotypes (**Figure 6C**). At the tissue level, the liver weight of *Slc25a35*^{Liver} KO mice was significantly lower than that of control mice, while no difference was observed in other organs (**Supplementary Fig. 9C**). Histological analysis by hematoxylin and eosin (H&E) staining revealed that the liver of *Slc25a35*^{Liver} KO mice displayed reduced lipid droplet area compared to that of control mice (**Figure 6D**). Quantitative assays revealed significantly lower levels of triglycerides in the livers of *Slc25a35*^{Liver} KO mice compared to control mice (**Figure 6E**). Furthermore, glycerol levels in the serum and liver of SLC25A35Liver KO mice were significantly lower than those of control mice (**Figure 6F, G**). Importantly, lipidomics analyses of the liver identified several lipid species that were lower in *Slc25a35*^{Liver} KO mice than in control, including triglycerides (TG), diacylglycerol (DG) (16:1_20:4), phosphatidylcholine (PC) (18:0_22:5), phosphatidylinositol (PI), and ceramides (**Figure 6H, Supplementary Table 4**). These changes in hepatic lipid content were accompanied by a reduced

inflammatory profile in the liver. Supporting this, histological analysis by immunostaining for macrophage marker (F4/80) found significantly less macrophage infiltration in the liver of liver-specific SLC25A35 KO mice than that in control mice (**Figure 6I**). Consistently, the liver of *Slc25a35*^{Liver} KO mice expressed significantly lower levels of genes involved in inflammation than that of control mice (**Supplementary Fig. 9D**).

The reduction of triglycerides and reduced inflammation in the liver is associated with improved systemic glucose homeostasis [62-66]. Thus, we next determined the extent to which liver-specific deletion of SLC25A35 protects mice from diet-induced insulin resistance. At 18 weeks of high-fat diet feeding, *Slc25a35*^{Liver} KO mice were more insulin sensitive than littermate controls, as shown by the insulin tolerance test (ITT) (**Figure 6J**). Similarly, pyruvate tolerance tests (PTT) at 17 weeks of high-fat diet showed that hepatic gluconeogenesis was significantly lower in *Slc25a35*^{Liver} KO mice than littermate control mice (**Supplementary Fig. 9E**). We then examined the extent to which SLC25A35 is required for gluconeogenesis. To this end, we used ^{13}C pyruvate as a tracer to measure ^{13}C glucose production in the conditioned media of cultured primary hepatocytes. Glucagon increased the release of ^{13}C-labeled glucose, validating this assay system for measuring gluconeogenesis. We found that *Slc25a35* KO hepatocytes generated similar levels of ^{13}C-labeled glucose to control hepatocytes (**Supplementary Fig. 9F**). The data suggest that mitochondrial PEP via SLC25A35 has an essential role in glycerolipid synthesis, while it has a minimal contribution to gluconeogenesis in the liver. The data also suggest that the improved pyruvate tolerance in *Slc25a35*^{Liver} KO mice would be a result of reduced TG and inflammation in the liver.

Lastly, we explored the therapeutic potential of blocking SLC25A35-mediated lipogenesis by determining the extent to which inducible depletion of SLC25A35 in obese mice ameliorates hepatic steatosis. Since tamoxifen can cause hepatic triacylglycerol accumulation and impaired mitochondrial β-oxidation in mouse liver [67,68], we chose to use AAV-Cre instead of developing *Alb*-Cre^{ERT2} model for the inducible depletion of *Slc25a35* in the liver. To this end, we acutely depleted SLC25A35 by delivering AAV8-TBG-iCre or AAV8-TBG-null (control) into the liver of *Slc25a35*$^{flox/flox}$ mice fed on a high-fat diet for 8 weeks at 30˚C (**Figure 6K**). At 10 weeks after AAV administration, delivery of AAV-Cre administration via tail-vein effectively reduced *Slc25a35* mRNA expression by over 90% (**Supplementary Fig. 10A**). Inducible depletion of SLC25A35 did not affect body weight (**Supplementary Fig. 10B**). Nonetheless, we found that inducible SLC25A35 depletion led to a significant reduction in hepatic triglyceride contents by 33.4% (**Figure 6L**). Consistent with the Alb-Cre cohort, liver lipidomics showed that other lipid species, including diacylglycerides, phosphatidylglycerol (PG), and phosphatidic acid (PA) (16:0_18:1), were also decreased in *Slc25a35* AAV-KO^{Liver} mice (**Supplementary Fig. 10C, Supplementary Table 5**). Histological

analyses showed that the liver of inducible *Slc25a35* KO mice displayed reduced lipid droplet area than the control liver (**Figure 6M, Supplementary Fig. 10D**). Lastly, serum levels of ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase), which are liver damage markers, were significantly reduced in *Slc25a35* AAV-KO^{Liver} mice compared with control mice (**Figure 6N**). We also found no difference in the hepatic expression of mitochondrial stress markers, including *Fgf21*, *Gdf15*, *Atf5*, and *Trib3,* between *Slc25a35* AAV-KO^{Liver} mice and control mice, although *Atf4* expression was modestly increased in AAV-KO^{Liver} mice (**Supplementary Fig. 10E**). These results indicate that inducible blockade of SLC25A35 alleviates hepatic steatosis and liver damage while avoiding mitochondrial stress under an obese condition. Together, SLC25A35 blockade in the liver by two complementary approaches, Alb-Cre–mediated deletion and AAV-Cre–induced depletion, effectively ameliorated obesity-associated hepatic steatosis *in vivo*.

DISCUSSION

Glyceroneogenesis is essential for generating glycerol-3-phosphate (G3P), the backbone required to esterify fatty acids into neutral triglycerides. By promoting fatty acid esterification and triglyceride storage, this pathway protects cells from lipotoxicity. When G3P accumulates in excess, Glycerol-3-Phosphate Phosphatase (G3PP) converts it to glycerol, thereby buffering the intracellular G3P pool, referred to as the glycerol shunt [4,69]. In turn, chronic overactivation of glyceroneogenesis drives hepatic lipid overload, inflammation, and fibrosis, ultimately contributing to MASLD [57,58]. Excess triglyceride accumulation in the liver is also a leading driver of insulin resistance and Type 2 diabetes [70,71]. The present study identifies SLC25A35 as a critical gatekeeper of PEP transport across the IMM that provides a key substrate for the synthesis of G3P and glycerolipids, including triglycerides (**Figure 7**). In lipogenic states, as elicited by PPARγ agonists, high-fat diet feeding, or thermoneutrality, SLC25A35 expression parallels that of key lipogenic enzymes, such as acetyl-CoA carboxylase and fatty acid synthase. We found that blockade of SLC25A35 effectively reduced the synthesis of pyruvate-derived G3P and glycerolipids in adipose tissue and the liver while preserving substrate oxidation in the TCA cycle. Significantly, inducible depletion of SLC25A35 effectively alleviated hepatic steatosis without inducing liver damage. Together, this study offers SLC25A35 as a promising target to selectively limit excess fatty acid esterification and triglyceride synthesis, which are hallmarks of hepatic steatosis and insulin resistance.

It is worth noting that PEP transport via SLC25A35 is pH gradient-dependent (see proteo-liposome study in Figure 3). The results suggest that mitochondrial PEP export into the cytosolic compartment can be facilitated when mitochondrial membrane potential is high, positioning SLC25A35-mediated PEP export as a metabolic checkpoint that coordinates mitochondrial energetic status with glycerolipid synthesis

(**Figure 7**). In this regard, thermoneutrality (housing at 30˚C), which attenuates mitochondrial proton uncoupling via UCP1, may facilitate the export of mitochondria-derived PEP and glycerolipid synthesis. Similarly, in the liver under an obese condition, excess substrate entry to the TCA cycle may accelerate PEP export and glycerolipid synthesis. It is worth noting that thermoneutrality housing and a high-fat diet promote lipogenesis in the liver and MASLD, which is also accompanied by the upregulation of lipogenic genes [72,73]. Our future study will test if *in vivo* manipulation of the membrane potential, such as liver-selective mitochondrial uncoupler [74,75], can limit mitochondrial PEP export and glycerolipid synthesis. Another important insight is the biological role of mitochondria-derived PEP via PCK2, even though PCK1 can catalyze the same reaction to generate PEP in the cytosolic compartment. We found that PCK1 overexpression was insufficient to restore TG synthesis in SLC25A35 KO adipocytes, indicating that the origin of PEP (*i.e.,* mitochondria-derived) is the crucial element, rather than its overall levels within a cell. Kibbey and colleagues proposed that PCK2 provides an efficient pathway to generate PEP because the PCK2 pathway requires fewer enzymatic reactions and metabolite transport [25,29]. Moreover, the availability of GTP – from the conversion of succinyl-CoA to succinate in the TCA cycle – is suitable for the GTP-consuming reaction by PCK2. An alternative possibility is the role of this pathway in a specialized subset of mitochondria — those in close contact with lipid droplets, *a.k.a.,* peridroplet mitochondria in adipocytes and hepatocytes [76-78]. Notably, the proteomic analyses of BAT mitochondria-associated lipid droplet proteins detected SLC25A35 and PCK2 at high levels [79,80]. In the liver, peridroplet mitochondria were observed during an early stage of hepatic steatosis [81]. Thus, peridroplet mitochondria expressing SLC25A35 are suited for providing not only ATP and citrate for fatty acid synthesis via SLC25A1 (citrate carrier), but also PEP for G3P generation to support triglyceride synthesis in adjacent lipid droplets. By targeting these "lipogenic mitochondria," through SLC25A35, it is possible to selectively suppress fatty acid esterification in individuals with MASLD while preserving substrate oxidation in the TCA cycle.

Limitations of the present work: The present study is limited to adipocytes and the liver. However, it is conceivable that mitochondrial PEP transport through SLC25A35 underpins additional physiological processes. For example, the glucose-induced PEP cycle in pancreatic beta cells, wherein mitochondria-derived PEP is consumed by pyruvate kinase (PK) to generate ATP in the cytosol, leads to the closure of the K_{ATP} channel and enhanced insulin secretion [6,8-13]. Additionally, several cancer cells, such as non-small cell lung carcinoma and breast cancer, express high levels of PCK2, which controls mitochondrial PEP synthesis and tumor cell growth under low-glucose conditions [82-86]. Future research is needed to investigate how mitochondrial PEP dynamics influence metabolic diseases, β-cell function, and cancer metabolism.

ACKNOWLEDGMENTS
We are grateful to Anthony R.P. Verkerke, Ichitaro Abe, Christopher Auger, Jake Wong, Risa Waki, Hiroko Oda, and Kazusa Miyachi for their technical support. We also thank Drs. Bo Yuan and Tony Hui of the Harvard Chan Advanced Multi-Omics Platform for lipidomics, John Asara and the BIDMC mass spectrometry core facility for metabolomics, Evan Rosen at Beth Israel Deaconess Medical Center for sharing Adiponectin-Cre mice, Alexander Banks at Beth Israel Deaconess Medical Center for his support in metabolic cage studies, Suzanne L White at Beth Israel Deaconess Medical Center for her support in tissue histology study. We are also grateful for the discussion with Dr. Marc Prentki at Université de Montréal. This work was supported by grants from the National Institutes of Health (NIH) (DK125283, DK097441, and DK126160) and Howard Hughes Medical Institute to S.K. T.Y. was supported by the Nakatomi Foundation, the Yamada Science Foundation, the Takeda Science Foundation, and the American Heart Association postdoctoral fellowship (24POST1193689). D.K. was supported by the Manpei Suzuki Diabetes Foundation and the Japan Society for the Promotion of Science (JSPS). S.O. was supported by JSPS and the Uehara Memorial Foundation. Y.H. was supported by JSPS and the Sunstar Foundation. H.N. was supported by JSPS and the Uehara Memorial Foundation. M.F. was supported by the Manpei Suzuki Diabetes Foundation and the Kowa Life Science Foundation. N.Y. was supported by JSPS. J.S. was supported by the Manpei Suzuki Diabetes Foundation.

AUTHORS CONTRIBUTION
Conceptualization, T.Y., S.K.; methodology, T.Y., D.K., G.M.S., S.O., Y.H., D.W., and N.Y.; investigation, T.Y., D.K., G.M.S., S.O., Y.H., D.W., H.N., N.Y., M. L., J.S., Z.Z., and J. -S. Y.; validation, T.Y., D.K., G.M.S., and Y.H.; formal analysis, T.Y., G.M.S., and M.F.; writing – original draft, T.Y., G.M.S., and S.K.; writing – review and editing, T.Y., G.M.S., and S.K.; funding acquisition, L.S. and S.K.; supervision, L.S. and S.K.

DECLARATION OF INTERESTS
The authors declare no competing interests.

METHODS

Animals: All of the animal experiments in this study were performed in compliance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Beth Israel Deaconess Medical Center. Unless otherwise specified, all of the mice had free access to food and water, and were housed under 12 h–12 h light–dark cycle, at 22 °C, and 45% humidity on average. Heterozygous *Slc25a35*-floxed mice in the C57BL/6J background were generated by the *Easi*-CRISPR technology [39]. Adipocyte-specific *Slc25a35* KO mice (*Slc25a35*^{Adipo} KO) and liver-specific *Slc25a35* KO mice (*Slc25a35*^{Liver} KO) were developed by crossing *Slc25a35*-floxed mice with Adiponectin-Cre mice (B6; FVB-Tg (Adipoq-Cre)1Evdr/J, 028020) and Albumin-Cre mice (B6.Cg-*Speer6-ps1*$^{Tg(Alb\text{-}cre)21Mgn}$/J, 003574), respectively. A list of the primer sequences used for genotyping and gRNA is provided in **Supplementary Table 6**.

Cells: The stromal vascular fraction (SVF) preadipocytes from the inguinal WAT of C57BL/6J mice and *Slc25a35*-floxed mice were immortalized by expressing the SV40 large T antigen as described previously [87]. For the generation of control and *Slc25a35*-KO cells, immortalized *Slc25a35*$^{flox/flox}$ preadipocytes were infected with empty and Cre-expressing (34565, Addgene) retrovirus, followed by hygromycin (10687010, Thermo Fisher Scientific) selection at a dose of 200 μg ml^{-1}, respectively. For the generation of *Slc25a35*-Flag–expressing cells, immortalized wild-type preadipocytes were infected with *Slc25a35*-Flag–expressing retrovirus, followed by blasticidin selection at a dose of 10 μg ml^{-1}. For the generation of control, *Pck1*- and *Pck2*-depleted cells, immortalized preadipocytes were infected with an eSpCas9-LentiCRISPR v2 lentivirus with scrambled control, mouse *Pck1*, and mouse *Pck2* sgRNAs, followed by blasticidin selection at a dose of 10 μg ml^{-1}, respectively. Unless otherwise specified, all of the cells were cultured in high-glucose DMEM containing 10% FBS, 1% penicillin–streptomycin, and 1% GlutaMAX™ at 37°C with 5% CO_2. White adipocyte differentiation was induced in high-glucose DMEM containing 10% FBS, 1% penicillin–streptomycin, 1% GlutaMAX™, 5 μg ml^{-1} insulin, 1 nM T3, 1 μM rosiglitazone, 0.5 mM isobutylmethylxanthine, 125 nM indomethacin, and 2 μg ml^{-1} dexamethasone. After 48 h, cells were cultured in high-glucose DMEM containing 10% FBS, 1% penicillin–streptomycin, 1% GlutaMAX™, 5 μg ml^{-1} insulin, 1 nM T3, and 1 μM rosiglitazone for another four days [88]. Brown adipocyte differentiation was induced in high-glucose DMEM containing 10% FBS, 1% penicillin–streptomycin, 1% GlutaMAX™, 0.5 μg ml^{-1} insulin, 1 nM T3, 0.5 mM isobutylmethylxanthine, 125 nM indomethacin, and 2 μg ml^{-1} dexamethasone. After 48 h, cells were cultured in high-glucose DMEM containing 10% FBS, 1% penicillin–streptomycin, 1% GlutaMAX™, 0.5 μg ml^{-1} insulin, and 1 nM T3 for another two days.

DNA constructs, Antibodies, and Viruses: Mouse *Slc25a35* cDNA constructs were amplified from mouse inguinal WAT and inserted into a blasticidin-resistant pMSCV vector (75085, Addgene). Mouse *Pck1* cDNA constructs were amplified from mouse liver and inserted into a blasticidin-resistant pMSCV vector. The sgRNA sequences for scrambled control, mouse *Pck1* #1, mouse *Pck1* #2, mouse *Pck2* #1, and mouse *Pck2* #2 were inserted into a blasticidin-resistant eSpCas9-LentiCRISPR v2, which was generated by replacing the puromycin resistance cassette of the original eSpCas9-LentiCRISPR v2 (GenScript) with a blasticidin resistance cassette. An empty, hygromycin-resistant pMSCV vector was generated by removing the Cre insert from the Cre-expressing pMSCV (Addgene #34565). A list of the sgRNA sequences used in the study is provided in **Supplementary Table 6**. All of the constructs were confirmed by sequencing.
The following antibodies were used in this study: anti-SLC25A35 (NBP2-85742, Novus Biologicals), anti-PEPCK1 (10004943, Cayman), anti-PEPCK2 (GTX114919, Genetex), anti-TOM20 (11802-1-AP, Proteintech), anti-ATP5A (ab14748, Abcam), anti-Citrate Synthase (sc-390693, Santa Cruz), anti-Calreticulin (12238S, Cell Signaling Technology), anti-PEX14 (ABC142, Sigma-Aldrich), anti-EEA1 (2411S, Cell Signaling Technology), anti-GM130 (610822, BD Biosciences), anti-GAPDH (GTX100118, Genetex), anti-Histone H3 (sc-517576, Santa Cruz), anti-PDH (2784S, Cell Signaling Technology), anti-phospho-PDH α1 (Ser293) (37115S, Cell Signaling Technology), anti-Pyruvate Carboxylase (16588-1-AP,

Proteintech), anti-F4/80 (70076S, Cell Signaling Technology), anti-Vinculin (66305-1-IG, Proteintech), anti-Flag (8146S, Cell Signaling Technology), anti-β-actin (A3854, Sigma-Aldrich), Strep-Tactin HRP conjugate (21502001, IBA), goat anti-rabbit light chain HRP-conjugated antibody (NBP2-75935, Novus), goat anti-mouse light chain HRP-conjugated antibody (91196S, Cell Signaling Technology), Alexa Fluor 488 (ab150117, Abcam), Alexa Fluor 555 (ab150062, Abcam), and Alexa Fluor 647 (A21245, Invitrogen). For retrovirus production, HEK293T packaging cells were transfected with 10 µg of retroviral transfer plasmids and 10 µg of packaging plasmids (gag-pol and pMD2.G) using Lipofectamine 3000. After 48 hours, the culture medium was collected and filtered using a 0.45 µm filter. Inguinal WAT-derived SVF cells were incubated in the four-times diluted viral medium supplemented with 10 µg ml^{-1} polybrene for 24 hours. For lentivirus production, HEK293T packaging cells were transfected with 10 µg of lentiviral transfer plasmids and 10 µg of packaging plasmids (psPAX2 and pMD2.G) using Lipofectamine 3000. After 48 hours, the culture medium was collected and filtered using a 0.45 µm filter. Inguinal WAT-derived SVF cells were incubated in the four-times diluted viral medium supplemented with 10 µg ml^{-1} polybrene for 24 hours.

Mitochondrial Isolation and Metabolomics: Following the established protocol [89,90], mitochondria were immunoprecipitated from SVF preadipocytes. In 150 mm cell culture dishes of SVF preadipocytes that express a MITO-Tag construct [40] (3xHA-EGFP-OMP25, 83356**,** Addgene), cells were washed twice with PBS. Cells were then scraped with KPBS (136 mM KCl, 10 mM KH2PO4, pH 7.25). Cells were pelleted by 1000 x g for 2 min at 4°C, and were resuspended in 1 mL of KPBS. One-tenth of cells was extracted directly into 80% MeOH as a whole-cell fraction. The remaining cells were homogenized with Teflon pestle and glass tube, and were centrifuged at 1000 x g for 2 min at 4°C. The supernatant was added to magnetic anti-HA beads (Pierce, 88836), and was rotated for 4 min at 4°C. The beads were collected for 1 min on a magnetic rack. The supernatant was aspirated and beads were washed three times with KPBS. After beads were washed, 80% MeOH was added to extract metabolites and the samples were stored at -80°C overnight. The samples were vortexed for 1 min and then centrifuged at 21000 x g for 10 min at 4°C. The supernatant was then transferred to a clean tube and was dried via a speed vac system. Dried metabolites were stored at -80°C for up to 1 week until resuspension in LC-MS grade H_2O for the following LC-MS analysis. The samples were analyzed on a 5500 QTRAP hybrid triple quad quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) with selected reaction monitoring (SRM) with positive/negative polarity switch. Peak areas were integrated using a Multi-Quant 2.1 software. The intensities were normalized to protein levels measured by a BCA assay. To minimize technical variance, values from *Slc25a35* KO cells were divided by those from the corresponding control cells within each individual sample. The data were analyzed using MetaboAnalyst. Missing values were estimated using the K-nearest neighbor (KNN) algorithm. Non-informative variables were filtered based on the interquartile range, with a 10% cutoff.

For differentiated adipocytes, cells cultured in a 150-mm dish were washed twice with ice-cold PBS and scraped into KPBS buffer (136 mM KCl, 10 mM KH_2PO_4, pH 7.25). The cell suspension was centrifuged at 1,000 × g for 2 min at 4°C, and the pellet was resuspended in 1 mL of KPBS. One-tenth of the cells were lysed in 80% methanol for whole-cell metabolomics analysis, and an aliquot was used for protein quantification by a BCA assay. The remaining cells were homogenized using a Teflon pestle and glass tube, followed by centrifugation at 600 × g for 5 min at 4°C. The supernatant was then centrifuged at 7,000 × g for 10 min at 4°C to isolate mitochondria. The resulting mitochondrial pellets were lysed in 80% methanol for metabolomics analysis, and an aliquot was used for protein quantification by a BCA assay. Metabolomics data were acquired using a UHPLC system (Vanquish Horizon, Thermo Scientific) coupled to an orbitrap mass spectrometer (Exploris 240, Thermo Scientific) as described previously [90]. Waters ACQUITY UPLC BEH Amide column (particle size, 1.7 µm; 100mm (length) × 2.1mm (i.d.)) was used for LC separation. The column temperature was kept at 25 °C. Mobile phases A = 25mM ammonium acetate and 25mM ammonium hydroxide in 100% water, and B = 100% acetonitrile, were used for negative mode. The linear gradient eluted from 95% B (0.0–1 min), 95% B to 65% B (1–7.0 min), 65% B to 40% B (7.0–

8.0 min), 40% B (8.0–9.0 min), 40% B to 95% B (9.0–9.1 min), then stayed at 95% B for 5.9 min. The flow rate was 0.4 mL/min. The sample injection volume was 2 μL for cell and 5 μL for media. ESI source parameters were set as follows: spray voltage, 3500 V or −2800 V, in positive or negative modes, respectively; vaporizer temperature, 350 °C; sheath gas, 50 arb; aux gas, 10 arb; ion transfer tube temperature, 325 °C. The full scan was set as: orbitrap resolution, 60,000; maximum injection time, 100 ms; scan range, 70–1050 Da. The ddMS2 scan was set as: orbitrap resolution, 30,000; maximum injection time, 60 ms; top N setting, 6; isolation width, 1.0 m/z; HCD collision energy (%), 30; Dynamic exclusion mode was set as auto. Metabolite peak areas were quantified using TraceFinder software.

Metabolite Tracing: For whole-cell tracing, cells were incubated in high-glucose DMEM with 10 mM fully ^{13}C-labeled pyruvate (Cambridge Isotope Laboratories, CLM-2440) at 37°C for one hour. Cells were washed in ice-cold PBS twice and were lysed in 80% MeOH. After one-hour incubation at -80°C, the supernatant was collected for metabolomics. For mitochondria tracing, cells in a 150 mm cell culture dish were washed in ice-cold PBS twice, and were scraped with KPBS (136 mM KCl, 10 mM KH_2PO_4, pH 7.25). Cells were pelleted by 1000 x g for 2 min at 4°C, and were resuspended in 1 mL of KPBS. Cells were homogenized with Teflon pestle and glass tube, and were centrifuged by 600 x g for 5 min at 4°C. The supernatant was centrifuged by 7,000 x g for 10 min at 4°C. The resultant pellets were incubated in KPBS with fully ^{13}C-labeled pyruvate for the indicated time at 4°C and were washed two times with KPBS. The pellets were lysed in 80% MeOH and were stored at -80°C for the following metabolomics.

Metabolomics data were acquired using the same UHPLC settings as those used for differentiated adipocytes. The labeling metabolomics was quantified by a FreeStyle 1.8 SP2 or Compound Discoverer 3.3. The annotation of metabolites was performed by searching the retention time and MS2 against our in-house library which was generated using the Mass Spectrometry Metabolite Library (MSMLS™) (IROA Technologies LLC®, Bolton, MA, USA). Labeling rate was calculated by dividing the level of labeled metabolites by the total metabolite level. An additive log-ratio (ALR) transformation using M+0 as the denominator was applied to analyze compositional data.

Mitochondrial PEP Export Assay: Cells in a 150 mm cell culture dish were washed in ice-cold PBS twice, and were scraped with KPBS (136 mM KCl, 10 mM KH_2PO_4, pH 7.25). Cells were pelleted by 1000 x g for 2 min at 4°C, and were resuspended in 1 mL of KPBS. Cells were homogenized with Teflon pestle and glass tube, and were centrifuged by 600 x g for 5 min at 4°C. The supernatant was centrifuged by 7,000 x g for 10 min at 4°C. The resultant pellets were incubated in KPBS with 10 mM fully ^{13}C-labeled pyruvate, 10 mM glutamate, 2 mM malate, and 10 mM succinate for the indicated time at 4°C and were centrifuged by 21,000 x g for 10 min at 4°C. The supernatant was added with MeOH to make the final concentration 80% for the following LC-MS analysis to detect $^{13}C_3$-labeled PEP. The protein concentration in the pellets was determined by a BCA assay for normalization.

Protein expression and purification: Sf9 cells (11496015, Thermo Fisher Scientific) were cultured in Sf-900 II SFM (10902088, Thermo Fisher Scientific) with 10% FBS, 1% penicillin–streptomycin, and 1% GlutaMAX™ at 27°C without CO_2. Baculovirus packaging and amplification were performed based on the commercial protocol for a Bac-to-Bac C-His TOPO Expression System (A11100, Thermo Fisher Scientific). In brief, codon-optimized c-terminally Twin-Strep-tagged *Slc25a35* cDNA was synthesized in Integrated DNA Technologies and was inserted into a pFastBac TOPO vector. The vector was transformed into DH10Bac *Escherichia coli* competent cells to form a bacmid. The bacmid was transfected into Sf9 cells using an ExpiFectamine Sf Transfection Reagent for the production of recombinant baculovirus particles (P0 virus). P0 virus was infected into Sf9 cells to generate P1 virus, which was further infected into Sf9 cells to generate high-titer P2 virus. For protein purification, Sf9 cells in 200 ml of medium were infected with P2 virus and 72-120 hours later collected by a centrifugation. Cells were homogenized with Teflon pestle and glass tube, and were centrifuged by 600 x g for 5 min at 4°C. The supernatant was centrifuged

by 10,000 x g for 10 min at 4°C. The resultant pellets were stored at −80 °C. The pellets were lysed in W buffer (IBA, 2-1003-100) with 2% Triton X-100 and a protease inhibitor cocktail (Roche) and were rotated at 4°C for 2 hours. The lysate was centrifuged at 21,000 rpm for 5 min and the supernatant was rotated with a Strep-TactinXT 4Flow high capacity resin (IBA, 2-5030-010) at 4°C for 3 hours. The resin was washed five times with W buffer containing 2% Triton X-100 and a protease inhibitor cocktail, followed by four rounds of rotation in BXT buffer (IBA, 2-1042-025) supplemented with 2% Triton X-100 and a protease inhibitor cocktail at 4°C for a total of 2 hours to purify the protein. For SLC25A35 mutant analysis, the codons TAT, AGA, and CGT were mutated to GCC to generate the Y124A, R175A, and R276A mutants, respectively, using an In-Fusion Cloning kit (Takara Bio).

Proteoliposomes: To prepare liposomes, 100 mg of the lipids (Egg PC, E coli Polar lipids, 18:1 Cardiolipin at 4:4.2:9 ratio) in 10 ml of chloroform was incubated in a rotary evaporator at 100 rpm at 50°C overnight. The lipid film on the internal surface of the flask was rehydrated with 2 ml of PIPES buffer (10 mM PIPES, 50 mM NaCl, pH 7.0) containing 20 mM unlabeled PEP. The liposomes were extruded 15 times using a mini-extruder with a 200-nm pore membrane at 60°C. Extruded liposomes were rotated with a purified SLC25A35 protein or background proteins (purified from empty virus-infected cells) at 4°C for 1 hour. Proteo-liposomes were rotated with Bio-Beads SM-2 five times to completely remove triton X-100. The resultant proteo-liposomes were isolated on a PD-10 desalting column to remove the external substrates, and were centrifuged at 100,000 rpm for 10 min. Proteo-liposomes were incubated with 5 mM of $^{13}C_2$-labeled PEP (Cambridge Isotope Laboratories, CLM-3398) in PIPES buffer at 37°C for 20 min, and centrifuged at 100,000 rpm for 5 min. The pellet was washed twice with PIPES buffer, each followed by centrifugation at 100,000 rpm for 5 min. The final pellet was lysed in 80% MeOH for the following LC/MS analysis to detect $^{13}C_2$-labeled PEP. To mimic more physiological conditions, liposomes were loaded with 4 mM or 10 mM non-labeled PEP and then incubated with 1 mM or 2.5 mM $^{13}C_2$-labeled PEP to evaluate PEP transport. For proteinase K assay, the liposomes were treated with or without 50 μ g/mL of proteinase K in PIPES buffer at 4°C for 10 min prior to the transport assay. To exclude non-specific signals, liposomes without reconstituted proteins were subjected to the same transport assay, and the average background signal was subtracted from the values obtained with control and SLC25A35 proteoliposomes, although the background signal itself was very low.

***In silico* Structural Studies:** The AlphaFold 2.0 structure of SLC25A35 was retrieved from AlphaFoldDB (https://alphafold.ebi.ac.uk/) under the code: AF-Q3KQZ1-F1-model_v4. All figures were generated using Pymol 3.0.2. The AlphaFold structure was submitted to the Protein Preparation Workflow on Maestro, by Schrodinger (Suite 2024-2), to re-assign bond orders using CCD (Chemical Component Dictionary) database, add/replace hydrogens, fill in missing side chains, generate disulfide bonds, optimize hydrogen bonds with PROPKA, and perform restrained minimization to 0.30 Å root-mean-square deviation (RMSD) using the OPLS4 force field.

Phosphoenolpyruvate (PEP) canonical SMILES string was retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov/) CID 1005. Ligprep was used in default settings to convert the SMILES string to 3D structure and minimize it to a most energetically favorable conformation, considering Epik pH = 7.0 ± 2.0, up to 32 tautomer/stereoisomers, and OPLS4 force field.

For docking studies, the Schrodinger's module Receptor Grid Generation was used to specify the ligand binding site based on the volume of the prioritized Sitemap pocket 1 within the SLC25A35 central channel. This grid corresponds to 20 and 10 Å of outer and inner enclosed boxes, respectively, and the centroid coordinates of x = 5.09, y = 2.07, and z = -2.02. This binding site was used to run PEP docking by using default parameters and up to 10 poses generation with both GlideSP and GlideXP scoring functions. The poses generated were submitted to the Molecular Mechanics with Generalized Born and Surface Area (MMGBSA) solvation module from Schrodinger's Prime to estimate binding free energy ΔG values in kcal/mol. The best pose (lowest ΔG) was then used as reference for conducting Induced-Fit Docking (IFD),

by considering default settings and up to 20 poses generation per molecule. The resulting IFD poses were again rescored through Prime MMGBSA and clustered by visual inspection in groups with matching poses (orientation + conformation). The most populated group consisted of 12 matching poses. From this, the pose with the lowest ΔG free energy value, in kcal/mol, was selected as the most representative SLC25A35-PEP docking complex.

Molecular dynamics (MD) simulation studies: MD simulations were performed for the *apo* AlphaFold prepared structure of SLC25A35, as well as those in complex/docked to the ligand PEP. Desmond's System Builder was used to prepare each system comprising the *apo* protein or the protein-ligand complex. These were solvated with water TIP3P solvent model and neutralized with addition of ions and buffer NaCl at 0.15 M. The OPM webserver (https://opm.phar.umich.edu/) was used to obtain a mitochondrial inner membrane orientation model (POPC at 300 K) for the SLC25A35 prepared structures. Also, we considered orthorhombic boxes with minimized volumes, keeping each side distanced by a minimum distance of 10 Å from protein atoms. The force field OPLS4 was used and all the other options were set to default values.
MD runs were conducted using Desmond by producing trajectories of 300 ns (ca. 1000 frames), 1.2 ps for energy recording interval, isothermal-isobaric (NPT) ensemble at 300 K and 1.01325 bar, and allowing relaxation of system before simulation. Each run was repeated 5 times (5x replicates). Jobs were written and conducted on the O2 High Performance Compute Cluster at Harvard Medical School, through licensed software of the SBGrid Consortium. Produced trajectories were submitted to Schrodinger's Simulation Interactions Diagram to build plots and related metrics for analysis, such as Root Mean Square Fluctuation (RMSF), RMSD, among others. Additionally, RMSD boxplots as well as merged RMSF graphs were generated using our in-house script at the https://github.com/guimsilvaa/desmotools repository.

The MMGBSA ΔG free energy values between protein-ligand complexes were calculated for each MD trajectory-frame by Schrodinger's thermal_mmgbsa.py script. These were calculated using the OPLS4 force field and the default Prime tool. The protocol involves five fundamental entities for energy calculations: optimized free protein, optimized free ligand, optimized complex, protein from optimized complex, and ligand from optimized complex. Different components contribute to the calculation of total ΔG binding affinity energy in kcal/mol: Coulomb energy, covalent binding energy, van der Waals (vdW) energy, lipophilic energy, generalized Born electrostatic solvation energy, total Prime energy, hydrogen-bonding correction, π-π stacking correction, and self-contact correction. Statistical parameters such as average and corresponding standard deviation values for ΔG and associated components were also calculated using available scripts at our custom-built desmotools repository.

Glycerolipid Synthesis Assay: To assess the contribution of pyruvate-to-PEP bypass in glycerolipid formation, we used ^{14}C pyruvate (1-^{14}C Sodium pyruvate, ARC) and determined the incorporation of ^{14}C pyruvate into the glycerol backbone of glycerolipids. In cultured differentiated adipocytes, media were replaced in high-glucose DMEM containing 10% FBS, 1% penicillin–streptomycin, and 1% GlutaMAX™ on day 5. Cells on day 6 were incubated in high-glucose DMEM (Wako, 048-33575) that contained ^{14}C pyruvate at 0.25 μCi ml^{-1} in the presence or absence of 5 μg ml^{-1} insulin at 37ºC with 5% CO_2 for 8 hours. Similarly, we used ^{14}C glucose (U-$^{14}C_6$ D-GLUCOSE, ARC) at 0.5 μCi ml^{-1} as an alternative tracer.

Cells were washed with PBS twice and lysed in 200 μl of lysis buffer (25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1% Triton X-100). One-fourth of the lysate was used to determine the protein concentration by a BCA assay for normalization. The remaining lysate was mixed with the same amount of Folch solution (2:1 (v/v) chloroform/methanol) and were centrifuged at 21,000 x g for 5 min. The lower (lipid) phase was added with 5 ml of scintillation cocktail Ultima Gold to measure the ^{14}C radioactivity (dpm) using a liquid scintillation counter.

Lipogenesis assays in white adipose tissue and the liver used approximately 50 mg of tissues that were incubated in high-glucose DMEM (Wako, 048-33575) containing 0.5 μCi ml^{-1} ^{14}C glucose (U-$^{14}C_6$ D-GLUCOSE, ARC) with or without 5 μg ml^{-1} insulin at 37ºC with 5% CO_2 for 4 hours. Tissues were washed

with PBS twice, were homogenized in 1 ml of Folch solution (2:1 (v/v) chloroform:methanol), and were incubated on an orbital shaker at room temperature overnight. The homogenates were mixed with 200 µL of 150 mM NaCl solution and were centrifuged at 21,000 x g for 5 min. The lower (lipid) phase was added with 5 ml of scintillation cocktail Ultima Gold to measure the ^{14}C radioactivity (dpm) using a liquid scintillation counter. The ^{14}C radioactivity was normalized to the initial tissue weight.

Glyceroneogenesis assay: To extract the glycerol fraction of glycerolipids in adipose tissues, we used periodic acid–Schiff staining following thin-layer chromatography (PAS–TLC) [56]. Approximately 50 mg of white adipose tissues that were incubated in high-glucose DMEM (Wako, 048-33575) containing 0.5 µCi ml^{-1} ^{14}C glucose (U-$^{14}C_6$ D-GLUCOSE, ARC) with or without 5 µg ml^{-1} insulin at 37ºC with 5% CO_2 for 4 hours. Tissues were washed with PBS twice, homogenized in 1 ml of Folch solution (2:1 (v/v) chloroform:methanol), and incubated on an orbital shaker at room temperature overnight. The homogenates were mixed with 200 µL of 150 mM NaCl solution and were centrifuged at 21,000 x g for 5 min. The lower (lipid) phase was collected, evaporated, mixed with 500 µl of 1 M KOH in methanol, and incubated at 60 °C for 1 h. To neutralize KOH and protonate fatty acids, 50 µl of 37% HCl was added. Fatty acids were extracted three times with 800 µl of hexane:diethyl ether (1:1, v/v), with vortexing and centrifugation after each extraction, followed by an additional wash with 500 µl of hexane to ensure complete removal of fatty acids. The remaining aqueous phase was evaporated to approximately 100 µl, mixed with 1 ml of acetone, and vortexed to precipitate KCl. After centrifugation, the supernatant was evaporated to dryness and resuspended in 50 µl of methanol. Samples (typically 10 µl) were spotted 1 cm from the bottom of TLC plates and developed in 80:19:1 (v/v/v) acetonitrile:water:acetic acid until the solvent front reached 10 cm. A 10% (v/v) glycerol solution in methanol was used as a standard. Based on the Rf (~0.55) of glycerol determined by PAS staining, the corresponding regions were scraped into 1 ml of water in scintillation vials. For PAS staining, plates were sprayed with 0.5% periodate in 70% ethanol, dried, then sprayed with 50% Schiff reagent in ethanol to visualize glycerol spots. Finally, 5 ml of scintillation cocktail (Ultima Gold) was added, and ^{14}C radioactivity (dpm) was measured using a liquid scintillation counter. Radioactivity values were normalized to the initial tissue weight.

Lipidomics: Liver lipids were extracted in butanol/methanol (1:1) with 5 mM ammonium formate, and were analyzed using a Dionex Ultimate 3000 RSLC system (Thermo Scientific) coupled with a QExactive mass spectrometer (Thermo Scientific, Waltham, MA, USA). Chromatographic separation was achieved on an ACQUITY UPLC CSH C18 column (130Å, 1.7 µm, 2.1 mm × 100 mm) with an ACQUITY UPLC CSH C18 VanGuard pre-column (130Å, 1.7 µm, 2.1 mm × 5 mm) (Waters, Milford, MA) with column temperature at 50°C. For the gradient, mobile phase A consisted of an acetonitrile-water mixture (6:4), and mobile phase B was a 2-propanol-acetonitrile mixture (9:1), both phases containing 10 mM ammonium formate and 0.1% formic acid. The linear elution gradient was: 0-3 min, 20% B; 3- 7 min, 20-55% B; 7-15 min, 55-65% B; 15-21 min, 65-70% B; 21-24 min, 70-100% B; and 24-26 min, 100% B, 26-28 min, 100-20% B, 28-30 min, 20% B, with a flow rate of 0.35 mL/ min. The autosampler was at 4°C. The injection volume was 5 µL. Needle wash was applied between samples using a mixture of dichloromethane-isopropanol-acetonitrile (1:1:1).

ESI-MS analysis was performed in positive and negative ionization polarities using a combined full mass scan and data-dependent MS/MS (Top 10) (Full MS/dd-MS2) approach. The experimental conditions for full scanning were as follows: resolving power, 70,000; automatic gain control (AGC) target, 1 × 106; and maximum injection time (IT), 100 ms. The scan range of the instrument was set to m/z 100-1200 in both positive and negative ion modes. The experimental conditions for the data-dependent product ion scanning were as follows: resolving power, 17,500; AGC target, 5 × 104; and maximum IT, 50 ms. The isolation width and stepped normalized collision energy (NCE) were set to 1.0 m/z, and 10, 20, and 40 eV. The intensity threshold of precursor ions for dd-MS2 analysis and the dynamic exclusion were set to 1.6 × 105 and 10 s. The ionization conditions in the positive mode were as follows: sheath gas flow rate, 50 arb;

auxiliary (AUX) gas flow rate, 15 arb; sweep gas flow rate, 1 arb; ion spray voltage, 3.5 kV; AUX gas heater temperature, 325°C; capillary temperature, 350°C; and S-lens RF level, 55. The ionization conditions in the negative mode were as follows: sheath gas flow rate, 45 arb; auxiliary (AUX) gas flow rate, 10 arb; sweep gas flow rate, 1 arb; ion spray voltage, 2.5 kV; AUX gas heater temperature, 320°C; capillary temperature, 320°C; and S-lens RF level, 55.

Thermo Scientific LipidSearch software version 5.0 was used for lipid identification and quantitation. First, the product search mode was used during which lipids are identified based on the exact mass of the precursor ions and the mass spectra resulting from product ion scanning. The precursor and product tolerances were set to 10 and 10 ppm mass windows. The absolute intensity threshold of precursor ions and the relative intensity threshold of product ions were set to 30000 and 1%. Next, the search results from the individual positive or negative ion files from each sample were aligned within a retention time window (±0.25 min) and then all the data were merged for each annotated lipid with a retention time correction tolerance of 0.5 min. The annotated lipids were then filtered to reduce false positives by only including the lipids with a total grade of A or B. To improve data quality and interpretability, lipid species with non-physiological features were excluded from downstream analysis. These included lipids with an unusually low (14 or fewer) or high (26 or greater) number of total carbon atoms, and those with odd-chain fatty acid moieties, as these are rarely found in mammalian tissues and may arise from artifacts or misannotation. Nonetheless, all of the statistically significant lipids are listed in **Supplementary Table 4 and 5** for *Slc25a35*^{Liver} KO and AAV-KO^{Liver} mice, respectively. The intensities were normalized to the sum of total lipid intensities. The data were analyzed using MetaboAnalyst. Non-informative variables were filtered based on the interquartile range, with a 20% cutoff.

Animal Physiology: *Slc25a35*^{Adipo} KO, *Slc25a35*^{Liver} KO and the respective littermate control mice were fed on an HFD (60% fat, D12492, Research Diets) from 6 weeks old at 30°C. Body weight was measured every week. For an insulin-tolerance test, mice were fasted for 6 hours and intraperitoneally injected with insulin (0.75 U kg^{-1} body weight). For a pyruvate-tolerance test, mice were fasted for 16 hours and intraperitoneally injected with pyruvate (1.5 g kg^{-1} body weight). Blood glucose levels were measured at the indicated time points using blood glucose test strips (Freestyle Lite). *Slc25a35*^{Adipo} KO mice and littermate control mice were monitored using a Promethion Metabolic Cage System (Sable Systems) to measure whole-body energy expenditure (VO_2, VCO_2), food intake, and locomotor activity (beam break counts). Mice were intraperitoneally injected with CL-316,243 (Sigma-Aldrich; 0.5 mg kg^{-1} body weight).

Histology: Adipose tissues and the liver were fixed in 4% paraformaldehyde at 4°C overnight, followed by incubation in 70% ethanol. After the dehydration procedure, tissues were embedded in paraffin and cut into sections at 5 µm thickness. The sections were stained with haematoxylin and eosin according to the standard protocol at the BIDMC pathology core. Images were acquired using a Zeiss AxioImager M1 microscope with a 20× objective at the BIDMC imaging core

Primary hepatocyte Assays: Mouse liver was perfused with liberase (05401127001, Sigma-Aldrich), and the dissociated cells were washed with William's E medium (12551032, Thermo Fisher Scientific). After purification by Percoll (17089101, Cytiva) density gradient centrifugation, the cells were cultured in William's E medium supplemented with 10% FBS, 1% penicillin–streptomycin, and 1% GlutaMAX™ at 37°C. After a 6-hour attachment period, the cells were subjected to gluconeogenesis assays and mitochondrial metabolomics. For the gluconeogenesis assay, cells were incubated in glucose-free DMEM containing 10 mM fully ^{13}C-labeled pyruvate with or without 100 nM glucagon at 37°C. The culture medium was collected at the indicated time points for measurement of ^{13}C-labeled glucose by LC-MS. The cells were lysed, and protein content was quantified using a BCA assay for normalization. For mitochondrial metabolomics, cells cultured in a 150-mm dish were washed twice with ice-cold PBS and scraped into KPBS buffer (136 mM KCl, 10 mM KH_2PO_4, pH 7.25). The cell suspension was centrifuged at 1,000 × g

for 2 min at 4°C, and the pellet was resuspended in 1 mL of KPBS. One-tenth of the cells were lysed in 80% methanol for whole-cell metabolomics analysis, and an aliquot was used for protein quantification by a BCA assay. The remaining cells were homogenized using a Teflon pestle and glass tube, followed by centrifugation at 600 × g for 5 min at 4°C. The supernatant was then centrifuged at 7,000 × g for 10 min at 4°C to isolate mitochondria. The resulting mitochondrial pellets were lysed in 80% methanol for metabolomics analysis, and an aliquot was used for protein quantification by a BCA assay. The mitochondrial metabolomics analysis was performed using the same method as that used for differentiated adipocytes.

Lipolysis and Glucose Oxidation Assays: Approximately 50 mg of adipose tissues were incubated in 600 µl of high-glucose DMEM containing 2% BSA with or without 10 µM isoproterenol (Sigma-Aldrich) at 37 °C for 3 hours. The cultured medium was collected to measure the glycerol levels using a free glycerol reagent (Sigma-Aldrich). The glycerol content was normalized to the initial tissue weight. Glucose oxidation assays were performed according to the protocol described in our previous work [89,91]. In brief, adipose tissues were minced into small pieces, placed into a polypropylene round-bottom tube, and incubated in 1 ml of KRB-HEPES buffer with 0.5 µCi ml^{-1} ^{14}C glucose (U-$^{14}C_6$ D-GLUCOSE, ARC) at 37 °C for 1 hour. The reaction mixture was added with 350 µl of 30% hydrogen peroxide, and $^{14}CO_2$ was trapped in the center well with 300 µl of 1 M benzethonium hydroxide solution for 20 min at room temperature. The ^{14}C radioactivity was measured using a liquid scintillation counter and normalized to the initial tissue weight.

Lipid profiling: For the measurement of liver triglyceride contents, approximately 50 mg of liver tissues were homogenized in 1 ml of Folch solution (2:1 (v/v) chloroform:methanol), and were incubated on an orbital shaker at room temperature overnight. The homogenates were mixed with 200 µL of 150 mM NaCl solution and were centrifuged at 21,000 x g for 5 min. The lower (lipid) phase was evaporated to measure the triglyceride amount using an Infinity Triglycerides kit (Thermo Fisher Scientific, TR22421). The liver triglyceride levels were normalized to the initial tissue weight. Serum AST and ALT levels were measured using a Stanbio AST testing (Stanbio, SBL-2930-430) and Stanbio ALT testing (Stanbio, SBL-2920-430), respectively. Serum glycerol levels were measured using a free glycerol reagent (F6428, Sigma-Aldrich) and glycerol standard solution (G7793, Sigma-Aldrich). For liver glycerol measurement, approximately 30-40 mg of liver tissues were homogenized in 1 ml of PBS. The glycerol levels in the homogenates were measured using a free glycerol reagent and glycerol standard solution. The liver glycerol levels were normalized to the initial tissue weight. Cellular glycerol-3P was determined using a Glycerol 3-Phosphate (G3P) Assay Kit (A3854, Sigma-Aldrich). The glycerol-3P levels were normalized to protein levels measured by a BCA assay. For cellular triglyceride measurement, cells were lysed in 200 µl of lysis buffer (25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1% Triton X-100). An aliquot of the lysate was mixed with the same amount of Folch solution (2:1 (v/v) chloroform/methanol). The lower phase was collected, and TG content determined, using an Infinity Triglycerides kit (Thermo Fisher Scientific, TR22421). Another aliquot of the lysate was used for protein normalization by a BCA assay.

Immunoblotting: Protein lysates were mixed with 5 x SDS sample buffer, were incubated at 37°C for 10 min, and were separated by SDS–PAGE to be transferred to a PVDF membrane. Membranes were blocked in 1% skim milk TBS-T and were incubated with a specific primary antibody. Immunoreactive bands were detected using an HRP-conjugated secondary antibody, were visualized with a Clarity Western ECL Substrate (Bio-Rad) or an ImmunoStar LD (Wako), and were imaged using a ChemiDoc Touch (Bio-Rad). β-actin was used as a loading control. The band intensity was normalized against the loading control for quantification. Band intensity was quantified using an ImageJ software (NIH).

Immunostaining: Cells were placed in glass-bottom dishes (VWR 10810-054) and cultured for 24 hours. Differentiation was induced and maintained on the same glass-bottom dish until day 3. The cells were

washed twice with PBS and were fixed with 4% PFA at 37°C for 30 min. The samples were rinsed three times with PBS and were permeabilized with 0.3% NP-40, 0.05% Triton X-100, and 0.1% BSA in PBS for 3 min. After three rinses with wash buffer (0.05% NP-40, 0.05% Triton X-100, and 0.2% BSA in PBS), the samples were blocked with SuperBlock Blocking Buffer (Thermo Fisher, 37515) at room temperature for 1 hour. The samples were incubated with a primary antibody in wash buffer at 4°C overnight, were washed three times with wash buffer. The samples were incubated with a secondary antibody at room temperature for 3 hours and washed three times with wash buffer. Images were acquired with a Zeiss LSM900 confocal microscope. Images were processed using Zeiss Zen software.

For immunostaining in the liver, liver tissues from *Slc25a35*^{liver} KO and control mice were fixed in 4% paraformaldehyde (PFA) overnight and processed them for paraffin embedding. Heat-mediated antigen retrieval was performed using citrate buffer (pH 6.0). After blocking with 10% donkey serum (D9663, Sigma-Aldrich) for 30 minutes, the sections were incubated with a rabbit monoclonal anti-F4/80 antibody (70076S, Cell Signaling Technology; 1:200) overnight at 4°C. The sections were then washed with PBS and incubated with a secondary antibody (ab150062, Abcam; 1:500) for 1 hour, followed by nuclear staining with Hoechst (ab228551, Abcam; 1:2000). Fluorescent images were acquired using a Zeiss LSM900 confocal microscope and analyzed in four randomly selected fields per liver to quantify the number of F4/80^{+} Hoechst^{+} cells (macrophages) in the liver tissue.

Proteinase K assay: Cells were scraped and pelleted at 1100 x g for 2 min. Cell pellets were washed with phosphate buffer solution (PBS) and re-pelleted at 1100 x g for 2 min. Cell pellets were then homogenized in buffer (22 mM mannitol, 75 mM sucrose, 1 mM EGTA, 30 mM Tris-HCl, pH 7.4). A part of the homogenate was served as a whole cell fraction. The remaining homogenate was centrifuged at 600 x g for 5 min and the supernatant was pelleted at 7000 x g for 10 min. The supernatant was served as a cytosol fraction. The pellet was added with 50 µg/mL of proteinase K in buffer (150 mM KCl, 10 mM HEPES, 200 µM CaCl2, pH 7.2), incubated on ice for 10 mi, and centrifuged at 7000 x g for 10 min. The resultant pellet was added with sample buffer for immunoblotting.

qRT-PCR: Total RNA was isolated from cells or tissues using a TRIzol reagent (Invitrogen) and a Zymo Direct-zol RNA preparation kit (R2052, Zymo). The RNA samples were reverse-transcribed into cDNAs using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories). The cDNAs were quantified using a QuantStudio 6 system (Applied Biosystems). *36b4* was served as an internal control. A list of the qRT-PCR primers used in this study is provided in **Supplementary Table 6.**

Single-nuclei RNA-seq: Data from GSE176171 [35] were analyzed and visualized using R and Seurat (v4.0.1), following standard workflows.

Statistics: Statistical analyses were performed using a GraphPad Prism v.10 (GraphPad). All data are represented as mean ± s.e.m. unless otherwise specified. Data were obtained from biologically independent samples. Unpaired Student's *t*-tests were used for two-group comparisons. One-way ANOVA with Holm-Šídák's multiple comparisons test was used for multiple-group comparisons. Two-way ANOVA followed by appropriate post-hoc tests was used to analyze the effects of two independent factors. Two-way repeated-measures ANOVA followed by Fisher's LSD test was used to determine the statistical difference in body weight, whole-body energy expenditure, food intake, locomotor activity, insulin tolerance, and pyruvate tolerance. The statistical parameters and sample numbers are provided in the figure legends. $P < 0.05$ was considered to be significant throughout the study.

Data Availability: All unique materials used are available from the authors on request. Other materials are available from commercial sources as described in the text.

REFERENCES

1. Chakrabarty, R.P., and Chandel, N.S. (2021). Mitochondria as Signaling Organelles Control Mammalian Stem Cell Fate. Cell stem cell *28*, 394-408. 10.1016/j.stem.2021.02.011.
2. Spinelli, J.B., and Haigis, M.C. (2018). The multifaceted contributions of mitochondria to cellular metabolism. Nature cell biology *20*, 745-754. 10.1038/s41556-018-0124-1.
3. Yu, S., Meng, S., Xiang, M., and Ma, H. (2021). Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis. Molecular metabolism *53*, 101257. 10.1016/j.molmet.2021.101257.
4. Possik, E., Al-Mass, A., Peyot, M.L., Ahmad, R., Al-Mulla, F., Madiraju, S.R.M., and Prentki, M. (2021). New Mammalian Glycerol-3-Phosphate Phosphatase: Role in beta-Cell, Liver and Adipocyte Metabolism. Frontiers in endocrinology *12*, 706607. 10.3389/fendo.2021.706607.
5. Nye, C., Kim, J., Kalhan, S.C., and Hanson, R.W. (2008). Reassessing triglyceride synthesis in adipose tissue. Trends in endocrinology and metabolism: TEM *19*, 356-361. 10.1016/j.tem.2008.08.003.
6. Merrins, M.J., Corkey, B.E., Kibbey, R.G., and Prentki, M. (2022). Metabolic cycles and signals for insulin secretion. Cell metabolism *34*, 947-968. 10.1016/j.cmet.2022.06.003.
7. Poursharifi, P., Madiraju, S.R.M., Oppong, A., Kajimura, S., Nolan, C.J., Blondin, D.P., and Prentki, M. (2025). Glycerolipid Cycling in Thermogenesis, Energy Homeostasis and Signaling. Physiological reviews. 10.1152/physrev.00024.2024.
8. Stark, R., Pasquel, F., Turcu, A., Pongratz, R.L., Roden, M., Cline, G.W., Shulman, G.I., and Kibbey, R.G. (2009). Phosphoenolpyruvate cycling via mitochondrial phosphoenolpyruvate carboxykinase links anaplerosis and mitochondrial GTP with insulin secretion. The Journal of biological chemistry *284*, 26578-26590. 10.1074/jbc.M109.011775.
9. Lewandowski, S.L., Cardone, R.L., Foster, H.R., Ho, T., Potapenko, E., Poudel, C., VanDeusen, H.R., Sdao, S.M., Alves, T.C., Zhao, X., et al. (2020). Pyruvate Kinase Controls Signal Strength in the Insulin Secretory Pathway. Cell metabolism *32*, 736-750 e735. 10.1016/j.cmet.2020.10.007.
10. Foster, H.R., Ho, T., Potapenko, E., Sdao, S.M., Huang, S.M., Lewandowski, S.L., VanDeusen, H.R., Davidson, S.M., Cardone, R.L., Prentki, M., et al. (2022). beta-cell deletion of the PKm1 and PKm2 isoforms of pyruvate kinase in mice reveals their essential role as nutrient sensors for the K(ATP) channel. eLife *11*. 10.7554/eLife.79422.
11. Jesinkey, S.R., Madiraju, A.K., Alves, T.C., Yarborough, O.H., Cardone, R.L., Zhao, X., Parsaei, Y., Nasiri, A.R., Butrico, G., Liu, X., et al. (2019). Mitochondrial GTP Links Nutrient Sensing to beta Cell Health, Mitochondrial Morphology, and Insulin Secretion Independent of OxPhos. Cell reports *28*, 759-772 e710. 10.1016/j.celrep.2019.06.058.
12. Kibbey, R.G., Pongratz, R.L., Romanelli, A.J., Wollheim, C.B., Cline, G.W., and Shulman, G.I. (2007). Mitochondrial GTP regulates glucose-stimulated insulin secretion. Cell metabolism *5*, 253-264. 10.1016/j.cmet.2007.02.008.
13. Abulizi, A., Cardone, R.L., Stark, R., Lewandowski, S.L., Zhao, X., Hillion, J., Ma, L., Sehgal, R., Alves, T.C., Thomas, C., et al. (2020). Multi-Tissue Acceleration of the Mitochondrial Phosphoenolpyruvate Cycle Improves Whole-Body Metabolic Health. Cell metabolism *32*, 751-766 e711. 10.1016/j.cmet.2020.10.006.
14. Ho, P.C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.C., Cui, G., Micevic, G., Perales, J.C., et al. (2015). Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell *162*, 1217-1228. 10.1016/j.cell.2015.08.012.
15. Lardy, H.A., Paetkau, V., and Walter, P. (1965). Paths of carbon in gluconeogenesis and lipogenesis: the role of mitochondria in supplying precursors of phosphoenolpyruvate. Proceedings of the National Academy of Sciences of the United States of America *53*, 1410-1415. 10.1073/pnas.53.6.1410.
16. Utter, M.F., and Kurahashi, K. (1954). Mechanism of action of oxalacetic carboxylase. The Journal of biological chemistry *207*, 821-841.

17. Sun, Y., Liu, S., Ferguson, S., Wang, L., Klepcyk, P., Yun, J.S., and Friedman, J.E. (2002). Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. The Journal of biological chemistry *277*, 23301-23307. 10.1074/jbc.M200964200.
18. Valera, A., Pujol, A., Pelegrin, M., and Bosch, F. (1994). Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America *91*, 9151-9154. 10.1073/pnas.91.19.9151.
19. She, P., Shiota, M., Shelton, K.D., Chalkley, R., Postic, C., and Magnuson, M.A. (2000). Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Molecular and cellular biology *20*, 6508-6517. 10.1128/MCB.20.17.6508-6517.2000.
20. Burgess, S.C., Hausler, N., Merritt, M., Jeffrey, F.M., Storey, C., Milde, A., Koshy, S., Lindner, J., Magnuson, M.A., Malloy, C.R., and Sherry, A.D. (2004). Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. The Journal of biological chemistry *279*, 48941-48949. 10.1074/jbc.M407120200.
21. Hakimi, P., Johnson, M.T., Yang, J., Lepage, D.F., Conlon, R.A., Kalhan, S.C., Reshef, L., Tilghman, S.M., and Hanson, R.W. (2005). Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism. Nutrition & metabolism *2*, 33. 10.1186/1743-7075-2-33.
22. Gomez-Valades, A.G., Mendez-Lucas, A., Vidal-Alabro, A., Blasco, F.X., Chillon, M., Bartrons, R., Bermudez, J., and Perales, J.C. (2008). Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice. Diabetes *57*, 2199-2210. 10.2337/db07-1087.
23. Burgess, S.C., He, T., Yan, Z., Lindner, J., Sherry, A.D., Malloy, C.R., Browning, J.D., and Magnuson, M.A. (2007). Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell metabolism *5*, 313-320. 10.1016/j.cmet.2007.03.004.
24. Rahim, M., Hasenour, C.M., Bednarski, T.K., Hughey, C.C., Wasserman, D.H., and Young, J.D. (2021). Multitissue 2H/13C flux analysis reveals reciprocal upregulation of renal gluconeogenesis in hepatic PEPCK-C-knockout mice. JCI Insight *6*. 10.1172/jci.insight.149278.
25. Stark, R., and Kibbey, R.G. (2014). The mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it been overlooked? Biochimica et biophysica acta *1840*, 1313-1330. 10.1016/j.bbagen.2013.10.033.
26. Bayraktar, E.C., Baudrier, L., Ozerdem, C., Lewis, C.A., Chan, S.H., Kunchok, T., Abu-Remaileh, M., Cangelosi, A.L., Sabatini, D.M., Birsoy, K., and Chen, W.W. (2019). MITO-Tag Mice enable rapid isolation and multimodal profiling of mitochondria from specific cell types in vivo. Proceedings of the National Academy of Sciences of the United States of America *116*, 303-312. 10.1073/pnas.1816656115.
27. Chen, W.W., Freinkman, E., Wang, T., Birsoy, K., and Sabatini, D.M. (2016). Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. Cell *166*, 1324-1337 e1311. 10.1016/j.cell.2016.07.040.
28. Cunningham, C.N., and Rutter, J. (2020). 20,000 picometers under the OMM: diving into the vastness of mitochondrial metabolite transport. EMBO reports *21*, e50071. 10.15252/embr.202050071.
29. Stark, R., Guebre-Egziabher, F., Zhao, X., Feriod, C., Dong, J., Alves, T.C., Ioja, S., Pongratz, R.L., Bhanot, S., Roden, M., et al. (2014). A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) in the regulation of hepatic gluconeogenesis. The Journal of biological chemistry *289*, 7257-7263. 10.1074/jbc.C113.544759.

30. Alvarez, Z., Hyrossova, P., Perales, J.C., and Alcantara, S. (2016). Neuronal Progenitor Maintenance Requires Lactate Metabolism and PEPCK-M-Directed Cataplerosis. Cereb Cortex *26*, 1046-1058. 10.1093/cercor/bhu281.
31. Walczak, R., and Tontonoz, P. (2002). PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. Journal of lipid research *43*, 177-186.
32. Stipani, I., Kramer, R., Palmieri, F., and Klingenberg, M. (1980). Citrate transport in liposomes reconstituted with triton extracts from mitochondria. Biochemical and biophysical research communications *97*, 1206-1214. 10.1016/0006-291x(80)91503-x.
33. Stipani, I., and Palmieri, F. (1983). Purification of the active mitochondrial tricarboxylate carrier by hydroxylapatite chromatography. FEBS letters *161*, 269-274. 10.1016/0014-5793(83)81023-0.
34. Kaplan, R.S., Mayor, J.A., and Wood, D.O. (1993). The mitochondrial tricarboxylate transport protein. cDNA cloning, primary structure, and comparison with other mitochondrial transport proteins. The Journal of biological chemistry *268*, 13682-13690.
35. Emont, M.P., Jacobs, C., Essene, A.L., Pant, D., Tenen, D., Colleluori, G., Di Vincenzo, A., Jorgensen, A.M., Dashti, H., Stefek, A., et al. (2022). A single-cell atlas of human and mouse white adipose tissue. Nature *603*, 926-933. 10.1038/s41586-022-04518-2.
36. Agrimi, G., Russo, A., Scarcia, P., and Palmieri, F. (2012). The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. The Biochemical journal *443*, 241-247. 10.1042/BJ20111420.
37. Abrams, A.J., Hufnagel, R.B., Rebelo, A., Zanna, C., Patel, N., Gonzalez, M.A., Campeanu, I.J., Griffin, L.B., Groenewald, S., Strickland, A.V., et al. (2015). Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat Genet *47*, 926-932. 10.1038/ng.3354.
38. Zaltsman, Y., Shachnai, L., Yivgi-Ohana, N., Schwarz, M., Maryanovich, M., Houtkooper, R.H., Vaz, F.M., De Leonardis, F., Fiermonte, G., Palmieri, F., et al. (2010). MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat Cell Biol *12*, 553-562. 10.1038/ncb2057.
39. Miura, H., Quadros, R.M., Gurumurthy, C.B., and Ohtsuka, M. (2018). Easi-CRISPR for creating knock-in and conditional knockout mouse models using long ssDNA donors. Nature protocols *13*, 195-215. 10.1038/nprot.2017.153.
40. Chen, W.W., Freinkman, E., and Sabatini, D.M. (2017). Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites. Nature protocols *12*, 2215-2231. 10.1038/nprot.2017.104.
41. Varadi, M., Bertoni, D., Magana, P., Paramval, U., Pidruchna, I., Radhakrishnan, M., Tsenkov, M., Nair, S., Mirdita, M., Yeo, J., et al. (2024). AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic acids research *52*, D368-D375. 10.1093/nar/gkad1011.
42. Ruprecht, J.J., and Kunji, E.R.S. (2020). The SLC25 Mitochondrial Carrier Family: Structure and Mechanism. Trends Biochem Sci *45*, 244-258. 10.1016/j.tibs.2019.11.001.
43. King, M.S., Kerr, M., Crichton, P.G., Springett, R., and Kunji, E.R.S. (2016). Formation of a cytoplasmic salt bridge network in the matrix state is a fundamental step in the transport mechanism of the mitochondrial ADP/ATP carrier. Biochimica et biophysica acta *1857*, 14-22. 10.1016/j.bbabio.2015.09.013.
44. Reshef, L., Niv, J., and Shapiro, B. (1967). Effect of propionate on pyruvate metabolism in adipose tissue. Journal of lipid research *8*, 688-691.
45. Reshef, L., Hanson, R.W., and Ballard, F.J. (1969). Glyceride-glycerol synthesis from pyruvate. Adaptive changes in phosphoenolpyruvate carboxykinase and pyruvate carboxylase in adipose tissue and liver. The Journal of biological chemistry *244*, 1994-2001.
46. Gorin, E., Tal-Or, Z., and Shafrir, E. (1969). Glyceroneogenesis in adipose tissue of fasted, diabetic and triamcinolone treated rats. European journal of biochemistry / FEBS *8*, 370-375. 10.1111/j.1432-1033.1969.tb00537.x.

47. Reshef, L., Olswang, Y., Cassuto, H., Blum, B., Croniger, C.M., Kalhan, S.C., Tilghman, S.M., and Hanson, R.W. (2003). Glyceroneogenesis and the triglyceride/fatty acid cycle. The Journal of biological chemistry *278*, 30413-30416. 10.1074/jbc.R300017200.
48. Nye, C.K., Hanson, R.W., and Kalhan, S.C. (2008). Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat. The Journal of biological chemistry *283*, 27565-27574. 10.1074/jbc.M804393200.
49. Guan, H.P., Li, Y., Jensen, M.V., Newgard, C.B., Steppan, C.M., and Lazar, M.A. (2002). A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nature medicine *8*, 1122-1128. 10.1038/nm780.
50. Margolis, S., and Vaughan, M. (1962). Alpha-Glycerophosphate synthesis and breakdown in homogenates of adipose tissue. The Journal of biological chemistry *237*, 44-48.
51. Kajimura, S., and Spiegelman, B.M. (2020). Confounding issues in the "humanized" BAT of mice. Nat Metab *2*, 303-304. 10.1038/s42255-020-0192-y.
52. Festuccia, W.T., Kawashita, N.H., Garofalo, M.A., Moura, M.A., Brito, S.R., Kettelhut, I.C., and Migliorini, R.H. (2003). Control of glyceroneogenic activity in rat brown adipose tissue. American journal of physiology. Regulatory, integrative and comparative physiology *285*, R177-182. 10.1152/ajpregu.00713.2002.
53. Brito, M.N., Brito, N.A., Brito, S.R., Moura, M.A., Kawashita, N.H., Kettelhut, I.C., and Migliorini, R.H. (1999). Brown adipose tissue triacylglycerol synthesis in rats adapted to a high-protein, carbohydrate-free diet. The American journal of physiology *276*, R1003-1009. 10.1152/ajpregu.1999.276.4.R1003.
54. Drahota, Z., Rauchova, H., Mikova, M., Kaul, P., and Bass, A. (1983). Phosphoenolpyruvate shuttle--transport of energy from mitochondria to cytosol. FEBS letters *157*, 347-349. 10.1016/0014-5793(83)80573-0.
55. Zhang, Y., Li, C., Li, H., Song, Y., Zhao, Y., Zhai, L., Wang, H., Zhong, R., Tang, H., and Zhu, D. (2016). miR-378 Activates the Pyruvate-PEP Futile Cycle and Enhances Lipolysis to Ameliorate Obesity in Mice. EBioMedicine *5*, 93-104. 10.1016/j.ebiom.2016.01.035.
56. Shaw, N. (1968). The detection of lipids on thin-layer chromatograms with the periodate-Schiff reagents. Biochimica et biophysica acta *164*, 435-436. 10.1016/0005-2760(68)90171-9.
57. Heeren, J., and Scheja, L. (2021). Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular metabolism *50*, 101238. 10.1016/j.molmet.2021.101238.
58. Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., and An, Z. (2023). Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic. Front Med (Lausanne) *10*, 1294267. 10.3389/fmed.2023.1294267.
59. Kalhan, S.C., Mahajan, S., Burkett, E., Reshef, L., and Hanson, R.W. (2001). Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans. The Journal of biological chemistry *276*, 12928-12931. 10.1074/jbc.M006186200.
60. Botion, L.M., Brito, M.N., Brito, N.A., Brito, S.R., Kettelhut, I.C., and Migliorini, R.H. (1998). Glucose contribution to in vivo synthesis of glyceride-glycerol and fatty acids in rats adapted to a high-protein, carbohydrate-free diet. Metabolism: clinical and experimental *47*, 1217-1221. 10.1016/s0026-0495(98)90326-2.
61. Kalhan, S.C., Bugianesi, E., McCullough, A.J., Hanson, R.W., and Kelley, D.E. (2008). Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism: clinical and experimental *57*, 305-312. 10.1016/j.metabol.2007.10.003.
62. Morrow, M.R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J.M., Mohammadi-Shemirani, P., Desjardins, E.M., Wang, Z., Tsakiridis, E.E., Lavoie, D.C.T., et al. (2022). Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell metabolism *34*, 919-936 e918. 10.1016/j.cmet.2022.05.004.
63. Smith, G.I., Shankaran, M., Yoshino, M., Schweitzer, G.G., Chondronikola, M., Beals, J.W., Okunade, A.L., Patterson, B.W., Nyangau, E., Field, T., et al. (2020). Insulin resistance drives

hepatic de novo lipogenesis in nonalcoholic fatty liver disease. The Journal of clinical investigation *130*, 1453-1460. 10.1172/JCI134165.
64. Solinas, G., Boren, J., and Dulloo, A.G. (2015). De novo lipogenesis in metabolic homeostasis: More friend than foe? Molecular metabolism *4*, 367-377. 10.1016/j.molmet.2015.03.004.
65. Perry, R.J., Samuel, V.T., Petersen, K.F., and Shulman, G.I. (2014). The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature *510*, 84-91. 10.1038/nature13478.
66. Fullerton, M.D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.P., O'Neill, H.M., Ford, R.J., Palanivel, R., O'Brien, M., et al. (2013). Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nature medicine *19*, 1649-1654. 10.1038/nm.3372.
67. Cole, L.K., Jacobs, R.L., and Vance, D.E. (2010). Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology *52*, 1258-1265. 10.1002/hep.23813.
68. Larosche, I., Letteron, P., Fromenty, B., Vadrot, N., Abbey-Toby, A., Feldmann, G., Pessayre, D., and Mansouri, A. (2007). Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. The Journal of pharmacology and experimental therapeutics *321*, 526-535. 10.1124/jpet.106.114546.
69. Mugabo, Y., Zhao, S., Seifried, A., Gezzar, S., Al-Mass, A., Zhang, D., Lamontagne, J., Attane, C., Poursharifi, P., Iglesias, J., et al. (2016). Identification of a mammalian glycerol-3-phosphate phosphatase: Role in metabolism and signaling in pancreatic beta-cells and hepatocytes. Proceedings of the National Academy of Sciences of the United States of America *113*, E430-439. 10.1073/pnas.1514375113.
70. Nagle, C.A., Klett, E.L., and Coleman, R.A. (2009). Hepatic triacylglycerol accumulation and insulin resistance. Journal of lipid research *50 Suppl*, S74-79. 10.1194/jlr.R800053-JLR200.
71. Loomba, R., Friedman, S.L., and Shulman, G.I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell *184*, 2537-2564. 10.1016/j.cell.2021.04.015.
72. Horakova, O., Sistilli, G., Kalendova, V., Bardova, K., Mitrovic, M., Cajka, T., Irodenko, I., Janovska, P., Lackner, K., Kopecky, J., and Rossmeisl, M. (2023). Thermoneutral housing promotes hepatic steatosis in standard diet-fed C57BL/6N mice, with a less pronounced effect on NAFLD progression upon high-fat feeding. Frontiers in endocrinology *14*, 1205703. 10.3389/fendo.2023.1205703.
73. Giles, D.A., Moreno-Fernandez, M.E., Stankiewicz, T.E., Graspeuntner, S., Cappelletti, M., Wu, D., Mukherjee, R., Chan, C.C., Lawson, M.J., Klarquist, J., et al. (2017). Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nature medicine *23*, 829-838. 10.1038/nm.4346.
74. Perry, R.J., Kim, T., Zhang, X.M., Lee, H.Y., Pesta, D., Popov, V.B., Zhang, D., Rahimi, Y., Jurczak, M.J., Cline, G.W., et al. (2013). Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell metabolism *18*, 740-748. 10.1016/j.cmet.2013.10.004.
75. Beretta, M., Dai, Y., Olzomer, E.M., Vancuylenburg, C.S., Santiago-Rivera, J.A., Philp, A.M., Hargett, S.R., Li, K., Shah, D.P., Chen, S.Y., et al. (2024). Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice. Diabetes *73*, 374-384. 10.2337/db23-0233.
76. Benador, I.Y., Veliova, M., Liesa, M., and Shirihai, O.S. (2019). Mitochondria Bound to Lipid Droplets: Where Mitochondrial Dynamics Regulate Lipid Storage and Utilization. Cell metabolism *29*, 827-835. 10.1016/j.cmet.2019.02.011.
77. Najt, C.P., Adhikari, S., Heden, T.D., Cui, W., Gansemer, E.R., Rauckhorst, A.J., Markowski, T.W., Higgins, L., Kerr, E.W., Boyum, M.D., et al. (2023). Organelle interactions compartmentalize hepatic fatty acid trafficking and metabolism. Cell reports *42*, 112435. 10.1016/j.celrep.2023.112435.

78. Benador, I.Y., Veliova, M., Mahdaviani, K., Petcherski, A., Wikstrom, J.D., Assali, E.A., Acin-Perez, R., Shum, M., Oliveira, M.F., Cinti, S., et al. (2018). Mitochondria Bound to Lipid Droplets Have Unique Bioenergetics, Composition, and Dynamics that Support Lipid Droplet Expansion. Cell metabolism *27*, 869-885 e866. 10.1016/j.cmet.2018.03.003.
79. Yu, J., Zhang, S., Cui, L., Wang, W., Na, H., Zhu, X., Li, L., Xu, G., Yang, F., Christian, M., and Liu, P. (2015). Lipid droplet remodeling and interaction with mitochondria in mouse brown adipose tissue during cold treatment. Biochimica et biophysica acta *1853*, 918-928. 10.1016/j.bbamcr.2015.01.020.
80. Mirza, A.H., Cui, L., Zhang, S., and Liu, P. (2021). Comparative proteomics reveals that lipid droplet-anchored mitochondria are more sensitive to cold in brown adipocytes. Biochim Biophys Acta Mol Cell Biol Lipids *1866*, 158992. 10.1016/j.bbalip.2021.158992.
81. Sun, X., Yu, Q., Qi, Y., Kang, B., Zhao, X., Liu, L., Wang, P., Cong, M., and Liu, T. (2024). Peridroplet mitochondria are associated with the severity of MASLD and the prevention of MASLD by diethyldithiocarbamate. Journal of lipid research *65*, 100590. 10.1016/j.jlr.2024.100590.
82. Hsu, H.P., Chu, P.Y., Chang, T.M., Huang, K.W., Hung, W.C., Jiang, S.S., Lin, H.Y., and Tsai, H.J. (2023). Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway. Cancer Med *12*, 1588-1601. 10.1002/cam4.4969.
83. Hyrossova, P., Arago, M., Moreno-Felici, J., Fu, X., Mendez-Lucas, A., Garcia-Roves, P.M., Burgess, S., Figueras, A., Vinals, F., and Perales, J.C. (2021). PEPCK-M recoups tumor cell anabolic potential in a PKC-zeta-dependent manner. Cancer Metab *9*, 1. 10.1186/s40170-020-00236-3.
84. Mendez-Lucas, A., Hyrossova, P., Novellasdemunt, L., Vinals, F., and Perales, J.C. (2014). Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) is a pro-survival, endoplasmic reticulum (ER) stress response gene involved in tumor cell adaptation to nutrient availability. The Journal of biological chemistry *289*, 22090-22102. 10.1074/jbc.M114.566927.
85. Vincent, E.E., Sergushichev, A., Griss, T., Gingras, M.C., Samborska, B., Ntimbane, T., Coelho, P.P., Blagih, J., Raissi, T.C., Choiniere, L., et al. (2015). Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth. Molecular cell *60*, 195-207. 10.1016/j.molcel.2015.08.013.
86. Leithner, K., Triebl, A., Trotzmuller, M., Hinteregger, B., Leko, P., Wieser, B.I., Grasmann, G., Bertsch, A.L., Zullig, T., Stacher, E., et al. (2018). The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America *115*, 6225-6230. 10.1073/pnas.1719871115.
87. Shinoda, K., Luijten, I.H., Hasegawa, Y., Hong, H., Sonne, S.B., Kim, M., Xue, R., Chondronikola, M., Cypess, A.M., Tseng, Y.H., et al. (2015). Genetic and functional characterization of clonally derived adult human brown adipocytes. Nature medicine *21*, 389-394. 10.1038/nm.3819.
88. Ohno, H., Shinoda, K., Spiegelman, B.M., and Kajimura, S. (2012). PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell metabolism *15*, 395-404. 10.1016/j.cmet.2012.01.019.
89. Yoneshiro, T., Wang, Q., Tajima, K., Matsushita, M., Maki, H., Igarashi, K., Dai, Z., White, P.J., McGarrah, R.W., Ilkayeva, O.R., et al. (2019). BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature *572*, 614-619. 10.1038/s41586-019-1503-x.
90. Verkerke, A.R.P., Wang, D., Yoshida, N., Taxin, Z.H., Shi, X., Zheng, S., Li, Y., Auger, C., Oikawa, S., Yook, J.S., et al. (2024). BCAA-nitrogen flux in brown fat controls metabolic health independent of thermogenesis. Cell *187*, 2359-2374 e2318. 10.1016/j.cell.2024.03.030.

91. Tajima, K., Ikeda, K., Chang, H.Y., Chang, C.H., Yoneshiro, T., Oguri, Y., Jun, H., Wu, J., Ishihama, Y., and Kajimura, S. (2019). Mitochondrial lipoylation integrates age-associated decline in brown fat thermogenesis. Nat Metab *1*, 886-898. 10.1038/s42255-019-0106-z.


A
TG
FA
Glycerol-3P
GAP/DHAP
PEP
PCK1
OAA
Citrate
TCA
OAA
PCK2
?
PEP
13C
12C
Pyruvate
PC
Acetyl-CoA
Citrate
[M+3]
PCK2
PEP
[M+1]
or
[M+2]
OAA
TCA
Malate
α-KG
Succinate
B
Mitochondrial 13C pyruvate tracing in white adipocytes
Labeling of PEP (%)
P = 0.0011
P = 0.0004
P < 0.0001
P < 0.0001
P < 0.0001
P = 0.0009
P = 0.0011
[M+1]
[M+2]
[M+3]
15 min
30 min
60 min
120 min
C
Mitochondrial 13C pyruvate tracing in brown adipocytes
Labeling of PEP (%)
P < 0.0001
[M+1]
[M+2]
[M+3]
15 min
30 min
60 min
120 min
D
White adipocytes
Brown adipocytes
Pck transcripts (TPM)
P = 0.0004
P < 0.0001
Pck1 Pck2
E
Glycerolipid synthesis in white adipocytes
sg-Control
sg-Pck2 #1
sg-Pck2 #2
Incorporation of 14C-pyruvate into lipids (dpm/µg protein)
P = 0.0004
P < 0.0001
No Insulin
+ Insulin
F
Tissue-specific enrichment
log2(TES_BAT)
log2(TES_WAT)
Slc25a35
Slc25a19
Slc25a9 (Ucp3)
Slc25a1
G
Correlation of SLC25A family genes
Correlation to Acaca
Correlation to Fasn
Slc25a35
Slc25a19
Slc25a20
Slc25a15
Slc25a51
Slc25a1
H
Lipogenesis-associated SLC25A genes
Adipose-enriched genes
SLC25A35
SLC25A1
Acc/Fas-related genes
Pioglitazone-induced genes
I
TOMM20 / SLC25A35-FLAG
TOMM20
SLC25A35-FLAG
Intensity
Distance (um)
J
Control
SLC25A35-FLAG
WCL
Cytosol
Mito PK–
Mito PK+
(kDa)
FLAG
Tomm20
ATP5A
CS
37.5
25
15
50
50

Figure 1

Figure 1. Identification of carrier proteins that are linked to mitochondrial PEP synthesis.

A. Schematic of mitochondrial PEP synthesis contributing to *de novo* lipogenesis. Fully ^{13}C-labeled pyruvate ($^{13}C_3$-pyruvate) is imported into the mitochondrial matrix and converted to PEP through two independent pathways. The first is catalyzed by pyruvate carboxylase (PC), which converts pyruvate to M+3 oxaloacetate (OAA); OAA is then converted to M+3 PEP by the mitochondrial PEPCK, PCK2. The second pathway is oxidation of pyruvate via the TCA cycle, in which pyruvate is converted to M+2 OAA; OAA is further converted to M+1 or M+2 PEP by PCK2. Mitochondrial PEP is exported to the cytosol via an unknown transporter, whereas cytosolic PEP can also be generated by the cytosolic form of PEPCK, PCK1. Cytosolic PEP is sequentially metabolized to GAP/DHAP, glycerol-3P (G3P), and then used for esterification of fatty acids (FAs) to form triglyceride (TG).

B. Mitochondria isolated from white adipocytes were incubated with $^{13}C_3$-pyruvate (10 mM) for the indicated time to detect PEP by LC-MS. Labeling of PEP (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Tukey's multiple comparisons test on additive log-ratio (ALR)-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

C. Mitochondria isolated from brown adipocytes were incubated with $^{13}C_3$-pyruvate (10 mM) for the indicated time at 4°C to detect PEP by LC-MS. n = 4 per group. Statistic: Two-way ANOVA with Tukey's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

D. The transcript levels of *Pck1* and *Pck2* (Transcripts Per Million: TPM) in white adipocytes (Left) and brown adipocytes (Right). The data were obtained from the deposited RNA-seq data (GSE173710) for white adipocytes at day 4 and (GSE173710) for brown adipocytes at day 4. n = 3. Statistic: unpaired t-test on $\log_2$(TPM+0.01). Bars represent mean ± s.e.m.

E. White adipocytes transduced with two independent sgRNAs targeting *Pck2* were incubated with 1-^{14}C-pyruvate in the presence or absence of insulin for 8 hours. ^{14}C radioactivity (dpm) was measured in lipids extracted from these cells and normalized to protein levels. n = 6 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

F. SLC25A genes were plotted based on their tissue-enrichment score (TES) to white adipose tissue (x-axis: WAT) and brown adipose tissue (y-axis: BAT) in mice. The TES was calculated from the deposited RNA-seq data (GSE152382).

G. SLC25A genes were plotted based on their correlation coefficient with *Acaca* and *Fasn* transcript levels across the six subpopulations of mouse white adipocytes. The correlation coefficient of each SLC25A gene with *Acaca* or *Fasn* was calculated from the deposited single-nuclei RNA-seq data (GSE176171).

H. Venn diagram identifying *Slc25a1* and *Slc25a35* as common SLC25A genes to all three lipogenesis-associated categories: adipose tissue-enriched genes (**F**), lipogenic genes (**G**), and pioglitazone-induced genes (**Supplementary Fig.1E**). Adipose-enriched genes were defined as those with $\log_2$(TES_BAT) > 0.45 and $\log_2$(TES_WAT) > 0.45. Acc/Fas-related genes were defined as those with a correlation to *Acaca* > 0.45 and a correlation to *Fasn* > 0.45. Pioglitazone-induced genes were defined as those with $\log_2$FC to *Acaca* > 0.45 and -$\log_{10}$(P-value) > 2.

I. Representative immunofluorescence image of white preadipocytes expressing SLC25A35-FLAG (green), TOMM20 (mitochondrial outer membrane; magenta), and DAPI (nucleus; cyan). Scale bars, 10 μm (left) and 2 μm (right). The right panel shows fluorescence intensity along the solid white line.

J. Proteinase K (PK) assay in mitochondria from white preadipocytes. The mitochondria from wild-type or SLC25A35-FLAG expressing cells were exposed to degradation by PK. Immunoblotting was performed to detect SLC25A35-FLAG, TOMM20 (mitochondrial outer membrane), ATP5A (mitochondrial inner membrane), and CS (mitochondrial matrix). Molecular weight (kDa) is on the right.


A
White preadipocytes
P = 0.0099
Relative Slc25a35 mRNA levels
Control
Slc25a35 KO
B
Whole cells
Isolated Mitochondria
Metabolite profiling (LC-MS)
C
Mitochondrial metabolome
Down in KO
Up in KO
succinate
NAD+ (nega)
NAD+ (posi)
PEP
MNA
GlcNAc-1P
isocitrate
GTP
citrate
malate
ATP
1,3-BPG
-log10(P-value)
log2(FC: Slc25a35 KO/Control)
D
Whole-cell metabolome
Down in KO
Up in KO
malate
citrate
GTP
ATP
succinate
isocitrate
PEP
NAD+ (nega)
NAD+ (posi)
1,3-BPG
-log10(P-value)
log2(FC: Slc25a35 KO/Control)
E
Mitochondrial metabolite enrichment (mitochondria/whole-cell)
Down in KO
Up in KO
NAD+ (nega)
succinate
NAD+ (posi)
malate
PEP
isocitrate
citrate
1,3-BPG
GTP
ATP
-log10(P-value)
log2(FC: Slc25a35 KO/Control)
F
Add 13C3-pyruvate
Isolated Mitochondria
Wash with KPBS
Detect labeled PEP
13C
12C
Pyruvate
Acetyl-CoA
[M+3]
PCK2
PEP
OAA
Citrate
[M+1]
or
[M+2]
TCA
G
Mitochondrial 13C pyruvate tracing
Control
Slc25a35 KO
P = 0.0021
P = 0.9844
P = 0.0001
Labeling of PEP (%)
[M+1]
[M+2]
[M+3]
13C PEP
H
Isolated Mitochondria
13C3 pyruvate
+malate, succinate, glutamate
Experimental Buffer
13C3 PEP [M+3]
I
Mito PEP export assay
Control
Slc25a35 KO
Two-way ANOVA: P < 0.0001
[M+3] PEP intensity per mito protein (µg)
P < 0.0001
Incubation time (min)

Figure 2

Figure 2. SLC25A35 is required for mitochondrial PEP export.

A. Relative mRNA levels in inguinal WAT-derived control or *Slc25a35* KO preadipocytes. n = 4 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

B. Schematic of mitochondrial and whole-cell metabolomics experiments. MITO-Tag (3xHA-EGFP-OMP25) was expressed in inguinal WAT-derived control or *Slc25a35* KO preadipocytes. The mitochondria were quickly isolated using magnetic beads, washed with KPBS, and subjected to metabolomics by LC-MS. Cells from the same culture were also analyzed by LC-MS to obtain whole-cell metabolomic data.

C. Mitochondrial metabolomics of inguinal WAT-derived control or *Slc25a35* KO preadipocytes in (B). The intensity was normalized to protein levels in each sample. n = 7 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

D. Whole-cell metabolomics in (B). The intensity was normalized to protein levels in each sample. n = 7 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

E. Mitochondrial metabolite enrichment in (B). Mitochondrial metabolite enrichment was calculated as the ratio of mitochondrial to whole-cell intensity for each metabolite. n = 7 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

F. Schematic of $^{13}C_3$-pyruvate tracing in isolated mitochondria. The mitochondria isolated from inguinal WAT-derived control or *Slc25a35* KO preadipocytes were incubated with $^{13}C_3$-pyruvate (2 mM) for 5 min, quickly washed with KPBS, and subjected to LC-MS to detect labeled PEP.

G. Mitochondrial $^{13}C_3$-pyruvate tracing in (F). Labeling of indicated ^{13}C-labeled PEP (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

H. Schematic of mitochondrial PEP export assay. The mitochondria isolated from inguinal WAT-derived control or *Slc25a35* KO cells were incubated with $^{13}C_3$-pyruvate (10 mM), glutamate (10 mM), malate (2 mM), and succinate (10 mM) in KPBS for the indicated time, and quickly spun down. The KPBS buffer was subjected to LC-MS to detect [M+3] PEP.

I. Mitochondrial PEP export assay in (H). [M+3] PEP intensity was shown. n = 4 per group. The values were normalized by mitochondrial protein levels. Statistic: Two-way ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.


A
SLC25A35 proteoliposome
Unlabeled PEP
13C2 PEP
Detected by LC-MS
B
Control
SLC25A35 -TwinStrep
(kDa)
CBB
75
50
37.5
25
20
15
StrepTag
25
SLC25A35
25
C
PEP transport
Control
SLC25A35
P < 0.0001
P = 0.1835
Net PEP transport rate (13C2/13C0)
0.6
0.4
0.2
0.0
Competitor (non-label)
–
PEP
D
PEP transport
Control
SLC25A35
P = 0.0168
P = 0.0023
0.06
0.04
0.02
0.00
In: 4 mM Out: 1 mM
In: 10 mM Out: 2.5 mM
E
Competition assay
Unlabeled PEP
13C2 PEP + Competitors (Unlabeled)
F
Competition assay
Control
SLC25A35
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
0.8
0.6
0.4
0.2
0.0
Competitor (Unlabeled)
–
OAA
Malate
Succinate
G
Competition assay
Control
SLC25A35
P = 0.0180
P < 0.0001
P < 0.0001
0.8
0.6
0.4
0.2
0.0
Competitor (Unlabeled)
–
Fumarate
H
H+
12C PEP
13C PEP
PEP
CH2
pH 8.0-3.0
I
pH-dependent changes
P = 0.0009
P = 0.0121
P = 0.0262
P > 0.8411
Δ Net PEP transport rate (relative to pH 8.0)
0.15
0.10
0.05
0.00
-0.05
pH 8.0
3.0
8.0
3.0
Control liposomes
SLC25A35 liposomes

Figure 3

Figure 3. Reconstitution of PEP transport by SLC25A35.

A. Schematic of PEP transport assays with proteo-liposomes. The mitochondria from Sf9 cells expressing TwinStrep-tagged SLC25A35 or a vector control were lysed and subjected to affinity purification using StrepTactin beads. Purified SLC25A35 protein or control was reconstituted into liposomes containing unlabeled PEP (20 mM). Liposomes containing SLC25A35 or control liposomes were incubated with $^{13}C_2$ PEP (5 mM) for 20 min. ^{13}C-PEP transport ($^{13}C_2/^{13}C_0$ PEP ratio) into the liposomes was analyzed by LC-MS.

B. SLC25A35 protein purification for liposomes. Sf9 cells infected with either empty-vector baculovirus (Control) or a SLC25A35-TwinStrep construct were subjected to affinity purification. Immunoblotting was performed to detect SLC25A35 and TwinStrep, alongside Coomassie Brilliant Blue (CBB) staining. Molecular weight (kDa) is on the right.

C. Proteo-liposomes with purified SLC25A35 or control from (A) were incubated with $^{13}C_2$-labeled PEP (5 mM). ^{13}C-PEP transport ($^{13}C_2/^{13}C_0$ PEP ratio) into the liposomes was analyzed by LC-MS. As a competitor, an excess amount of unlabeled PEP (50 mM) was added to the uptake assays. n = 4 per group. Statistic: Two-way ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

D. PEP transport assay using proteo-liposomes under the indicated conditions of intra- and extra-liposomal PEP concentrations. n = 4 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

E. Schematic of the competition assay for PEP transport. An excess amount of indicated non-labeled metabolites was used as competitors in liposome-based PEP transport assays. Note: specific substrates are expected to inhibit SLC25A35-mediated PEP transport by competing for the transporter.

F. Competition assays as described in (E). An excess amount (50 mM) of unlabeled OAA, malate, and succinate was added to compete with the uptake of labeled PEP into SLC25A35 proteo-liposomes or control liposomes. n = 4 per group. Statistic: Two-way ANOVA with Bonferroni's multiple comparisons test. Bars represent mean ± s.e.m.

G. Competition assay with fumarate. An excess amount (50 mM) of unlabeled metabolites was added to compete with the uptake of labeled PEP into SLC25A35 proteo-liposomes or control liposomes. n = 4 per group. Statistic: Two-way ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

H. Schematic of pH dependency in PEP transport via SLC25A35. PEP is negatively charged and can release up to three protons in a pH-dependent manner. Under the condition of high membrane potential in the mitochondria (*i.e.,* low pH), PEP transport in SLC25A35 proteo-liposomes would be enhanced.

I. PEP transport into SLC25A35 proteo-liposomes at differential pH. Net PEP transport ratio of control or SLC25A35 proteo-liposomes was determined at pH 8.0, 7.0, 6.0, 5.0, 4.0, and 3.0. Δ Net PEP transport rate was calculated by the subtraction of the mean value at pH 8.0 from each value at the corresponding pH. n = 4 per group. Statistic: Two-way ANOVA with Tukey's multiple comparisons test. Bars represent mean ± s.e.m.


A
Intermembrane space
Inner mitochondrial membrane
Mitochondrial matrix
B
K127
Y124
R276
R175
Y72
Q73
N77
R80
C
D
M76
R80
Y72
Q73
R175
H280
Y124
K127
R276
E
ΔG free energy
Overall Mean (–26.58)
Overall SD (±10.53)
ΔG binding affinity (kcal/mol)
0
-10
-20
-30
-40
-50
Replicate 1
Replicate 2
Replicate 3
Replicate 4
Replicate 5
F
H-bonds
Hydrophobic
Ionic
Water bridges
Halogen bonds
Interactions Fraction
2.0
1.5
1.0
0.5
0.0
E21
K24
Y72
Q73
M76
N77
R80
G113
Y124
K127
R175
S180
Q183
D227
R276
L277
H280
T281
S284
G
SLC25A35 Mutant analysis
Relative transport rate (%)
200
150
100
50
0
P = 0.9524
P = 0.8073
P = 0.0020
P = 0.0004
WT
Y124A
R175A
Y124A; R175A
Y124A; R175A; R276A

Figure 4

Figure 4. Structural insights into SLC25A35-mediated PEP transport.

A. Side view of SLC25A35 structure at the inner mitochondrial membrane.

B. Key amino acid residues (green sticks) at the detected SLC25A35 central channel-like cavity.

C. Left: Side view of PEP (magenta carbons and surface) within the SLC25A35 binding site. Right: Top view of PEP within the SLC25A35 binding cavity.

D. Close-up 3D view of PEP (magenta carbons in ball and stick) key interactions (dashed lines in yellow and magenta correspond to hydrogen bond and salt bridge, respectively) established with SLC25A35 key residues after stabilizing on one of the molecular dynamics (MD) replicate simulations.

E. Molecular mechanics with generalized Born and surface area solvation (MMGBSA) ΔG binding affinity estimation for five replicates of MD simulations performed for the complex of PEP at the SLC25A35 binding site.

F. Interaction bar chart for one of the PEP-SLC25A35 MD replicate simulations, showing per residue interaction fractions.

G. Relative PEP transport activities of the wild-type and indicated mutants of the SLC25A35 protein by proteo-liposomes. The original data are shown in **Supplementary Fig. 6F, G**. The relative transport rate of each mutant was calculated based on the transport activity of the wild-type SLC25A35 liposomes in each assay. n = 4 per group. Statistic: Two-way ANOVA with Holm-Šídák's multiple comparisons test. The P-values calculated in each assay are shown as a reference. Bars represent mean ± s.e.m.


A
TG
Lipid Droplet
FA
Glycerol-3P
GA3P/DHAP
PEP
SLC25A35
PEP
Pyruvate
OAA
PCK2
B
GA3P/DHAP
P < 0.0001
Labeling of GA3P/DHAP (%)
Control
Slc25a35 KO
C
Glycerol-3P
P < 0.0001
P < 0.0001
P = 0.0079
Cellular Glycerol-3P levels (nmol/mg protein)
Control
Slc25a35 KO
Preadipo
Adipocytes
D
Glycerolipid synthesis in white adipocytes
P = 0.0006
P < 0.0001
P = 0.0319
Incorporation of 14C-pyruvate into lipids (dpm/µg protein)
Control
Slc25a35 KO
No Insulin
+ Insulin
E
White adipocytes
P = 0.6900
P = 0.1268
P < 0.0001
P < 0.0001
Cellular TG levels (µg/µg protein)
Control
Slc25a35 KO
Control
Pck1 OE
F
GA3P/DHAP
P < 0.0001
P < 0.0001
P = 0.9833
Labeling of GA3P/DHAP (%)
Control
Slc25a35 KO
Slc25a35/Pck2 DKO
G
Control (Slc25a35flox/flox)
Slc25a35Adipo KO
(Adipoq-Cre x Slc25a35flox/flox)
Male 6 weeks old
High-Fat Diet (HFD)
30°C
Tissue Harvest
H
Body weight on HFD at 30°C
ANOVA: P < 0.0001
P = 0.0407
P = 0.0178
P = 0.0309
P = 0.0144
P = 0.0154
P = 0.0249
P = 0.0227
P = 0.0210
P = 0.0230
P = 0.0258
P = 0.0452
P = 0.0279
Body weight (g)
Control
Slc25a35Adipo KO
Age (week)
I
Tissue weight on HFD at 30°C
P = 0.0415
P = 0.0412
P = 0.0002
P = 0.3346
P = 0.0787
P = 0.9534
Tissue weight (g)
Control
Slc25a35Adipo KO
EpiWAT
IngWAT
BAT
Liver
Muscle
Heart
J
BAT on HFD at 30˚C
Control
Slc25a35Adipo KO
P = 0.0012
Mean LD size per mouse (µm2)
Con
KO
K
Glycerolipid synthesis in IngWAT
P < 0.0001
P = 0.0002
P = 0.0207
Incorporation of 14C-glucose into glycerol (dpm/mg tissue)
No Insulin
+ Insulin
L
Glycerolipid synthesis in EpiWAT
P = 0.0005
P = 0.0013
P = 0.0013
Incorporation of 14C-glucose into glycerol (dpm/mg tissue)
Control
Slc25a35Adipo KO
No Insulin
+ Insulin

Figure 5

Figure 5. PEP transport via SLC25A35 is required for glyceroneogenesis in adipose tissue.

A. A model of mitochondrial PEP transport via SLC25A35 contributing to glycerolipid synthesis in adipocytes. Mitochondrial pyruvate is converted to OAA and then to PEP by PCK2. PEP is exported to the cytosol via SLC25A35, where PEP is converted to glyceraldehyde-3-P (GA3P) and dihydroxyacetone phosphate (DHAP), and further converted to glycerol-3-phosphate (G3P). G3P is esterified with fatty acids (FA) to form triglycerides (TG), which accumulate in lipid droplets.

B. Whole-cell $^{13}C_3$-pyruvate tracing in control or *Slc25a35* KO preadipocytes. Labeling of GA3P/DHAP (%) was shown. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

C. Cellular glycerol-3P levels in control or *Slc25a35* KO preadipocytes (day 0) or adipocytes (day 6). The values were normalized by protein levels. n = 6 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

D. Glycerolipid synthesis assay in control and *Slc25a35* KO adipocytes. Inguinal WAT-derived adipocytes were incubated with 1-^{14}C-pyruvate in the presence or absence of insulin for 8 hours. ^{14}C radioactivity (dpm) was measured in lipids extracted from these cells and normalized to protein levels. n = 6 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

E. Cellular triglyceride (TAG) levels in control and *Slc25a35* KO adipocytes with control or mouse *Pck1* overexpression. The values were normalized by protein levels. n = 6 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

F. Whole-cell $^{13}C_3$-pyruvate tracing in control or *Slc25a35* KO preadipocytes transduced with control or *Pck2* #1 sgRNAs. Labeling of GA3P/DHAP (%) was shown. n = 5 per group. Statistic: One-way ANOVA with Tukey's multiple comparisons test. Bars represent mean ± s.e.m.

G. Schematic of metabolic studies in fat-specific SLC25A35KO mice (*Slc25a35*^{Adipo} KO). Male mice at 6 weeks old were fed a high-fat diet (HFD) and housed at 30°C for 23 weeks.

H. Body weight changes of male control and *Slc25a35*^{Adipo} KO mice on an HFD at 30˚C. n = 10 for control and 12 for *Slc25a35*^{Adipo} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

I. Tissue weight of male mice in (H) after 23 weeks of HFD. n = 10 for control and 12 for *Slc25a35*^{Adipo} KO. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

J. Representative images of H&E staining of interscapular brown adipose tissue (BAT) from male mice in (I). Scale bars, 100 μm. Quantification of mean lipid droplet (LD) size per mouse is shown in the graphs on the right. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

K. Glycerolipid synthesis assay in inguinal white adipose tissue (IngWAT) explants from male control and *Slc25a35*^{Adipo} KO mice on an HFD. Tissue explants were incubated with $^{14}C_6$-glucose in the presence or absence of insulin for 4 hours. Lipids were extracted from inguinal WAT, saponified, and glycerol was separated by thin-layer chromatography; ^{14}C radioactivity (dpm) was measured in the glycerol fraction. The values were normalized to the initial tissue weight (mg). n = 12 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

L. Glycerolipid synthesis assay in epididymal white adipose tissue (EpiWAT) explants from male control and *Slc25a35*^{Adipo} KO mice on an HFD, performed as in (K). n = 12 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.


A
Human liver
SLC25A35 transcripts (TPM)
P < 0.0001
Healthy
MASLD
B
Mouse liver
Slc25a35 transcripts (TPM)
P = 0.0020
NCD
HFD
C
HFD at 30 °C
ANOVA: 0.1824
Body weight (g)
Control
Slc25a35Liver KO
Age (week)
D
Liver
Control
Slc25a35Liver KO
LD area (%)
P = 0.0102
Con
KO
E
Liver TG
Liver triglyceride (mg/g liver)
P = 0.0195
F
Serum Glycerol
Serum glycerol levels (mg/mL)
P = 0.0184
G
Liver Glycerol
Hepatic glycerol levels (µg/mg tissue)
P = 0.0343
H
Liver lipidomics
Control
Slc25a35Liver KO
P-value
TG(16:0_16:3_22:6)
TG(16:0_22:6_22:6)
TG(18:1_18:1_20:3)
TG(18:1_18:1_20:1)
TG(16:0_18:1_22:6)
TG(16:0_18:1_22:5)
TG(40:7_16:0)+O:(s)
TG(20:4_18:2_18:2)+O:(s)
TG(18:1_18:2_18:2)+O:(s)
TG(16:0_18:1_16:2)+O:(s)
TG(16:1_18:1_18:2)+O:(s)
TG(18:1_18:1_16:3)+O:(s)
DG(16:1_20:4)
PC(18:0_22:5)
PI(18:0_18:0)
PI(22:4_18:0)
LPS(18:0)
Cer(d18:1_22:1)
Cer(d18:0_24:1)
Cer(d18:0_16:0)
0.0463
0.0411
0.0418
0.0383
0.0307
0.0326
0.0264
0.0063
0.0156
0.0282
0.0482
0.0472
0.0066
0.0429
0.0130
0.0216
0.0364
0.0396
0.0183
0.0458
Z-score
I
Control
Slc25a35Liver KO
F4/80 / Hoechst
Macrophages
F4/80-positive cells/HPF
P = 0.0241
J
ITT
Blood glucose (mg/dl)
P = 0.0241
P = 0.0116
P = 0.0403
ANOVA:
P = 0.0290
Control
Slc25a35Liver KO
min
ITT AUC (mg*min/dl)
P = 0.0252
K
Slc25a35flox/flox mice injected with AAV8-TBG-Empty (Control) or AAV8-TBG-iCre (Liver KO)
Male 6 weeks old
HFD
8 weeks
30°C
AAV
injection
30°C
Tissue
Harvest
L
Liver triglyceride (mg/g liver)
P = 0.0072
M
LD area (%)
P = 0.0009
N
Serum ALT (IU/l)
P = 0.0046
Serum AST (IU/l)
P = 0.0242
Control
AAV-KOLiver

Figure 6

Figure 6. Blockade of mitochondrial PEP transport ameliorates hepatic steatosis *in vivo*.

A. *Slc25a35* transcripts (TPM) in the human liver isolated from healthy individuals and MASLD patients. The data were obtained from the deposited RNA-seq data (GSE246221). n = 4 healthy individuals and n = 28 MASLD patients. Statistic: unpaired t-test on $\log_2$(TPM+0.01). Bars represent mean ± s.e.m.

B. *Slc25a35* transcripts (TPM) in the liver samples from mice fed a normal chow diet (NCD) or high-fat diet (HFD). The data were obtained from the deposited RNA-seq data (GSE199105). n = 6 per group. Statistic: unpaired t-test on $\log_2$(TPM+0.01). Bars represent mean ± s.e.m.

C. Body weight changes of male control mice and liver-specific SLC25A35 KO mice (*Slc25a35*^{Liver} KO) on an HFD at 30˚C for the indicated time points. n = 10 for control and 18 for *Slc25a35*^{Liver} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

D. Representative H&E staining images of the liver from male control and *Slc25a35*^{Liver} KO mice on an HFD for 19 weeks. Scale bars, 100 μm. Quantification of LD area (%) is shown in the graphs on the right. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

E. Liver triglyceride (TG) levels in male control and *Slc25a35*^{Liver} KO mice. The values were normalized to tissue weight (g). n = 10 for control and 18 for *Slc25a35*^{Liver} KO. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

F. Serum glycerol levels in male control and *Slc25a35*^{Liver} KO mice. n = 10 for control and 18 for *Slc25a35*^{Liver} KO. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

G. Liver glycerol levels in male control and *Slc25a35*^{Liver} KO mice. The values were normalized to the initial tissue weight (g). n = 10. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

H. Lipidomics of the liver from male control and *Slc25a35*^{Liver} KO mice. The top 20 lipid species significantly reduced in *Slc25a35*^{Liver} KO mice are shown. Intensities were normalized to the sum of total lipid intensities. n = 10 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

I. Representative immunostaining images of the liver from male control and *Slc25a35*^{Liver} KO mice on an HFD for 19 weeks, stained with an anti-F4/80 antibody. Scale bars, 50 μm. Right panel: Quantification of F4/80-positive cells per high-power field (HPF) is shown in the graphs on the right. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

J. Insulin tolerance test (ITT) of male control and *Slc25a35*^{Liver} KO mice on an HFD for 18 weeks. Mice were fasted for 6 hours. n = 10 for control and 18 for *Slc25a35*^{Liver} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. unpaired t-test for AUC analysis. Bars represent mean ± s.e.m.

K. Schematic of inducible SLC25A35 depletion in the liver. Male *Slc25a35*$^{flox/flox}$ mice were fed an HFD at 30°C for 8 weeks. AAV8-TBG-iCre or AAV8-TBG-null (control) was delivered into the liver via tail-vein injection. Their liver tissues were harvested, and subsequent metabolic studies were performed.

L. Liver triglyceride levels in male control and AAV-KO^{Liver} mice on an HFD. The values were normalized to tissue weight (g). n = 13 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

M. Quantification of LD area (%) of the liver from male control and AAV-KO^{Liver} mice based on H&E staining images of the liver. n = 13 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

N. Left: Serum ALT levels in male control and AAV-KO^{Liver} mice on an HFD. Right: Serum AST levels in male control and AAV-KO^{Liver} mice on an HFD. n = 13 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.



Figure 7. A proposed model of how mitochondria-derived PEP via SLC25A35 licenses glycerolipid synthesis.

Lipogenic cells, such as adipocytes, abundantly express the mitochondrial isoform of PEPCK (PCK2). These cells can generate phosphoenol pyruvate (PEP) within the mitochondria by converting oxaloacetate (OAA) to PEP by PCK2. Mitochondria-derived PEP is exported into the cytosolic compartment via SLC25A35. PEP efflux is facilitated when mitochondrial membrane potential is high. Exported PEP in the cytosolic compartment is converted to glycerol-3P through multiple enzymatic steps, which is then esterified with fatty acids to yield glycerolipids (triglycerides, diacylglycerols, and phospholipids). Thus, mitochondria support lipogenesis by providing PEP for the synthesis of the glycerol backbone, in addition to ATP and citrate for fatty acid synthesis. Note that citrate carrier SLC25A1 is also expressed highly in lipogenic cells.

Adipocyte-specific deletion of SLC25A35 limits lipid accumulation on a high-fat diet. Blockade of SLC25A35 in the liver, by Alb-Cre mediated deletion or inducible deletion by AAV delivery, reduces the synthesis of glycerolipid and effectively ameliorates hepatic steatosis on a high-fat diet.


A
Mitochondrial 13C pyruvate tracing in white preadipocytes
Labeling of PEP (%)
P = 0.1098
P = 0.0253
P = 0.0176
P = 0.0247
P < 0.0001
P = 0.0013
P < 0.0001
P < 0.0001
P = 0.0001
P < 0.0001
P = 0.0021
[M+1]
[M+2]
[M+3]
15 min
30 min
60 min
120 min
B
Mitochondrial 13C pyruvate tracing in brown adipocytes
Labeling rate (%)
P < 0.0001
P = 0.1133
P = 0.5715
P = 0.7573
P = 0.6386
P = 0.0325
P = 0.0101
P = 0.0081
P = 0.0029
P = 0.0116
[M+1]
[M+2]
[M+3]
[M+4]
[M+5]
[M+6]
Citrate /Isocitrate
AlphaKG
Succinate
Malate
C
Mitochondrial 13C pyruvate tracing in white adipocytes
Labeling rate (%)
P < 0.0001
P = 0.5588
[M+1]
[M+2]
[M+3]
[M+4]
[M+5]
[M+6]
Citrate /Isocitrate
AlphaKG
Succinate
Malate
D
Mitochondrial 13C pyruvate tracing in white preadipocytes
Labeling rate (%)
P < 0.0001
[M+1]
[M+2]
[M+3]
[M+4]
[M+5]
[M+6]
Citrate /Isocitrate
AlphaKG
Succinate
Malate
E
Mitochondrial 13C pyruvate tracing in C2C12 myoblasts
Labeling of PEP (%)
P < 0.0001
P = 0.0008
P = 0.0016
P = 0.9497
P = 0.4453
P = 0.0748
[M+1]
[M+2]
[M+3]
15 min
30 min
60 min
120 min
F
Mitochondrial 13C pyruvate tracing in HEK293T cells
Labeling of PEP (%)
P < 0.0001
P = 0.0011
P = 0.0914
P = 0.2622
[M+1]
[M+2]
[M+3]
15 min
30 min
60 min
120 min

Figure S1

Figure S1. Mitochondrial pyruvate tracing studies in adipocytes, related to Figure 1.

A. $^{13}C_3$-pyruvate tracing to detect mitochondria-derived PEP in white preadipocytes. Mitochondria isolated from white preadipocytes were incubated with $^{13}C_3$-pyruvate (10 mM) for the indicated time to detect mitochondria-derived PEP by LC-MS. Labeling of indicated ^{13}C-labeled PEP (%) was shown. n = 4 per group. Statistic: Two-way ANOVA with Tukey's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

B. Mitochondria isolated from brown adipocytes were incubated with $^{13}C_3$-pyruvate (10 mM) for 15 min to detect the indicated TCA metabolites by LC-MS (see Figure 1C). Labeling of the metabolite (%) was shown on the Y-axis. n = 4 per group. Statistic: One-way ANOVA with Tukey's multiple comparisons test on additive log-ratio (ALR)-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

C. Mitochondria isolated from white adipocytes were incubated with $^{13}C_3$-pyruvate (10 mM) for 15 min to detect the indicated TCA metabolites by LC-MS (see Figure 1B). Labeling of the metabolite (%) was shown on the Y-axis. n = 4 per group. Statistic: One-way ANOVA with Tukey's multiple comparisons test on additive log-ratio (ALR)-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

D. Mitochondria isolated from white adipocytes were incubated with $^{13}C_3$-pyruvate (10 mM) for 15 min to detect the indicated TCA metabolites by LC-MS (see Figure S1A). Statistic: One-way ANOVA with Tukey's multiple comparisons test on additive log-ratio (ALR)-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

E. $^{13}C_3$-pyruvate tracing to detect mitochondria-derived PEP in myoblasts. Mitochondria isolated from C2C12 myoblasts were incubated with $^{13}C_3$-pyruvate (10 mM) to detect mitochondria-derived PEP by LC-MS. Labeling of indicated ^{13}C-labeled PEP (%) was shown. n = 4 per group. Statistic: Two-way ANOVA with Tukey's multiple comparisons test on ALR-transformed data using M+0 as the denominator.

F. $^{13}C_3$-pyruvate tracing to detect mitochondria-derived PEP in HEK293T cells. Mitochondria isolated from HEK293T cells were incubated with $^{13}C_3$-pyruvate (10 mM) to detect mitochondria-derived PEP by LC-MS. Labeling of indicated ^{13}C-labeled PEP (%) was shown. n = 4 per group. Statistic: Two-way ANOVA with Tukey's multiple comparisons test on ALR-transformed data using M+0 as the denominator.


A
Pck1 OE
Pck2 KO
White Preadipo
White Adipo
Brown Preadipo
Brown Adipo
(kDa)
PEPCK1
Non-specific
50
PEPCK2
50
Ponceau-S
50
B
sg-Control
sg-Pck1 #1
sg-Pck1 #2
sg-Pck2 #1
sg-Pck2 #2
(kDa)
PEPCK2
75
β-actin
50
PCK2 protein levels
P < 0.0001
P < 0.0001
P = 0.6099
P = 0.5234
Relative PEPCK2 levels
C
Glycerolipid synthesis in white adipocytes
P = 0.0008
P = 0.0010
P = 0.8011
P = 0.3335
Incorporation of 14C-glucose into lipids (dpm/µg protein)
D
Pioglitazone-induced genes
Slc25a20
Slc25a10
Slc25a5
Slc25a35
Slc25a1
Slc25a7 (Ucp1)
Slc25a30
-log10(P-value)
log2(Pioglitazone / Control)
Slc25a35
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
Normalized microarray intensity
Control
Rosiglitazone
Troglitazone
Pioglitazone
AG035029
PPARγ agonists
E
Adipocyte
ASPC
Mesothelial
Endothelial
Lymphatic Endo
Pericyte
Smooth Muscle
Macrophage
Monocyte
Dendritic Cell
Mast Cell
Neutrophil
B Cell
NK Cell
T Cell
Male Epithelial
Female Epithelial
Identity
Slc25a35
Average mRNA abundance
Percent Transcript-positive
F
mAd1
mAd2
mAd3
mAd4
mAd5
mAd6
Identity
Slc25a35
Acaca
Fasn
Elovl6
Percent Transcript-positive
Average mRNA abundance
G
SLC25A35-FLAG / TOMM20
TOMM20
SLC25A35-FLAG
Relative intensity
Distance (µm)

Figure S2

Figure S2. Mitochondrial carrier proteins that are linked to mitochondrial PEP synthesis, related to Figure 1.

A. Immunoblotting of preadipocytes or adipocytes using PEPCK1 and PEPCK2 antibodies. Ponceau-S staining was used as a loading control. White and brown adipocytes were used at day 6 and 4, respectively. Mouse *Pck1*-overexpressing cells were used as positive controls for the PEPCK1 antibody. *Pck2* #1 sgRNA-transduced cells were used as a negative control for the PEPCK2 antibody. Molecular weight (kDa) is on the right.

B. Left: Immunoblotting of white preadipocytes transduced with the indicated sgRNAs targeting PCK1 or PCK2 using antibodies for PEPCK2. β-actin was used as a loading control. Note that the PEPCK1 protein was undetected by the PCK1 antibody used in the study in white preadipocytes. Right: Quantification of the relative PEPCK2 protein levels to β-actin. n = 4 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

C. White adipocytes transduced with two independent sgRNAs targeting either *Pck1* or *Pck2* were incubated with $^{14}C_6$-glucose and insulin for 8 hours. ^{14}C radioactivity (dpm) was measured in lipids extracted from these cells and normalized to protein levels. n = 4 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

D. Left: Volcano plot showing changes in transcript levels of *Slc25a* family genes in epididymal WAT of rats fed an HFD with or without pioglitazone treatment. Log_2 fold changes (x-axis) and $-log_{10}$ adjusted P-values (y-axis) were calculated from microarray data (GSE21329). Right: Normalized microarray intensity of *Slc25a35* in epididymal WAT of rats fed an HFD with or without various PPARγ agonists from microarray data (GSE21329). n = 3 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test on log_2-transformed values. Bars represent mean ± s.e.m.

E. Dot plot showing *Slc25a35* transcript abundance across cell types identified in mouse single-nuclei RNA-seq data (GSE176171) of white adipose tissue. Dot size indicates the percentage of cells in each cluster with detectable *Slc25a35* transcripts, and color represents the average scaled transcript abundance. *Slc25a35* mRNA was most abundant in adipocytes.

F. Dot plot showing *Slc25a35*, *Acaca*, *Fasn*, and *Elovl6* mRNA abundance across white adipocyte subclusters (mAd1–mAd6) from mouse single-nuclei RNA-seq data (GSE176171). Dot size indicates the percentage of cells in each cluster with detectable transcripts, and color represents average scaled transcript abundance. Note that SLC25A35 was expressed in the mAd5 population that highly expressed representative lipogenic genes, *Acaca*, *Fasn*, and *Elovl6.*

G. Representative immunofluorescence image of differentiated white adipocytes at day 3 expressing SLC25A35-FLAG (green). TOMM20 (magenta) and DAPI (cyan) were used to stain the mitochondrial outer membrane and the nucleus, respectively. Scale bars, 10 μm (left) and 2 μm (right). The right panel shows fluorescence intensity along the mitochondria, indicated by a white line.


A
Input
Mito-IP
Con
KO
Con
KO
ATP5A (Mitochondria)
Calreticulin (ER)
PEX14 (Peroxisome)
GM130 (Golgi)
EEA1 (Endosome)
GAPDH (Cytosol)
Histone H3 (Nucleus)
50
50
50
150
150
37.5
15
B
Differentiated adipocytes
Mitochondrial metabolome
Down in KO
Up in KO
Aspartate
Uracil
AlphaKG
Kynurenate
Folate
Inosine
PEP
Homocystine
Succinate
Malate
-log10(P-value)
log2(FC: Slc25a35 KO/Control)
C
Differentiated adipocytes
Whole-cell metabolome
Down in KO
Up in KO
Aspartate
AlphaKG
Xanthine
PEP
Malate
Succinate
-log10(P-value)
log2(FC: Slc25a35 KO/Control)
D
Differentiated adipocytes
Mitochondrial metabolite enrichment
(mitochondria / whole-cell)
Down in KO
Up in KO
Pipecolate
3-MT
Aspartate
PEP
Malate
-log10(P-value)
log2(FC: Slc25a35 KO/Control)
E
13C pyruvate tracing
(Mitochondria)
Control
Slc25a35 KO
ANOVA: P = 0.0002
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
[M + 3] PEP rate (%)
5 min
15 min
60 min
120 min
F
13C pyruvate tracing
(Whole-cell)
Control
Slc25a35 KO
P = 0.9566
P = 0.2536
P = 0.1148
P = 0.8908
Labeling of Succinate (%)
[M+1]
[M+2]
[M+3]
[M+4]
13C Succinate
G
13C pyruvate tracing
(Whole-cell)
Control
Slc25a35 KO
P = 0.9984
P = 0.8425
P = 0.9588
P = 0.9998
P = 0.9666
P = 0.7125
Labeling of Citrate (%)
[M+1]
[M+2]
[M+3]
[M+4]
[M+5]
[M+6]
13C Citrate
H
13C pyruvate tracing
(Mitochondria)
Control
Slc25a35 KO
P = 0.8453
P = 0.9774
P = 0.0002
P > 0.9999
P > 0.9999
P = 0.1194
Labeling of Citrate/Isocitrate (%)
[M+1]
[M+2]
[M+3]
[M+4]
[M+5]
[M+6]
13C Citrate/Isocitrate
I
13C pyruvate tracing
(Mitochondria)
Control
Slc25a35 KO
P = 0.9998
P = 0.0511
P =0.8493
P = 0.1514
P = 0.0834
Labeling of AlphaKG (%)
[M+1]
[M+2]
[M+3]
[M+4]
[M+5]
13C AlphaKG
J
13C pyruvate tracing
(Mitochondria)
Control
Slc25a35 KO
P = 0.9996
P = 0.9979
P = 0.5590
P = 0.9889
Labeling of Succinate (%)
[M+1]
[M+2]
[M+3]
[M+4]
13C Succinate
K
13C pyruvate tracing
(Mitochondria)
Control
Slc25a35 KO
P = 0.9897
P = 0.9145
P = 0.4676
P = 0.1002
Labeling of Malate (%)
[M+1]
[M+2]
[M+3]
[M+4]
13C Malate
L
Control
Slc25a35 KO
EBSS (1 hour):
–
+
–
+
(kDa)
p-PDH (S293)
PDH
PC
Vinculin
50
37.5
50
37.5
150
100
150
100

Figure S3

Figure S3. SLC25A35 deletion results in the mitochondrial accumulation of PEP, related to Figure 2.

A. Mitochondrial isolation using MITO-Tag isolation from inguinal WAT-derived control or *Slc25a35* KO preadipocytes. Immunoblotting was performed to detect the indicated organelle marker proteins. Molecular weight (kDa) is on the right.

B. Mitochondrial metabolomics of differentiated inguinal WAT-derived control or *Slc25a35* KO adipocytes. The intensity was normalized to protein levels in each sample. n = 5 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

C. Whole-cell metabolomics of differentiated inguinal WAT-derived control or *Slc25a35* KO adipocytes in (B). The intensity was normalized to protein levels in each sample. n = 5 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

D. Mitochondrial metabolite enrichment of differentiated inguinal WAT-derived control or *Slc25a35* KO adipocytes in (B). Mitochondrial metabolite enrichment was calculated as the ratio of mitochondrial to whole-cell intensity for each metabolite. n = 5 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

E. Time course changes of $^{13}C_3$-pyruvate tracing in inguinal WAT-derived control or *Slc25a35* KO preadipocytes at the indicated time points. Labeling of indicated ^{13}C-labeled PEP (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

F. Whole-cell $^{13}C_3$-pyruvate tracing to detect succinate in inguinal WAT-derived control or *Slc25a35* KO preadipocytes. Labeling of indicated ^{13}C-labeled succinate (%) was shown. n = 5 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

G. Whole-cell $^{13}C_3$-pyruvate tracing to detect citrate in inguinal WAT-derived control or *Slc25a35* KO preadipocytes in (F). Labeling of indicated ^{13}C-labeled citrate (%) was shown. n = 5 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

H. Mitochondrial $^{13}C_3$-pyruvate tracing to detect citrate/isocitrate at 15 min in (E). Labeling of citrate/isocitrate (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

I. Mitochondrial $^{13}C_3$-pyruvate tracing to detect alphaKG at 15 min in (E). Labeling of alphaKG (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

J. Mitochondrial $^{13}C_3$-pyruvate tracing to detect succinate at 15 min in (E). Labeling of succinate (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

K. Mitochondrial $^{13}C_3$-pyruvate tracing to detect malate at 15 min in (E). Labeling of malate (%) was shown on the Y-axis. n = 4 per group. Statistic: Two-way ANOVA with Šídák's multiple comparisons test on ALR-transformed data using M+0 as the denominator. Bars represent mean ± s.e.m.

L. Immunoblotting to detect the indicated proteins in inguinal WAT-derived control or *Slc25a35* KO preadipocytes with or without one-hour EBSS starvation. Molecular weight (kDa) is on the right.



Figure S4. The substrate specificity of SLC25A35, related to Figure 3.

A. Liposome-based PEP transport assay. Liposomes were partially digested with Proteinase K (50 µg/mL) or left untreated for 10 min at 4°C prior to the transport assay. The liposomes containing non-labeled PEP (20 mM) were incubated with $^{13}C_2$ PEP (5 mM) for 20 min. ^{13}C-PEP transport ($^{13}C_2/^{13}C_0$ PEP ratio) into the liposomes was analyzed by LC-MS. n = 4 per group. Statistic: Two-way ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.



Figure S5. Structure of SLC25A35 predicted by AlphaFold, related to Figure 4.

A. AlphaFold structure (AF-Q3KQZ1-F1-model_v4). This structure presents all residues with very high or confident (pLDDT > 90 or between 90-70, respectively) per-residue confidence scores, except for residues D298, T299, and K300 with pLDDT of 66.64, 62.10, and 46.45, respectively. The pLDDT for putative substrate-binding site residues A10, Y72, Q73, M76, N77, R80, A117, Y124, K127, R175, V176, S180, M223, R276, L277, and H280 are 87.52, 93.85, 90.99, 87.90, 85.36, 86.20, 90.86, 94.61, 95.99, 90.24, 88.90, 86.03, 93.42, 89.62, 84.53, and 88.56, respectively. The average pLDDT is 89.25 for the whole structure and is 89.66 for the binding site residues.

B. Cartoon/ribbon representation of the predicted SLC25A35 structure showing its eleven (six in vertical) transmembrane alpha helices and corresponding range of amino acids, with a respective color scheme.

C. Surface and cartoon (in white) representation of the predicted SLC25A35 structure with the cavities (pockets) identified by SiteMap.


A
B
V176
A117
M76
Y72
R175
Y124
Q73
K127
R276
H280
C
RMSD (Å)
Time (ns)
Apo
PEP
D
E
F
SLC25A35 Mutant Analysis
Net PEP transport rate
($^{13}C_2/^{13}C_0$)
P < 0.0001
P = 0.0020
P = 0.8073
P = 0.9524
Control
WT
Y124A
R175A
Y124A; R175A
SLC25A35
G
SLC25A35 Mutant Analysis
P < 0.0001
P = 0.0004
Control
WT
Y124A; R175A; R276A
SLC25A35

Figure S6

Figure S6. Molecular interactions between SLC25A35 and PEP revealed by MD simulation, related to Figure 4.

A. Side view of the SLC25A35-PEP complex. The "before" structure corresponds to the best-scoring induced fit docking pose and is shown in yellow (protein) and blue (PEP), while the "after" structure is shown in green (protein) and magenta (PEP).

B. Close-up view of the SLC25A35–PEP binding site showing minor shifts in PEP position and overlapping residues before and after MD simulation. Key interacting pairs of residues are labeled in red.

C. Root Mean Square Deviation (RMSD) of the protein backbone plotted against simulation time (ns), obtained from MD simulations of SLC25A35 in the apo form (blue) and in complex with PEP (orange).

D. 2D interaction diagram of PEP in the docking pose (before MD simulation). Magenta arrows indicate hydrogen bonds; blue-to-red lines indicate salt bridges.

E. 2D interaction diagram for PEP after MD simulation. Magenta arrows indicate hydrogen bonds; blue-to-red lines indicate salt bridges.

F. Liposome-based PEP transport assay with control, the wild-type, and the indicated mutants of SLC25A35 proteins. n = 4 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m. The data are shown in **Figure 4G** as relative transport activity to the wild-type SLC25A35 protein.

G. Liposome-based PEP transport assay with control, the wild-type, and Y124A; R175A; R276A mutant of SLC25A35 proteins. Control and wild-type SLC25A35 samples are identical to those shown in Fig. S4A. n = 4 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m. The data are shown in **Figure 4G** as relative transport activity to the wild-type SLC25A35 protein.


A
Glycerolipid synthesis in white adipocytes
Incorporation of 14C-glucose into lipids (dpm/µg protein)
P = 0.0023
P = 0.0023
P = 0.0155
Control
Slc25a35 KO
No Insulin
+ Insulin
B
Glycerol-3P
Cellular Glycerol-3P levels (nmol / mg protein)
P = 0.7622
P = 0.1883
P = 0.0005
P = 0.0385
Control
Pck1 OE
C
GA3P/DHAP
Labeling of GA3P/DHAP (%)
P < 0.0001
Control
Pck2 KO
D
Relative Slc25a35 mRNA levels
Slc25a35Adipo KO
P < 0.0001
P < 0.0001
P = 0.6769
IngWAT
BAT
Liver
E
Male, IngWAT
Control
Slc25a35Adipo KO
Mean LD size per mouse (µm2)
P = 0.0002
Con
KO
F
Female, HFD
Body weight (g)
ANOVA:
P < 0.0001
Age (week)
G
Female, HFD
Tissue weight (g)
P < 0.0001
P = 0.0192
P = 0.0055
P = 0.0882
P = 0.2638
P = 0.5327
EpiWAT
IngWAT
BAT
Liver
Muscle
Heart
H
Female, BAT
P = 0.0084
I
Female, IngWAT
P = 0.0321
J
Male, NCD at RT
ANOVA:
P = 0.8067
K
Female, NCD at RT
ANOVA:
P = 0.8126

Figure S7

Figure S7. SLC25A35 is required for glyceroneogenesis in adipose tissue, related to Figure 5.

A. Lipogenesis assay in control and *Slc25a35* KO adipocytes. Inguinal WAT-derived adipocytes were incubated with $^{14}C_6$-glucose in the presence or absence of insulin for 8 hours. ^{14}C radioactivity (dpm) was measured in lipids extracted from these cells and normalized to protein levels. n = 4 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

B. Cellular glycerol-3P levels in control or *Slc25a35* KO adipocytes with control or mouse *Pck1* overexpression. The values were normalized by protein levels. n = 6 per group. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

C. Whole-cell $^{13}C_3$-pyruvate tracing to detect GA3P/DHAP in preadipocytes transduced with control or *Pck2* #1 sgRNAs. Labeling of GA3P/DHAP (%) was shown. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

D. Relative *Slc25a35* mRNA levels in the indicated tissues from male control and *Slc25a35*^{Adipo} KO mice on an HFD at 30 ˚C, measured by qPCR. *n* = 8 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

E. Representative H&E staining images of inguinal WAT sections from male control and *Slc25a35*^{Adipo} KO mice on an HFD at 30 ˚C. Scale bars, 100 μm. Right panel: Quantification of mean lipid droplet (LD) size per mouse is shown in the graphs on the right. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

F. Body weight changes in female control and *Slc25a35*^{Adipo} KO mice on an HFD at 30 ˚C. n = 15 for control and 9 for *Slc25a35*^{Adipo} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

G. Tissue weight of female control and *Slc25a35*^{Adipo} KO mice on an HFD. n = 15 for control and 9 for *Slc25a35*^{Adipo} KO. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

H. Representative H&E staining images of interscapular BAT sections from female control and *Slc25a35*^{Adipo} KO mice on an HFD at 30 ˚C. Scale bars, 100 μm. Right panel: Quantification of mean lipid droplet (LD) size per mouse is shown in the graphs on the right. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

I. Representative H&E staining images of inguinal WAT sections from female control and *Slc25a35*^{Adipo} KO mice on an HFD at 30 ˚C. Scale bars, 100 μm. Right panel: Quantification of mean lipid droplet (LD) size per mouse is shown in the graphs on the right. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

J. Body weight changes in male control and *Slc25a35*^{Adipo} KO mice on a normal chow diet (NCD) at room temperature (RT). n = 16 for control and 21 for *Slc25a35*^{Adipo} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

K. Body weight changes in female control and *Slc25a35*^{Adipo} KO mice on a NCD at room temperature (RT). n = 21 for control and 15 for *Slc25a35*^{Adipo} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.


A
Thermogenesis
Control
Slc25a35Adipo KO
ANOVA: 0.7010
CL316,243
@ 30°C
Energy Expenditure (kcal/day)
Time (hour)
B
Energy Expenditure
@ 30°C
Control
Slc25a35Adipo KO
ANOVA: 0.9031
Light
Dark
Energy Expenditure (kcal/day)
Time (hour)
C
Food Intake
@ 30°C
Control
Slc25a35Adipo KO
ANOVA: 0.7893
Total Food Consumption (kcal)
Time (hour)
D
Locomotor Activity
@ 30°C
Control
Slc25a35Adipo KO
ANOVA: 0.0789
Locomotor Activity (beam breaks/hr)
Time (hour)
E
Lipolysis in IngWAT
P < 0.0001
P = 0.5640
P = 0.9312
Control
Slc25a35Adipo KO
Glycerol (mg/g tissue)
Basal state
With ISO
F
Lipolysis in BAT
P = 0.0014
P = 0.5640
P = 0.9312
Control
Slc25a35Adipo KO
Glycerol (mg/g tissue)
Basal state
With ISO
G
Glucose oxidation
Control
Slc25a35Adipo KO
P = 0.8140
P = 0.5786
P = 0.3062
[U-14C]Glucose oxidation (dpm per mg tissue)
EpiWAT
IngWAT
BAT

Figure S8

Figure S8. Metabolic characterization of *Slc25a35*^{Adipo} KO mice, related to Figure 5.

A. Whole-body energy expenditure of male control and *Slc25a35*^{Adipo} KO mice on an HFD, measured using the Comprehensive Lab Animal Monitoring System (CLAMS). Mice were housed at 30˚C and received an intraperitoneal injection of CL316,243 (0.5 mg kg-1) at 0 hour (arrow). n = 8 per group. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

B. Whole-body energy expenditure of male control and *Slc25a35*^{Adipo} KO mice on an HFD, measured for 48 hours at 30 °C using CLAMS. n = 8 per group. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

C. Total food consumption of male control and *Slc25a35*^{Adipo} KO mice in (C). n = 8 per group. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

D. Locomotor activity of male control and *Slc25a35*^{Adipo} KO mice in (C). n = 8 per group. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

E. Lipolysis assay in the inguinal WAT from male control and *Slc25a35*^{Adipo} KO mice on an HFD. Tissue explants were incubated in the absence (basal state) or presence of isoproterenol (ISO) for 4 hours. Glycerol levels in the media were measured using a free glycerol reagent and normalized to tissue weight (g). n = 11 for control and 12 for *Slc25a35*^{Adipo} KO. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

F. Lipolysis assay in the interscapular BAT from male control and *Slc25a35*^{Adipo} KO mice on an HFD. Tissue explants were incubated in the absence (basal state) or presence of isoproterenol (ISO) for 4 hours. Glycerol levels in the media were measured using a free glycerol reagent and normalized to tissue weight (g). n = 11 for control and 12 for *Slc25a35*^{Adipo} KO. Statistic: One-way ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.

G. Glucose oxidation assay in the indicated tissues from male control and *Slc25a35*^{Adipo} KO mice on an HFD. The radioactivity was normalized to tissue weight (mg). *n* = 6 for the group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.


A
Mitochondrial metabolite (Hepatocyte)
Control
Slc25a35 KO
Mitochondrial metabolite enrichment (mitochondria / whole-cell)
P = 0.0025
P = 0.3086
P = 0.2273
P = 0.1923
PEP
GSH
Inosine
Hexose phosphate
B
Control
Slc25a35Liver KO
Relative Slc25a35 mRNA levels
P < 0.0001
P = 0.2048
P = 0.5216
Liver
IngWAT
BAT
C
HFD at 30 °C
Tissue weight (g)
P = 0.0465
P = 0.1419
P = 0.1419
P = 0.2857
P = 0.0647
P = 0.9843
Control
Slc25a35Liver KO
Liver
EpiWAT
IngWAT
BAT
Muscle
Heart
D
Control
Slc25a35Liver KO
Relative mRNA levels
P = 0.0009
P = 0.0002
P < 0.0001
P = 0.4053
Col1a1
Acta2
Adgre1
Col3a1
E
PTT
Blood glucose (mg/dl)
P = 0.0129
P = 0.0117
P = 0.0134
P = 0.0030
P = 0.0016
ANOVA:
P = 0.0030
Control
Slc25a35Liver KO
min
PTT AUC (mg*min/dl)
P = 0.0054
Con
KO
F
Hepatic gluconeogenesis assay
Control Glu–
Control Glu+
Slc25a35 KO Glu–
Slc25a35 KO Glu+
13C-labelled glucose in media
P = 0.0458
P = 0.1401
P = 0.7902
1 hour
2 hour
3 hour

Figure S9

Figure S9. Blockade of mitochondrial PEP transport in the liver ameliorates hepatic steatosis *in vivo*, related to Figure 6.

A. Mitochondrial metabolite enrichment of primary hepatocytes isolated from control and *Slc25a35*^{Liver} KO mice. Metabolites in isolated mitochondria and whole cells were analyzed by metabolomics. Mitochondrial metabolite enrichment was calculated as the ratio of mitochondrial to whole-cell intensity for each metabolite. n = 5 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

B. Relative *Slc25a35* mRNA levels in the indicated tissues from male control and *Slc25a35*^{Liver} KO mice on an HFD, measured by qPCR. *n* = 8 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

C. Tissue weight of male control and *Slc25a35*^{Liver} KO mice on an HFD. n = 10 for control and 18 for *Slc25a35*^{Liver} KO. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

D. Relative mRNA levels of pro-inflammatory and fibrosis genes in the liver of control and *Slc25a35*^{Liver} KO mice on an HFD. n = 8 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

E. Pyruvate tolerance test (PTT) of male control and *Slc25a35*^{Liver} KO mice on an HFD for 17 weeks. Mice were fasted for 16 hours. n = 10 for control and 18 for *Slc25a35*^{Liver} KO. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. unpaired t-test for AUC analysis. Bars represent mean ± s.e.m.

F. Gluconeogenesis assay in the primary hepatocytes from control and *Slc25a35*^{Liver} KO mice. As a positive control of gluconeogenesis, hepatocytes were treated with or without glucagon at 100 nM. n = 3 per group. Statistic: Two-way repeated-measures ANOVA with Holm-Šídák's multiple comparisons test. Bars represent mean ± s.e.m.



Figure S10. AAV-based blockade of mitochondrial PEP transport in the liver ameliorates hepatic steatosis *in vivo*, related to Figure 6.

A. Relative *Slc25a35* mRNA levels in the livers from control and AAV-KO^{Liver} mice on an HFD. n = 8 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

B. Body weight chart for male control and AAV-KO^{Liver} mice on an HFD. n = 13 per group. Statistic: Two-way repeated-measures ANOVA with uncorrected Fisher's LSD test. Bars represent mean ± s.e.m.

C. Lipidomics of the liver from male control and AAV-KO^{Liver} mice. The top 20 lipid species significantly reduced in AAV-KO^{Liver} mice are shown. Intensities were normalized to the sum of total lipid intensities. n = 13 per group. Statistic: unpaired t-test on $\log_{10}$-transformed values.

D. Representative images of H&E staining of liver sections from male control and AAV-KO^{Liver} mice on an HFD. Scale bars, 100 µm. Quantification of LD area (%) is shown in the graphs in **Figure 6M**.

E. Relative mRNA levels of indicated mitokines and mitochondrial stress marker genes in the liver of male control and AAV-KO^{Liver} mice on an HFD. n = 8 per group. Statistic: unpaired t-test. Bars represent mean ± s.e.m.

Table S1. Mitochondrial metabolome in white preadipocytes (P-value < 0.05)

Detected in negative ion mode

Metabolite	FC	log_2(FC)	P-value	-log_{10}(P-value)
PEP	11.313	3.5	5.05E-05	4.2963
1,3-BPG	6.5276	2.7065	0.004467	2.35
2,3-BPG	4.3703	2.1277	0.0031327	2.5041
NAD+	3.6488	1.8674	4.19E-09	8.3778
IDP	3.6437	1.8654	0.014107	1.8506
Glutathione disulfide	3.6231	1.8572	2.65E-05	4.5771
NADP+	2.4277	1.2796	0.002372	2.6249
N-carbamoyl-L-aspartate	2.2635	1.1786	0.026998	1.5687
dGDP	2.1671	1.1157	0.00034007	3.4684
Myo-inositol	1.989	0.99206	0.00015592	3.8071
UDP-D-glucose	1.9231	0.94344	0.00054668	3.2623
Pantothenate	1.6462	0.7191	0.031365	1.5036
ADP	1.4905	0.57584	0.037204	1.4294
p-Hydroxybenzoate	0.80804	-0.3075	0.044113	1.3554
Pyrophosphate	0.78851	-0.3428	0.0054717	2.2619
2-Isopropylmalic acid	0.76574	-0.38507	0.030711	1.5127
dTTP	0.75155	-0.41206	0.048522	1.3141
Glucose-1-phosphate	0.75067	-0.41374	0.043039	1.3661
Lactate	0.72554	-0.46288	0.009162	2.038
Oxaloacetate	0.71312	-0.48779	0.00047587	3.3225
Ribose-phosphate	0.71063	-0.49283	0.0035489	2.4499
Orotidine-5-phosphate	0.69861	-0.51743	0.04981	1.3027
Hydroxyisocaproic acid	0.68268	-0.55071	0.0080463	2.0944

Nicotinate	0.6729	-0.57154	0.0024572	2.6096
Succinate	0.67124	-0.57511	3.60E-09	8.4434
Methylmalonic acid	0.67004	-0.57767	0.00019697	3.7056
Glycolate	0.66775	-0.58261	0.049519	1.3052
UTP	0.64346	-0.63607	0.046267	1.3347
O8P-O1P	0.63406	-0.6573	0.0068197	2.1662
KIV	0.63164	-0.66284	0.00616	2.2104
Indole-3-carboxylic acid	0.622	-0.68502	0.0029617	2.5285
Citramalate	0.59976	-0.73753	1.13E-06	5.9456
Hydroxyphenylpyruvate	0.59918	-0.73893	0.0082194	2.0852
Atrolactic acid	0.57759	-0.79189	0.0078693	2.1041
Shikimate	0.57395	-0.80101	0.00067513	3.1706
SBP	0.55034	-0.86161	0.02785	1.5552
Trehalose-6-phosphate	0.54718	-0.86991	0.011921	1.9237
Cholic acid	0.5348	-0.90293	0.011627	1.9345
2-Dehydro-D-gluconate	0.53194	-0.91066	0.00015064	3.8221
Kynurenic acid	0.52527	-0.92887	0.0005645	3.2483
Xanthine	0.52441	-0.93122	0.0061272	2.2127
Deoxyuridine	0.50749	-0.97856	0.0063001	2.2007
Orotate	0.50172	-0.99503	0.0052227	2.2821
Citrate	0.49844	-1.0045	0.033355	1.4768
Isocitrate	0.41563	-1.2666	0.0025722	2.5897
Hypoxanthine	0.41501	-1.2688	0.0032769	2.4845
GlcNAc-1P	0.35461	-1.4957	0.00030243	3.5194

Detected in positive ion mode

Metabolite	FC	log_2(FC)	P-value	-log_{10}(P-value)
NAD+	3.8811	1.9565	6.89E-06	5.1617
Phosphorylcholine	3.4105	1.77	3.40E-05	4.468
NADP+	3.2937	1.7197	0.0015624	2.8062
Glutathione disulfide	3.2288	1.691	0.007612	2.1185
Adenosine	2.4111	1.2697	7.67E-05	4.1152
Nicotinamide	2.1539	1.1069	0.00070315	3.153
Creatine	2.0111	1.008	0.004455	2.3511
Glycerophosphocholine	1.8389	0.87883	0.0061687	2.2098
CMP	1.8008	0.84866	0.026267	1.5806
N-acetyl-L-alanine	1.7339	0.79405	0.0029267	2.5336
AMP	1.6065	0.68396	0.0011597	2.9357
Phenylalanine	1.4827	0.56821	0.014325	1.8439
FAD	1.4631	0.54907	0.00010183	3.9921
Cholesterol	0.71542	-0.48313	0.0012747	2.8946
Putrescine	0.71078	-0.49252	0.0018243	2.7389
Urea	0.69688	-0.52101	0.049519	1.3052
Cysteine	0.68876	-0.53792	0.0076617	2.1157
Betaine	0.67314	-0.57102	0.01466	1.8339
Serine	0.65871	-0.60229	0.040778	1.3896
Betaine aldehyde	0.65224	-0.61652	0.013633	1.8654
Carnitine	0.64586	-0.63072	0.0052957	2.2761
Tryptophan	0.64472	-0.63325	0.031959	1.4954
Ethanolamine	0.61506	-0.70119	0.041701	1.3798
N-acetyl-L-ornithine	0.61126	-0.71015	0.020839	1.6811
Indole	0.58228	-0.78022	0.016577	1.7805

N-acetyl spermine	0.56878	-0.81407	0.00041088	3.3863
S-methyl-5-thioadenosine	0.5678	-0.81655	0.0050257	2.2988
Spermidine	0.5358	-0.90025	3.05E-06	5.5155
N-acetylputrescine	0.52076	-0.94131	0.016373	1.7859
Methylnicotinamide	0.42086	-1.2486	0.00020289	3.6927

Table S2. Whole-cell metabolome in white preadipocytes (P-value < 0.05)

Detected in negative ion mode

Metabolite	FC	log_2(FC)	P-value	-log_{10}(P-value)
Lactate	2.0187	1.0134	9.63E-06	5.0162
Citrate	1.8919	0.91983	1.02E-07	6.9926
N-carbamoyl-L-aspartate	1.8547	0.89116	0.00018779	3.7263
Isocitrate	1.8065	0.85319	0.002623	2.5812
dCDP	1.7405	0.79952	0.00068783	3.1625
Trehalose-sucrose	1.724	0.78572	2.75E-07	6.5603
Allantoate	1.7126	0.77621	0.0027406	2.5622
Thymidine	1.6257	0.70105	0.028826	1.5402
UDP	1.5878	0.66703	7.60E-06	5.1189
Malate	1.5426	0.62537	1.77E-08	7.7529
Geranyl-PP	1.5151	0.5994	0.0056658	2.2467
Aconitate	1.5047	0.5895	1.42E-05	4.8478
Maleic acid	1.5008	0.58571	8.63E-07	6.0641
Fumarate	1.5003	0.58524	7.69E-07	6.1139
Myo-inositol	1.4737	0.55948	1.34E-06	5.8745
Fructose-1,6-bisphosphate	1.4684	0.55422	0.00024299	3.6144
SBP	1.461	0.54695	0.013057	1.8842
CDP	1.4602	0.54615	2.72E-07	6.5655
2-Hydroxyglutarate	1.46	0.54597	5.72E-06	5.2429
Citramalate	1.444	0.5301	0.00010063	3.9973
KIV	1.441	0.52708	1.08E-06	5.9658
Pyroglutamic acid	1.4376	0.52367	0.017342	1.7609
2-Ketohexanoic acid	1.4376	0.52364	0.00059229	3.2275

Glutathione	1.433	0.51901	0.00015515	3.8093
dTDP	1.4159	0.50168	0.0024816	2.6053
Itaconic acid	1.3864	0.47135	0.00044053	3.356
UTP	1.3841	0.46897	3.87E-05	4.4122
GDP	1.3754	0.45983	0.0029839	2.5252
Citraconic acid	1.3669	0.45092	0.00011046	3.9568
Hydroxyisocaproic acid	1.3532	0.43637	0.021331	1.671
Cholesteryl sulfate	1.3528	0.43591	0.00028434	3.5462
ADP	1.3455	0.42817	0.00016669	3.7781
dATP	1.3296	0.41098	0.0011065	2.956
Succinate	1.3286	0.40993	0.00055793	3.2534
Allantoin	1.2901	0.36746	0.02876	1.5412
dGDP	1.2882	0.36536	0.00034705	3.4596
Methylmalonic acid	1.2774	0.35321	0.0070195	2.1537
CTP	1.2682	0.34276	0.00012336	3.9088
IDP	1.2636	0.33753	0.00028995	3.5377
Ascorbic acid	1.2603	0.33378	0.021408	1.6694
dCTP	1.2472	0.31867	0.0033225	2.4785
Glutathione disulfide	1.2466	0.318	0.00043501	3.3615
GTP	1.2464	0.31773	6.82E-05	4.1661
D-sedoheptulose-1-7-phosphate	1.2173	0.28365	0.00085287	3.0691
N-acetyl-L-alanine	1.2109	0.27614	0.0011393	2.9433
ATP	1.209	0.27381	6.99E-05	4.1558
D-erythrose-4-phosphate	1.1984	0.26115	0.0036626	2.4362
dGTP	1.1834	0.24298	0.00044974	3.347
NAD+	1.1759	0.23371	0.010964	1.96

UDP-D-glucose	1.1745	0.23204	0.0017673	2.7527
Phenylpropiolic acid	0.89592	-0.15857	0.028476	1.5455
Ribose-phosphate	0.85358	-0.2284	0.00049798	3.3028
Quinolinate	0.84729	-0.23908	0.010847	1.9647
Pyrophosphate	0.83001	-0.2688	0.0021479	2.668
6-Phosphoglucono-δ-lactone	0.82697	-0.2741	0.035892	1.445
PRPP	0.81223	-0.30005	0.0065168	2.186
Carbamoyl phosphate	0.79142	-0.33748	0.004699	2.328
Deoxyribose-phosphate	0.77803	-0.3621	0.0071386	2.1464
2-Isopropylmalic acid	0.76963	-0.37776	0.0045696	2.3401
Trehalose-6-phosphate	0.76613	-0.38433	0.00090725	3.0423
Xanthosine	0.76283	-0.39056	0.0075732	2.1207
2,3-Dihydroxybenzoic acid	0.76065	-0.3947	0.0074275	2.1292
3-Methylphenylacetic acid	0.74218	-0.43016	0.00024156	3.617
Homocysteic acid	0.72022	-0.47349	0.0057324	2.2417
Taurodeoxycholic acid	0.71503	-0.48392	0.031383	1.5033
Uridine	0.67924	-0.55802	0.034896	1.4572
GlcNAc-1P	0.63779	-0.64884	8.33E-05	4.0793
Guanidoacetic acid	0.62898	-0.66891	2.80E-05	4.5533
Indoleacrylic acid	0.5884	-0.76512	0.00015307	3.8151
Hypoxanthine	0.44926	-1.1544	0.0032642	2.4862

Detected in positive ion mode

Metabolite	FC	log_2(FC)	P-value	-log_{10}(P-value)
4-Aminobutyrate	3.7522	1.9077	6.46E-05	4.1897
Adenosine	2.458	1.2975	0.012089	1.9176
SAM	2.2042	1.1402	0.026118	1.5831
N-acetylaspartylglutamic acid	1.9948	0.99623	0.00032088	3.4937
Succinyl-CoA	1.7658	0.82033	0.015744	1.8029
Xanthosine-5-phosphate	1.7614	0.8167	0.011528	1.9382
Argininosuccinic acid	1.7344	0.79446	0.0009097	3.0411
Glucosamine	1.5958	0.6743	0.028886	1.5393
Alanine	1.5004	0.58538	0.00010935	3.9612
Glutathione disulfide	1.4716	0.55739	3.24E-06	5.4894
Pyridoxine	1.4704	0.55625	3.06E-05	4.5136
L-arginino-succinate	1.4629	0.54884	0.035146	1.4541
Glutathione	1.4514	0.53747	0.0079637	2.0989
Proline	1.419	0.50491	8.91E-05	4.0501
Coenzyme A	1.3734	0.4578	0.0023613	2.6268
N-acetyl-L-alanine	1.3554	0.43876	0.020615	1.6858
Sarcosine	1.3472	0.43	7.36E-06	5.1332
Creatine	1.3312	0.4127	0.00051439	3.2887
Phenylalanine	1.2921	0.36971	0.019361	1.7131
AMP	1.2916	0.36918	0.00018125	3.7417
Tyrosine	1.2586	0.33178	0.0042586	2.3707
NAD+	1.2388	0.309	0.021858	1.6604
DL-pipecolic acid	1.2066	0.27097	0.041907	1.3777
Kynurenine	1.2016	0.26497	0.047394	1.3243
Leucine/Isoleucine	1.1075	0.14728	0.017959	1.7457

Asparagine	0.75701	-0.40162	0.0011359	2.9447
dCMP	0.7498	-0.41541	0.0054062	2.2671
UMP	0.73015	-0.45374	0.0024275	2.6148
Carnitine	0.69833	-0.51802	0.00066938	3.1743
D-glucosamine-6-phosphate	0.62991	-0.66677	0.02365	1.6262

Table S3. Mitochondrial metabolite enrichment (Mito/Whole ratio; P-value < 0.05)

Detected in negative ion mode

Metabolite	FC	log_2(FC)	P-value	-log_{10}(P-value)
PEP	9.4068	3.2337	0.00019936	3.7004
1,3-BPG	5.3866	2.4294	0.0039683	2.4014
2,3-BPG	4.0233	2.0084	0.044286	1.3537
NAD+	3.1142	1.6388	7.98E-09	8.098
Glutathione disulfide	2.9733	1.5721	0.00031403	3.503
Xanthosine	2.806	1.4885	0.0043053	2.366
NADP+	2.3164	1.2119	0.0018933	2.7228
dGDP	1.7212	0.78343	0.013124	1.8819
UDP-D-glucose	1.6238	0.69937	0.0015652	2.8054
Myo-inositol	1.3535	0.43666	0.042123	1.3755
6-Phospho-D-gluconate	1.3239	0.40478	0.0066092	2.1799
Oxaloacetate	0.73162	-0.45084	0.022373	1.6503
Nicotinate	0.71749	-0.47896	0.0045445	2.3425
O8P-O1P	0.70455	-0.50523	0.023993	1.6199
Itaconic acid	0.70017	-0.51421	0.00028494	3.5452
UDP	0.69962	-0.51536	0.04024	1.3953
dTTP	0.68979	-0.53577	0.025298	1.5969
Cholesteryl sulfate	0.68886	-0.53773	0.0018983	2.7216
dTDP	0.68203	-0.55208	0.030723	1.5125
Glycerate	0.67966	-0.55711	0.034088	1.4674
Trehalose-6-Phosphate	0.66771	-0.5827	0.039425	1.4042
ATP	0.66492	-0.58875	0.039163	1.4071
dGTP	0.65891	-0.60184	0.029265	1.5337

GTP	0.65798	-0.60389	0.027675	1.5579
Citraconic acid	0.65674	-0.6066	0.024393	1.6127
Glutathione	0.64267	-0.63784	0.00017197	3.7646
Phenylpyruvate	0.63606	-0.65276	0.012649	1.8979
Aconitate	0.63411	-0.6572	0.002161	2.6653
Phenyllactic acid	0.624	-0.68038	0.014099	1.8508
2-Hydroxyglutarate	0.60667	-0.72103	0.0015947	2.7973
Xanthine	0.59467	-0.74985	0.008507	2.0702
Shikimate	0.59399	-0.75148	0.003905	2.4084
GlcNAc-1P	0.59292	-0.7541	0.01475	1.8312
Indole-3-carboxylic acid	0.58826	-0.76547	0.002551	2.5933
Hydroxyisocaproic acid	0.56885	-0.81389	0.0056825	2.2455
Fructose-1,6-bisphosphate	0.55688	-0.84455	0.0045901	2.3382
Maleic acid	0.55063	-0.86085	0.00045047	3.3463
Atrolactic acid	0.55044	-0.86134	0.017777	1.7501
Methylmalonic acid	0.54837	-0.86677	0.00024337	3.6137
Fumarate	0.54694	-0.87054	0.0058505	2.2328
Malate	0.54081	-0.88679	6.45E-05	4.1905
Succinate	0.51615	-0.95414	3.22E-07	6.4926
UTP	0.47325	-1.0793	0.0088739	2.0519
Kynurenic acid	0.45173	-1.1465	0.0024091	2.6181
KIV	0.43613	-1.1972	0.00012904	3.8893
Citramalate	0.42518	-1.2339	3.95E-07	6.4037
Lactate	0.37	-1.4344	1.26E-06	5.9009
SBP	0.3543	-1.497	0.0022776	2.6425
Citrate	0.28809	-1.7954	0.0047038	2.3276

Isocitrate	0.27756	-1.8491	0.0013914	2.8566

Detected in positive ion mode

Metabolite	FC	log_2(FC)	P-value	-log_{10}(P-value)
NADP+	3.2416	1.6967	0.0016731	2.7765
NAD+	3.111	1.6374	7.93E-06	5.101
Nicotinamide	2.8821	1.5271	0.0095716	2.019
Phosphorylcholine	2.7953	1.483	0.00062614	3.2033
Glycerophosphocholine	1.8672	0.90086	0.01373	1.8623
FAD	1.6007	0.67874	0.013781	1.8607
Creatine	1.508	0.59262	0.048826	1.3114
Cholesterol	0.74128	-0.43191	0.0046586	2.3317
Serine	0.64465	-0.63341	0.03916	1.4072
Glutathione	0.60286	-0.7301	0.0071256	2.1472
Tryptophan	0.58244	-0.77983	0.018957	1.7222
N-acetyl-glutamine	0.58025	-0.78526	0.004202	2.3765
N-acetyl spermidine	0.57242	-0.80487	0.013972	1.8547
Spermidine	0.53371	-0.90588	0.0002391	3.6214
Putrescine	0.53232	-0.90964	6.11E-05	4.2141
Indole	0.48249	-1.0514	0.014877	1.8275
S-methyl-5-thioadenosine	0.44918	-1.1546	0.0024362	2.6133
Pyridoxine	0.44319	-1.174	0.0076904	2.1141

Table S4. Liver lipidomics of control and *Slc25a35* KO^{Liver} mice (P-value < 0.05)

Lipid	FC	log_2(FC)	P-value	-log_{10}(P-value)
TG(40:7_16:0)+O:(s)	0.57122	-0.80789	0.026388	1.5786
TG(14:0_18:2_22:6)	0.60338	-0.72886	0.033985	1.4687
PG(30:0_16:0)	0.60934	-0.71467	0.03043	1.5167
TG(20:4_18:2_18:2)+O:(s)	0.6229	-0.68292	0.0063108	2.1999
TG(12:0_18:2_18:3)	0.63048	-0.66547	0.029964	1.5234
d5-TG(32:5_22:6)	0.63359	-0.65838	0.045333	1.3436
TG(28:3_16:0)	0.63664	-0.65146	0.039697	1.4012
TG(10:0_16:0_20:4)	0.63722	-0.65014	0.041954	1.3772
DG(16:1_20:4)	0.64174	-0.63994	0.0065615	2.183
TG(16:0_16:3_22:6)	0.64384	-0.63524	0.046288	1.3345
PG(O-24:0_18:2)	0.6702	-0.57734	0.021409	1.6694
TG(18:1_18:2_18:2)+O:(s)	0.67077	-0.57612	0.015569	1.8078
TG(15:0_18:2_20:5)	0.68018	-0.55601	0.04185	1.3783
PG(O-28:0_22:6)	0.68772	-0.54011	0.023304	1.6326
PEt(O-12:0_20:3)	0.68937	-0.53664	0.047624	1.3222
TG(16:0_14:1_18:1)+O:(s)	0.69006	-0.53521	0.048572	1.3136
TG(16:0_18:1_16:2)+O:(s)	0.69458	-0.52578	0.028204	1.5497
TG(16:1_18:1_18:2)+O:(s)	0.69633	-0.52215	0.048166	1.3173
TG(16:0_15:2_22:6)	0.71458	-0.48484	0.03246	1.4887
PEt(23:6_18:0)	0.72036	-0.47321	0.046256	1.3348
TG(18:1_18:1_16:3)+O:(s)	0.72918	-0.45566	0.047214	1.3259
TG(16:0_22:6_22:6)	0.73641	-0.44142	0.041115	1.386
Cer(d18:1_22:1)	0.74454	-0.42557	0.039551	1.4028
TG(16:0_13:1_18:2)	0.74636	-0.42205	0.029561	1.5293

PI(18:0_18:0)	0.75487	-0.40569	0.013035	1.8849
PC(18:0_22:5)	0.75559	-0.40432	0.042893	1.3676
PI(22:4_18:0)	0.75739	-0.4009	0.021613	1.6653
TG(18:1_18:1_20:3)	0.76028	-0.3954	0.041778	1.3791
Cer(d18:0_24:1)	0.77365	-0.37025	0.018319	1.7371
LPS(18:0)	0.77933	-0.35968	0.036381	1.4391
TG(18:1_18:1_20:1)	0.79095	-0.33834	0.038308	1.4167
TG(18:1_15:2_18:2)	0.7998	-0.32229	0.035004	1.4559
d5-TG(18:3_16:0_20:4)	0.80708	-0.30921	0.04071	1.3903
Cer(d18:0_16:0)	0.83643	-0.25768	0.045802	1.3391
TG(16:0_18:1_22:6)	0.83997	-0.25158	0.030713	1.5127
TG(16:0_18:1_22:5)	0.85085	-0.23303	0.032551	1.4874
d5-TG(36:5_20:2)	0.85398	-0.22772	0.023344	1.6318
TG(36:7_25:7)+O:(s)	1.0745	0.1036	0.0056993	2.2442
TG(26:1_9:0)+OO:(s)	1.1277	0.17338	0.041832	1.3785
d5-TG(36:6_20:4)	1.1279	0.1737	0.045671	1.3404
SM(t34:1)	1.1352	0.18301	0.041257	1.3845
TG(14:0_16:0_18:1)	1.1677	0.22372	0.04058	1.3917
SM(d15:0_21:5)	1.1745	0.23204	0.0051183	2.2909
TG(16:0_16:0_18:1)	1.1968	0.25923	0.04496	1.3472
PEt(O-23:5_16:1)	1.2206	0.28755	0.022309	1.6515
SM(d44:6)	1.2206	0.28756	0.048151	1.3174
TG(13:1_21:0_21:0)	1.228	0.2963	0.042382	1.3728
DG(O-18:4_18:2)	1.249	0.3208	0.0294	1.5316
TG(18:2_18:2_22:5)	1.2664	0.34077	0.038751	1.4117
TG(30:1_9:0)+OO:(s)	1.2701	0.3449	0.029242	1.534

SM(d42:5)	1.2955	0.37348	0.029677	1.5276
PG(O-30:1_18:2)	1.3074	0.38675	0.0097043	2.013
SPH(d19:0)	1.3115	0.39117	0.02762	1.5588
PC(18:1_22:6)	1.3118	0.39157	0.021946	1.6587
TG(37:7_22:6)	1.3224	0.40318	0.035872	1.4452
PE(18:2_17:0)	1.3506	0.43361	0.042375	1.3729
DG(O-42:6)	1.3612	0.44489	0.031779	1.4979
d5-TG(36:5_22:6)	1.3781	0.46266	0.0075338	2.123
d5-DG(14:0_16:0)	1.4375	0.52354	0.029879	1.5246
PE(16:0_18:2)	1.4598	0.54578	0.0090021	2.0457
TG(34:2_6:0)+OO:(s)	1.4681	0.55397	0.023077	1.6368
ChE(22:6)	1.4827	0.56825	0.04796	1.3191
PE(22:6_15:0)	1.5111	0.59558	0.0092944	2.0318
AcCa(16:2)	1.6365	0.71059	0.047258	1.3255
SM(d41:6)	1.6422	0.71561	0.0052426	2.2805
ChE(18:2)	1.9298	0.94848	0.0083663	2.0775
TG(O-16:0_18:1_22:6)	2.4262	1.2787	0.018623	1.73
TG(23:0_18:1_18:1)	2.7218	1.4446	0.022076	1.6561

Table S5. Liver lipidomics of control and AAV-KO^{Liver} mice (P-value < 0.05)

Lipid	FC	log_2(FC)	P-value	-log_{10}(P-value)
MePC(33:3)	0.096679	-3.3707	0.036075	1.4428
TG(3:0_16:0_18:1)	0.30328	-1.7213	0.034741	1.4592
DG(16:0_22:5)	0.48863	-1.0332	0.019057	1.72
TG(27:3_16:0)	0.48932	-1.0311	0.028877	1.5395
AcCa(3:0)	0.50782	-0.97762	0.00098931	3.0047
DG(19:0_17:3)	0.52784	-0.92182	0.043772	1.3588
DG(P-22:7_16:0)	0.53436	-0.90413	0.039664	1.4016
TG(O-13:0_22:6_3:0)	0.53692	-0.89723	0.039125	1.4075
DG(P-41:10)	0.55196	-0.85737	0.016952	1.7708
DG(22:6_18:0)	0.55616	-0.84642	0.0029755	2.5264
TG(P-21:6_16:0_3:0)	0.5687	-0.81426	0.045551	1.3415
TG(P-11:0_20:2_7:0)	0.57124	-0.80783	0.013608	1.8662
TG(O-23:7_18:1_3:0)	0.57705	-0.79323	0.037604	1.4248
PA(16:0_18:1)	0.57848	-0.78966	0.0059761	2.2236
PG(30:2_16:0)	0.57891	-0.7886	0.025567	1.5923
DG(16:0_24:5)	0.58911	-0.76338	0.030082	1.5217
DG(18:0_22:5)	0.59549	-0.74784	0.0073074	2.1362
PG(18:0_20:3)	0.60537	-0.72411	0.0015424	2.8118
DG(17:2_22:6)	0.6072	-0.71976	0.034832	1.458
TG(O-13:1_3:0_18:1)	0.60937	-0.71461	0.022973	1.6388
DG(20:1_22:6)	0.62165	-0.68583	0.044142	1.3552
DG(16:0_20:4)	0.62317	-0.68231	0.023517	1.6286
DG(20:5_20:1)	0.64449	-0.63378	0.033433	1.4758
Cer(m18:0_24:1)	0.64691	-0.62836	0.029198	1.5346

TG(O-15:1_22:5_3:0)	0.6521	-0.61683	0.034987	1.4561
DG(18:0_22:6)	0.65781	-0.60425	0.0071063	2.1484
PEt(O-12:0_21:3)	0.65818	-0.60345	0.032314	1.4906
PG(18:1_18:1)	0.6652	-0.58813	0.013765	1.8612
PG(22:4_22:6)	0.69517	-0.52456	0.02782	1.5556
LBPA(22:5_22:6)	0.70242	-0.5096	0.03273	1.4851
DG(18:0_22:4)	0.70419	-0.50596	0.027551	1.5599
SQDG(18:2_18:3)	0.70622	-0.5018	0.049067	1.3092
LBPA(18:0_18:2)	0.7114	-0.49127	0.019979	1.6994
SQDG(18:3_22:6)	0.71279	-0.48844	0.04051	1.3924
PG(30:1_16:0)	0.71437	-0.48525	0.019688	1.7058
Cer(m18:0_24:0)	0.71868	-0.47658	0.020584	1.6865
MGDG(18:2_18:2)	0.71891	-0.47611	0.030716	1.5126
PG(18:0_20:4)	0.71899	-0.47595	0.011385	1.9436
PI(O-18:1_20:4)	0.72046	-0.473	0.00039765	3.4005
PA(20:4_25:5)	0.72653	-0.4609	0.033884	1.47
LBPA(18:0_18:3)	0.73171	-0.45065	0.0044624	2.3504
PG(18:1_22:5)	0.73502	-0.44415	0.016622	1.7793
LBPA(20:3_22:6)	0.73821	-0.43789	0.019401	1.7122
LBPA(18:0_22:6)	0.73931	-0.43575	0.043258	1.3639
TG(9:0_16:1_18:1)	0.73999	-0.43443	0.049045	1.3094
TG(P-7:0_20:3_13:0)	0.74574	-0.42325	0.028027	1.5524
PE(O-16:1_22:6)	0.75192	-0.41135	0.033753	1.4717
LBPA(20:4_22:5)	0.75239	-0.41044	0.025461	1.5941
PG(30:1_18:2)	0.75287	-0.40952	0.045685	1.3402
Cer(d18:0_22:1)	0.75457	-0.40627	0.04983	1.3025

DG(18:0_20:4)	0.75862	-0.39855	0.012223	1.9128
PE(O-16:0_22:4)	0.75941	-0.39704	0.00065571	3.1833
LBPA(22:6_22:6)	0.76881	-0.3793	0.022254	1.6526
PG(20:4_22:4)	0.77841	-0.3614	0.014497	1.8387
PG(18:2_20:3)	0.79049	-0.33919	0.034471	1.4626
PG(16:0_20:3)	0.79315	-0.33434	0.0070401	2.1524
TG(20:3_16:0_15:2)	0.7999	-0.3221	0.036679	1.4356
LBPA(22:5_16:0)	0.80255	-0.31734	0.031089	1.5074
PC(34:4)	0.80258	-0.31727	0.021188	1.6739
LBPA(18:1_20:4)	0.81007	-0.30389	0.030769	1.5119
DG(O-20:5_18:3)	0.83828	-0.2545	0.03221	1.492
CL(18:2_18:2_20:3_22:6)	0.84706	-0.23947	0.036611	1.4364
AcCa(20:4)	0.85135	-0.23218	0.030551	1.515
Hex1Cer(d18:1_20:0)	0.85341	-0.22868	0.024444	1.6118
Cer(d18:2_24:1)	0.85493	-0.22613	0.032746	1.4848
Cer(d18:1_16:0)	0.8731	-0.19577	0.047695	1.3215
PC(18:0_22:4)	0.87842	-0.18702	0.006051	2.2182
Cer(d18:1_24:1)	0.88082	-0.18307	0.0042124	2.3755
PC(O-14:1_22:4)	0.89087	-0.16671	0.043649	1.36
TG(16:0_16:0_18:1)	0.89582	-0.15872	0.04941	1.3062
PE(O-18:2_22:6)	0.90659	-0.14148	0.032083	1.4937
PG(18:0_18:2)	0.90994	-0.13616	0.011574	1.9365
CL(18:1_18:1_18:2_20:4)	0.92166	-0.11769	0.03294	1.4823
DG(O-18:4_18:2)	1.0655	0.091481	0.021183	1.674
PC(O-24:0_23:7)	1.0861	0.1192	0.0083393	2.0789
DG(O-16:2_18:1)	1.0925	0.12758	0.027684	1.5578

TG(16:0_18:1_20:3)	1.0935	0.12895	0.0068729	2.1629
DG(O-22:6_16:0)	1.1039	0.14259	0.025342	1.5962
TG(18:1_18:2_20:5)	1.1168	0.15939	0.018487	1.7331
TG(17:1_18:1_18:2)	1.1255	0.17058	0.017101	1.767
PS(20:4_22:6)	1.1273	0.17285	0.033927	1.4695
PA(47:11)	1.1336	0.18088	0.01617	1.7913
TG(16:0_18:1_23:4)	1.1356	0.1834	0.013783	1.8607
TG(17:1_18:1_18:1)	1.1374	0.18573	0.0055926	2.2524
TG(16:0_18:1_19:2)	1.1375	0.18587	0.0074218	2.1295
CL(20:4_18:2_18:2_18:2)	1.1376	0.18602	0.0036444	2.4384
PS(20:3_22:6)	1.1399	0.18895	0.01308	1.8834
TG(20:0_18:1_20:4)	1.1413	0.19066	0.0078036	2.1077
PS(18:2_20:2)	1.1428	0.19254	0.030833	1.511
TG(17:1_18:2_22:6)	1.1499	0.20155	0.037403	1.4271
PC(36:5)	1.1502	0.20189	0.041647	1.3804
DG(O-18:3_18:0)	1.1622	0.21689	0.015146	1.8197
TG(17:1_18:2_18:2)	1.1634	0.2184	0.028631	1.5432
PI(18:1_18:2)	1.171	0.22772	0.022358	1.6506
TG(16:0_18:1_21:4)	1.1727	0.22979	0.013739	1.8621
TG(18:1_20:0_22:6)	1.1817	0.24083	0.0044844	2.3483
PC(22:7_18:2)	1.1828	0.24217	0.0023312	2.6324
PC(35:5)	1.1898	0.25078	0.024321	1.614
Cer(d16:1_44:6)	1.2031	0.26671	0.044936	1.3474
TG(15:2_18:2_22:7)	1.204	0.26783	0.002692	2.5699
DG(O-20:6_19:0)	1.2102	0.27524	0.031785	1.4978
PS(25:4_20:4)	1.2155	0.28153	0.040101	1.3968

TG(36:3_25:5)	1.2201	0.28702	0.037141	1.4301
SM(d42:4)	1.2248	0.29254	0.031586	1.5005
TG(O-15:2_16:0_21:3)	1.2318	0.30082	0.046852	1.3293
SM(t42:1)	1.2421	0.31273	0.04468	1.3499
TG(16:0_18:2_25:5)	1.2526	0.32496	0.0035171	2.4538
PE(22:7_18:2)	1.254	0.32651	0.01345	1.8713
TG(13:0_21:1_23:2)	1.2551	0.32779	0.0045536	2.3416
TG(18:1_19:1_18:2)	1.2583	0.33152	0.03104	1.5081
PC(P-41:12)	1.2591	0.33237	0.0044407	2.3525
PG(O-28:1_17:3)	1.2679	0.3424	0.0023566	2.6277
PE(20:5_18:0)	1.2768	0.35254	0.02344	1.63
SM(t42:0)	1.2933	0.37102	0.045016	1.3466
TG(16:0_18:1_18:1)	1.3088	0.38821	0.032079	1.4938
PC(16:0_18:3)	1.3242	0.40516	0.022062	1.6564
MePC(38:4)	1.3483	0.43115	0.023324	1.6322
PE(22:7_19:0)	1.3578	0.44126	0.0016385	2.7856
TG(17:1_18:3_22:6)	1.374	0.45837	0.0062024	2.2074
TG(17:2_19:2_21:3)	1.3878	0.47285	0.0054381	2.2646
AcCa(14:2)	1.4529	0.5389	0.031436	1.5026
TG(P-29:8)	1.5948	0.67338	0.03617	1.4417
TG(O-18:2_16:0_18:1)	1.6092	0.68634	0.047857	1.3201
ChE(18:2)	1.624	0.69956	0.032588	1.4869
TG(O-20:0_18:1_22:5)	1.6297	0.70463	0.032226	1.4918
PI(20:0_20:4)	1.6518	0.72401	0.012623	1.8988
TG(18:1_16:0_19:3)	1.8706	0.90353	0.012352	1.9083
Cer(d12:0_18:1)	6.4141	2.6812	0.0047678	2.3217

SPH(d14:0)	37.119	5.2141	0.0018983	2.7216
SPH(d16:0)	42.949	5.4246	0.0044741	2.3493

Table S6. Primer sequences used for gRNA, genotyping, LentiCRISPR, and qPCR, related to STAR Methods

gRNA sequence for generating *Slc25a35*-flox mice	
gRNA1 for insertion of the 5′ loxP site	GCCTAAGAGATCCGTCCCCTGGG
gRNA2 for insertion of the 3′ loxP site	TCGAGGATCAGTGATCCCTTAGG

Gene	Forward Primer	Reverse Primer
Genotyping		
The 5′ loxP site in *Slc25a35*	AGAGGCAAGGCATCCAGAACTT	GCCCTACAGCAATTTCAGAGGC
The 3′ loxP site in *Slc25a35*	TCAAGGACCTCTTGAGCCAGTG	AAGGGTGTCATTGCCACGACTA
Adipo-Cre	CTCTGGGAGAGGCGAGTATG	ATGTTTAGCTGGCCCAAATG
Alb-Cre	GAAGCAGAAGCTTAGGAAGATGG	TTGGCCCCTTACCATAACTG
LentiCRISPR		
Control	CACCGCCTGGGTTAGAGCTACCGCA	AAACTGCGGTAGCTCTAACCCAGGC
mPck1 #1	CACCGATGCGGATCATGACTCGGAT	AAACATCCGAGTCATGATCCGCATC
mPck1 #2	CACCGCTGGGCATAACTAACCCCGA	AAACTCGGGGTTAGTTATGCCCAGC
mPck2 #1	CACCGAGGGTTTGGATGCTACGGCA	AAACTGCCGTAGCATCCAAACCCTC
mPck2 #2	CACCGGAGATCGTCTCCTTCGGCAG	AAACCTGCCGAAGGAGACGATCTCC
qPCR		
mSlc25a35	CAGGCAGCCTCTGAAATTG	TGGGTAGAGGAGCCGATG
mTnfa	ATGGCCTCCCTCTCATCAGT	TTTGCTACGACGTGGGCTAC
mIl1b	ATGCCACCTTTTGACAGTGAT	AGCCCTTCATCTTTTGGGGT
mIl6	CCCCAATTTCCAATGCTCTCC	GGATGGTCTTGGTCCTTAGCC
mFgf21	GTGTCAAAGCCTCTAGGTTTCTT	GGTACACATTGTAACCGTCCTC

mGdf15	AGCCGAGAGGACTCGAACTCAG	GGTTGACGCGGAGTAGCAGCT
mAtf4	AAGGAGGAAGACACTCCCTCT	CAGGTGGGTCATAAGGTTTGG
mAtf5	TGGGCTGGCTCGTAGACTAT	AGTCCACCCGCTCAGTCAT
mDdit3	CTGGAAGCCTGGTATGAGGAT	CAGGGTCAAGAGTAGTGAAGGT
mTrib3	CAGGAAGAAACCGTTGGAGTT	CCAAAAGGATATAAGGCCCCAGT
mAsns	CACAAGGCGCTACAGCAAC	CCAGCATACAGATGGTTTTCTCG
mCol1a1	GAGAACCAGCAGAGCCA	GAACAAGGTGACAGAGGCATA
mCol3a1	GAAAGGATGGAGAGTCAGGAA	CATTGCGTCCATCAAAGCC
mActa2	CACTGAACCCTAAGGCCAAC	GAGTCCAGCACAATACCAGTT
mAdgre1	CTGCACCTGTAAACGAGGCTT	GCAGACTGAGTTAGGACCACAA
m36b4	GCTCCAAGCAGATGCAGCA	CCGGATGTGAGGCAGCAG